<!DOCTYPE html> <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Blood pressure control for diabetic retinopathy - Do, DV - 2015 | Cochrane Library</title> <meta property="og:title" content="Blood pressure control for diabetic retinopathy - Do, DV - 2015 | Cochrane Library" /> <meta property="og:url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006127.pub2/references" /> <meta property="og:type" content="article" /> <meta property=”og:image” content=”https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png” /> <meta content="initial-scale=1.0, width=device-width" name="viewport" /> <meta name="dc.identifier" scheme="DOI" content="10.1002/14651858.CD006127.pub2" /> <meta name="citation_title" content="Blood pressure control for diabetic retinopathy" /> <meta name="citation_author" content="Diana V Do" /> <meta name="citation_author_institution" content="University of Nebraska Medical Center" /> <meta name="citation_author_email" content="diana.do@unmc.edu" /> <meta name="citation_author" content="Xue Wang" /> <meta name="citation_author_institution" content="Johns Hopkins Bloomberg School of Public Health" /> <meta name="citation_author" content="Satyanarayana S Vedula" /> <meta name="citation_author_institution" content="Johns Hopkins University" /> <meta name="citation_author" content="Michael Marrone" /> <meta name="citation_author_institution" content="Johns Hopkins Bloomberg School of Public Health" /> <meta name="citation_author" content="Gina Sleilati" /> <meta name="citation_author_institution" content="Clemenceau Medical Center" /> <meta name="citation_author" content="Barbara S Hawkins" /> <meta name="citation_author_institution" content="Johns Hopkins University School of Medicine" /> <meta name="citation_author" content="Robert N Frank" /> <meta name="citation_author_institution" content="Kresge Eye Institute" /> <meta name="citation_journal_title" content="Cochrane Database of Systematic Reviews" /> <meta name="citation_publisher" content="John Wiley &amp; Sons, Ltd" /> <meta name="citation_issue" content="1" /> <meta name="citation_doi" content="10.1002/14651858.CD006127.pub2" /> <meta name="citation_date" content="2015" /> <meta name="citation_online_date" content="2015/01/31" /> <meta name="citation_abstract_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006127.pub2/abstract" /> <meta name="citation_fulltext_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006127.pub2/full" /> <meta name="citation_pdf_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006127.pub2/pdf/CDSR/CD006127/CD006127.pdf" /> <meta name="citation_issn" content="1465-1858" /> <meta name="citation_language" content="en" /> <meta name="citation_keywords" content="Antihypertensive Agents [*therapeutic use]; Blood Pressure; Diabetes Mellitus, Type 1 [*complications]; Diabetes Mellitus, Type 2 [*complications]; Diabetic Retinopathy [epidemiology, *prevention &amp; control]; Disease Progression; Hypertension [complications, *drug therapy]; Incidence; Randomized Controlled Trials as Topic" /> <script type="text/javascript" src="//script.crazyegg.com/pages/scripts/0056/6375.js" async="async"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <script type="text/javascript">var o={auth:{customerIds:["P#DRAAEAC","EAL00000056729","DRAA3TITLES","TSINGH009S","EAL0001468","EAL00000045347"],individualId:null,brandedCustomer:"EAL0001468",roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=UTF-8" http-equiv="content-type" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/favicon.ico" rel="Shortcut Icon" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" rel="canonical" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-CN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh_TW&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-TW" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;hr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="hr-HR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="x-default" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="en-US" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fr-FR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;de&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="de-DE" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ja&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ja-JP" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ko&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ko-KR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ms&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ms-MY" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fa&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fa-IR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pl&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pl-PL" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pt&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pt-PT" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ru&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ru-RU" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;es&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="es-ES" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ta&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ta-IN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;th&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="th-TH" rel="alternate" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;aui&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link href="&#x2f;html&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1513680834000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718256000" rel="stylesheet" type="text/css" /> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 13},getRevision:function(){return"605.1"},getVersion:function(){return"13.0"},isAir:function(){return false},isChrome:function(){return false},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return false},isMac:function(){return true},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EfT7x5RD";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dreferences\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006127\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006127\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article References"},article:{availableLanguage:["en","es","de","ru","pt","ms","hr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006127.pub2",title:"Blood pressure control for diabetic retinopathy",firstPublishedDate:"Jan 31, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;custom&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <style type="text/css"></style> <script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-b0f13d7a13ebe8b0b1b00a9f0730a084926e292f.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1581422282000" type="text/javascript"></script> <![endif]--> </head> <body class=" yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div id="js-cookie-message" class="cookie-message cookie-message--hidden system-message-container"> <div class="container"> <a href="#" class="fa fa-times js-cookie-close pull-right" aria-label="Close cookies message"></a> <div class="system-message-wrapper container"> <i class="fa fa-exclamation-triangle" aria-hidden="true"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/N7XGCZUQPW4C675JNSTYTLUDN7XB/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a href="#" class="btn secondary js-cookie-close js-cookie-accept">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/"> <span class="brand-name">The Cochrane Library</span> <img class="brand-logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_logo.png" alt="Cochrane Library logo" title="Cochrane Library" /> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="owel__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006127.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006127.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a href="/en/browse-by-topic" class="btn secondary">Browse</a>
<a href="/en/advanced-search" class="btn primary advanced-search-button">Advanced search</a>
</div>
</div>
<a href="#" class="toggle-menu-switch"><i class="fa fa-bars" aria-hidden="true"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<p class="auxiliary-menu-item access">Access provided by: <strong>Tsinghua University</strong></p>
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="bvrs__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="language-selector-modal-content" style="display: none;" data-modal-title="Language selection" data-size="large"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div> <a href="/en/cdsr/doi/10.1002/14651858.CD006127.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD006127.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <button class="btn primary btn-cancel" type="button">Cancel</button> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006127.pub2%2Freferences" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
</a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
<div class="access-provider-mobile">
<p class="access">Access provided by: <strong>Tsinghua University</strong></p>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class=" nav-root-item parent">
<a href="#">Cochrane Reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_14" role="presentation">
<a aria-labelledby="layout_14" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews" role="menuitem">
Search Reviews (CDSR)
</a>
</li>
<li class=" child-nav-item" id="layout_15" role="presentation">
<a aria-labelledby="layout_15" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews&#x2f;topics" role="menuitem">
Browse Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_18" role="presentation">
<a aria-labelledby="layout_18" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;table-of-contents" role="menuitem">
Issues
</a>
</li>
<li class=" child-nav-item" id="layout_17" role="presentation">
<a aria-labelledby="layout_17" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;editorials" role="menuitem">
Editorials
</a>
</li>
<li class=" child-nav-item" id="layout_19" role="presentation">
<a aria-labelledby="layout_19" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;special-collections" role="menuitem">
Special Collections
</a>
</li>
<li class=" child-nav-item" id="layout_20" role="presentation">
<a aria-labelledby="layout_20" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;supplements" role="menuitem">
Supplements
</a>
</li>
<li class=" child-nav-item" id="layout_13" role="presentation">
<a aria-labelledby="layout_13" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;about-cdsr" role="menuitem">
About the CDSR
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_22" role="presentation">
<a aria-labelledby="layout_22" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central" role="menuitem">
Search Trials (CENTRAL)
</a>
</li>
<li class=" child-nav-item" id="layout_114" role="presentation">
<a aria-labelledby="layout_114" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central&#x2f;about-central" role="menuitem">
About CENTRAL
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_29" role="presentation">
<a aria-labelledby="layout_29" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca" role="menuitem">
Browse Clinical Answers
</a>
</li>
<li class=" child-nav-item" id="layout_91" role="presentation">
<a aria-labelledby="layout_91" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca&#x2f;about" role="menuitem">
About Clinical Answers
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_116" role="presentation">
<a aria-labelledby="layout_116" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-library" role="menuitem">
About the Cochrane Library
</a>
</li>
<li class=" child-nav-item" id="layout_34" role="presentation">
<a aria-labelledby="layout_34" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochrane&#x2e;org&#x2f;about-us" role="menuitem">
About Cochrane
</a>
</li>
<li class=" child-nav-item" id="layout_121" role="presentation">
<a aria-labelledby="layout_121" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-reviews" role="menuitem">
About Cochrane Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_92" role="presentation">
<a aria-labelledby="layout_92" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;author-information" role="menuitem">
Information for authors
</a>
</li>
<li class=" child-nav-item" id="layout_188" role="presentation">
<a aria-labelledby="layout_188" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;releases" role="menuitem">
What&#039;s new
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_177" role="presentation">
<a aria-labelledby="layout_177" href="https&#x3a;&#x2f;&#x2f;www&#x2e;wiley&#x2e;com&#x2f;network&#x2f;cochranelibrarytraining" role="menuitem">
Cochrane Library Training
</a>
</li>
<li class=" child-nav-item" id="layout_44" role="presentation">
<a aria-labelledby="layout_44" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;access" role="menuitem">
Access options
</a>
</li>
<li class=" child-nav-item" id="layout_150" role="presentation">
<a aria-labelledby="layout_150" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;permissions" role="menuitem">
Permissions and reprints
</a>
</li>
<li class=" child-nav-item" id="layout_93" role="presentation">
<a aria-labelledby="layout_93" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;media" role="menuitem">
Media information
</a>
</li>
<li class=" child-nav-item" id="layout_97" role="presentation">
<a aria-labelledby="layout_97" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;contact-us" role="menuitem">
Contact us
</a>
</li>
<li class=" child-nav-item" id="layout_125" role="presentation">
<a aria-labelledby="layout_125" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;terms-and-conditions" role="menuitem">
Terms and conditions
</a>
</li>
<li class=" child-nav-item" id="layout_176" role="presentation">
<a aria-labelledby="layout_176" href="https&#x3a;&#x2f;&#x2f;hub&#x2e;wiley&#x2e;com&#x2f;docs&#x2f;cochrane-library&#x2f;cochrane-library-known-issues-DOC-16221&#x3f;referrer&#x3d;cochrane" role="menuitem">
Known issues
</a>
</li>
</ul>
</li>
<li class="about-link"><a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img id="etlj__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <section class="content-language-banner system-message-container" data-content-language="en" data-portal-language="en" style="display: none"> <div class="container"> <a href="#0" class="fa fa-times content-language-banner-close pull-right" aria-label="Close"></a> <i class="fa fa-globe" aria-hidden="true"></i> <div class="system-message-title">Content Language Selection</div> <div class="system-message-description">Your language preference is set to <strong class="language">English</strong>. Where translations are available, article sections will display in this language. Return to <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=reset-content-language&p_p_cacheability=cacheLevelPage" class="language secondary">English</a>.</div> </div> </section> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div id="content" class="">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="rjus__column1__0" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools"> <li class="cdsr-nav-link pulldown-menu readcube-menu closed"> <a href="#0" class="pulldown-menu-trigger"> <i class="icon fa fa-file-pdf-o"></i>View PDF <i aria-hidden="true" class="fa fa-caret-up"></i> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/pdf/full/en" class="download media pdf-link-full pdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/epdf/full/en" class="download media pdf-link-full readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/pdf/standard/en" class="download media pdf-link-standard pdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/epdf/standard/en" class="download media pdf-link-standard readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/pdf/abstract/en" class="download media pdf-link-abstract pdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/epdf/abstract/en" class="download media pdf-link-abstract readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="cdsr-nav-link cite-article-link" data-article-id="CD006127.PUB2" data-modal-title="Cite this Review"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/#"> <i class="icon fa fa-share"></i>Cite this Review </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-english-only-message="Please note, that requesting permissions is available in English only. Apologies for any inconvenience." href="/cdsr/doi/10.1002/14651858.CD006127.pub2/#" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false"> <span class="request-permissions-icon"></span> Request Permissions </a> </li> <li class="cdsr-nav-link comment-on-review"> <a id="comment-on-review" class="js-old-version-modal-trigger" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/comment" data-new-version="" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience."> <i class="icon fa fa-comment"></i>Comment on Review </a> </li> <li class="cdsr-nav-link comment-on"> <span>Read comments on this Review(0)</span> </li> </ul> <ul class="share clearfix"> <li class="cdsr-nav-link print-cdsr-link" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006127.pub2/print" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Data and analysis&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;}]}]"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/#"> <i class="icon fa fa-print"></i>Print </a> </li> <li class="cdsr-nav-link share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006127.pub2/full"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/#"> <i class="icon fa fa-share-alt"></i>Share </a> </li> <li class="cdsr-nav-link"> <a href="/c/portal/login" class="article-not-followed cochrane-link signin"> <span class="article-follow-display"><i class="icon fa fa-plus"></i>Follow</span> </a> </li> </ul> <ul id="linked-articles" data-type="cdsr" class="linked-content tools clearfix linked-content-trigger"> <li> <a href="#0"> <span class="linked-to-this"> Linked to this Review <span class="linked-content-count"></span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> </li> </ul> <ul class="linked-content-dropdown"> <li data-type="cca" class="linked-cca"> <p>Cochrane Clinical Answers</p> </li> <li data-type="editorial" class="linked-editorials"> <p>Editorials</p> </li> <li data-type="podcast" class="linked-podcasts"> <p>Podcasts</p> </li> <li data-type="sc" class="linked-sc"> <p>Special Collections</p> </li> </ul> <ul class="nav-long-form"> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-sec1-0006"> Discussion </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/appendices#CD006127-sec1-0012"> Appendices </a> </li> </ul> <ul> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/information"> Information </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/information#authors"> Authors </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/information#history"> History </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/information#keywords"> Keywords </a> </li> </ul> <ul> <li class="cdsr-nav-link bold-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/#"> <i class="icon fa fa-globe"></i>Translation notes </a> </li> </ul> <ul> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references"> References </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#dataAndAnalyses"> Data and analyses </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/#"> <i class="icon fa fa-line-chart"></i>Figures and tables </a> </li> <li class="cdsr-nav-link download-stats-data-link " data-download-href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/table_n/CD006127StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/table_n/CD006127StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <i class="icon fa fa-download"></i>Download statistical data </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i>Related content <span class="note podcast-indicator">Podcast available</span> </a> </li> </ul> </nav> </div> <article class="information" data-article-id="CD006127.PUB2"> <header> <h1 class="publication-title"><h1 lang="en" class="publication-title">Blood pressure control for diabetic retinopathy</h1></h1> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div><h2 class="title section-collapse-title"> References <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <section class="references bibliographies" id="references"> <section> <div class="section-header" id="CD006127-bbs1-0001"> <h3 class="title">References to studies included in this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006127-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0001"> <div class="reference-title-banner"> <h4 class="title">ABCD (1) {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0001"> <div class="citation-journal">Schrier RW, Estacio RO, Esler A, Mehler P. <span class="citation-title">Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes</span>. <span class="citation"> Kidney International </span><span class="pubYear">2002</span>;<span class="volume">61</span>(3):1086‐97. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11849464" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+aggressive+blood+pressure+control+in+normotensive+type+2+diabetic+patients+on+albuminuria,+retinopathy+and+strokes+&author=RW+Schrier&author=RO+Estacio&author=A+Esler&author=P+Mehler&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0002"> <div class="citation-journal">Schrier RW, Estacio RO, Jeffers B. <span class="citation-title">Appropriate Blood Pressure Control in NIDDM (ABCD) Trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1996</span>;<span class="volume">39</span>(12):1646‐54. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8960857" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Appropriate+Blood+Pressure+Control+in+NIDDM+(ABCD)+Trial&author=RW+Schrier&author=RO+Estacio&author=B+Jeffers&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0003"> <div class="citation-journal">Schrier RW, Savage S. <span class="citation-title">Appropriate Blood Pressure Control in Type II Diabetes (ABCD Trial): implications for complications</span>. <span class="citation"> American Journal of Kidney Diseases </span><span class="pubYear">1992</span>;<span class="volume">20</span>(6):653‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1462999" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Appropriate+Blood+Pressure+Control+in+Type+II+Diabetes+(ABCD+Trial):+implications+for+complications+&author=RW+Schrier&author=S+Savage&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0002"> <div class="reference-title-banner"> <h4 class="title">ABCD (2) {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0004"> <div class="citation-journal">Estacio RO, Jeffers BW, Gifford N, Schrier RW. <span class="citation-title">Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2000</span>;<span class="volume">23</span>(Suppl 2):B54‐64. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10860192" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+blood+pressure+control+on+diabetic+microvascular+complications+in+patients+with+hypertension+and+type+2+diabetes+&author=RO+Estacio&author=BW+Jeffers&author=N+Gifford&author=RW+Schrier&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0005"> <div class="citation-journal">Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. <span class="citation-title">The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non‐insulin dependent diabetes and hypertension</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">1998</span>;<span class="volume">338</span>(10):645‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9486993" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+nisoldipine+as+compared+with+enalapril+on+cardiovascular+outcomes+in+patients+with+non%E2%80%90insulin+dependent+diabetes+and+hypertension+&author=RO+Estacio&author=BW+Jeffers&author=WR+Hiatt&author=SL+Biggerstaff&author=N+Gifford&author=RW+Schrier&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0006"> <div class="citation-journal">Savage S, Nagel NJ, Estacio RO, Feig PU, MacCarthy EP, Lukken NJ, et al. <span class="citation-title">The ABCD (Appropriate Blood Pressure Control in Diabetes) Trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes</span>. <span class="citation"> Online Journal of Current Clinical Trials </span> 1993 Nov 24:Doc No 104. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0003"> <div class="reference-title-banner"> <h4 class="title">ACCORD EYE {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0007"> <div class="citation-journal">Ambrosius WT, Danis RP, Goff DC, Greven CM, Gerstein HC, Cohen RM, et al. <span class="citation-title">Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">128</span>(3):312‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20212201" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Lack+of+association+between+thiazolidinediones+and+macular+edema+in+type+2+diabetes:+the+ACCORD+eye+substudy+&author=WT+Ambrosius&author=RP+Danis&author=DC+Goff&author=CM+Greven&author=HC+Gerstein&author=RM+Cohen&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0008"> <div class="citation-journal">Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. <span class="citation-title">Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):21i‐33i. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599422" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+Trial:+design+and+methods&author=JB+Buse&author=JT+Bigger&author=RP+Byington&author=LS+Cooper&author=WC+Cushman&author=WT+Friedewald&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0011"> <div class="citation-journal">Chew EY, Ambrosius WT. <span class="citation-title">Update of the ACCORD Eye Study</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">2011</span>;<span class="volume">364</span>(2):188‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21226603" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Update+of+the+ACCORD+Eye+Study&author=EY+Chew&author=WT+Ambrosius&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0009"> <div class="citation-journal">Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. <span class="citation-title">Effects of medical therapies on retinopathy progression in type 2 diabetes</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">2010</span>;<span class="volume">363</span>(3):233‐44. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20587587" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+medical+therapies+on+retinopathy+progression+in+type+2+diabetes&author=EY+Chew&author=WT+Ambrosius&author=MD+Davis&author=RP+Danis&author=S+Gangaputra&author=CM+Greven&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0010"> <div class="citation-journal">Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, et al. <span class="citation-title">Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE)</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):103i‐11i. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599420" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale,+design,+and+methods+of+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+Eye+Study+(ACCORD%E2%80%90EYE)+&author=EY+Chew&author=WT+Ambrosius&author=LT+Howard&author=CM+Greven&author=S+Johnson&author=RP+Danis&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0012"> <div class="citation-journal">Cushman WC, Grimm RH, Cutler JA, Evan GW, Capes S, Corson MA. <span class="citation-title">Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):44i‐55i. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599425" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale+and+design+for+the+blood+pressure+intervention+of+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial+&author=WC+Cushman&author=RH+Grimm&author=JA+Cutler&author=GW+Evan&author=S+Capes&author=MA+Corson&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0013"> <div class="citation-journal">Ismail‐Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. <span class="citation-title">Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2010</span>;<span class="volume">376</span>(9739):419‐30. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20594588" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+treatment+of+hyperglycaemia+on+microvascular+outcomes+in+type+2+diabetes:+an+analysis+of+the+ACCORD+randomised+trial+&author=F+Ismail%E2%80%90Beigi&author=T+Craven&author=MA+Banerji&author=J+Basile&author=J+Calles&author=RM+Cohen&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0014"> <div class="citation-journal">Ismail‐Beigi F, Craven TE, O'Connor PJ, Karl D, Calles‐Escandon J, Hramiak I, et al. <span class="citation-title">Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients</span>. <span class="citation"> Kidney International </span><span class="pubYear">2012</span>;<span class="volume">81</span>(6):586‐94. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22166848" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Combined+intensive+blood+pressure+and+glycemic+control+does+not+produce+an+additive+benefit+on+microvascular+outcomes+in+type+2+diabetic+patients+&author=F+Ismail%E2%80%90Beigi&author=TE+Craven&author=PJ+O'Connor&author=D+Karl&author=J+Calles‐Escandon&author=I+Hramiak&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0015"> <div class="citation-journal">Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen J, et al. <span class="citation-title">Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):90i‐102i. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599429" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Health%E2%80%90related+quality+of+life+and+cost%E2%80%90effectiveness+components+of+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial:+rationale+and+design+&author=MD+Sullivan&author=RT+Anderson&author=D+Aron&author=HH+Atkinson&author=A+Bastien&author=J+Chen&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0004"> <div class="reference-title-banner"> <h4 class="title">ADVANCE/AdRem {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0016"> <div class="citation-journal">ADVANCE Collaborative Group. <span class="citation-title">ADVANCE ‐ Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2005</span>;<span class="volume">22</span>(7):882‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15975103" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0017"> <div class="citation-journal">ADVANCE Collaborative Group. <span class="citation-title">Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2007</span>;<span class="volume">370</span>(9590):829‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17765963" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0018"> <div class="citation-journal">ADVANCE Collaborative Group. <span class="citation-title">Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">2008</span>;<span class="volume">358</span>(24):2560‐72. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18539916" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0019"> <div class="citation-journal">ADVANCE Management Committee. <span class="citation-title">Study rationale and design of ADVANCE: Action in Diabetes and Vascular Disease ‐ preterax and diamicron MR controlled evaluation</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2001</span>;<span class="volume">44</span>(9):1118‐20. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11596665" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0020"> <div class="citation-journal">Beulens JWJ, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, et al. <span class="citation-title">Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomized controlled trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2009</span>;<span class="volume">52</span>(10):2027‐46. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19633827" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+blood+pressure+lowering+and+intensive+glucose+control+on+the+incidence+and+progression+of+retinopathy+in+patients+with+type+2+diabetes+mellitus:+a+randomized+controlled+trial+&author=JWJ+Beulens&author=A+Patel&author=JR+Vingerling&author=JK+Cruickshank&author=AD+Hughes&author=A+Stanton&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0021"> <div class="citation-journal">Patel A, Chalmers J, Neal B, Chapman N, Girgis S, MacMahon S. <span class="citation-title">Blood pressure lowering in diabetes: a brief review of current evidence and description of a new trial</span>. <span class="citation"> Clinical and Experimental Pharmacology and Physiology </span><span class="pubYear">2001</span>;<span class="volume">28</span>(12):1108‐11. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11903327" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Blood+pressure+lowering+in+diabetes:+a+brief+review+of+current+evidence+and+description+of+a+new+trial+&author=A+Patel&author=J+Chalmers&author=B+Neal&author=N+Chapman&author=S+Girgis&author=S+MacMahon&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0022"> <div class="citation-journal">Poulter NR. <span class="citation-title">Blood pressure and glucose control in subject with diabetes: new analysis from ADVANCE</span>. <span class="citation"> Journal of Hypertension </span><span class="pubYear">2009</span>;<span class="volume">27</span>(1):S3‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19483505" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Blood+pressure+and+glucose+control+in+subject+with+diabetes:+new+analysis+from+ADVANCE&author=NR+Poulter&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0023"> <div class="citation-journal">Stolk RP, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, Juming L, et al. <span class="citation-title">Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus</span>. <span class="citation"> Contemporary Clinical Trials </span><span class="pubYear">2007</span>;<span class="volume">28</span>(1):6‐17. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17030155" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale+and+design+of+the+AdRem+study:+evaluating+the+effects+of+blood+pressure+lowering+and+intensive+glucose+control+on+vascular+retinal+disorders+in+patients+with+type+2+diabetes+mellitus+&author=RP+Stolk&author=JR+Vingerling&author=JK+Cruickshank&author=AD+Hughes&author=A+Stanton&author=L+Juming&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0024"> <div class="citation-journal">Stolk RP, Schooneveld MJ, Cruickshank JK, Hughes AD, Stanton A, Lu J, et al. <span class="citation-title">Retinal vascular lesions in patients of Caucasian and Asian origin with type 2 diabetes: baseline results from the ADVANCE Retinal Measurements (AdRem) study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2008</span>;<span class="volume">31</span>(4):708‐13. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18184903" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Retinal+vascular+lesions+in+patients+of+Caucasian+and+Asian+origin+with+type+2+diabetes:+baseline+results+from+the+ADVANCE+Retinal+Measurements+(AdRem)+study+&author=RP+Stolk&author=MJ+Schooneveld&author=JK+Cruickshank&author=AD+Hughes&author=A+Stanton&author=J+Lu&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0005"> <div class="reference-title-banner"> <h4 class="title">BENEDICT {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0025"> <div class="citation-journal">BENEDICT Group. <span class="citation-title">The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT)</span>. <span class="citation"> Controlled Clinical Trials </span><span class="pubYear">2003</span>;<span class="volume">24</span>(4):442‐61. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12865039" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0026"> <div class="citation-journal">Ruggenenti P, Fassi A, Parvanova I, Bruno S, Iliev IP, Brusegan V, et al. <span class="citation-title">Preventing microalbuminuria in type 2 diabetes</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">2004</span>;<span class="volume">351</span>(19):1941‐51. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15516697" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Preventing+microalbuminuria+in+type+2+diabetes&author=P+Ruggenenti&author=A+Fassi&author=I+Parvanova&author=S+Bruno&author=IP+Iliev&author=V+Brusegan&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0027"> <div class="citation-journal">Ruggenenti P, Iliev I, Filipponi M, Tadini S, Perna A, Ganeva M. <span class="citation-title">Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial</span>. <span class="citation"> Journal of Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">2010</span>:Article ID 106384. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+trandolapril+on+regression+of+retinopathy+in+hypertensive+patients+with+type+2+diabetes:+a+prespecified+analysis+of+the+benedict+trial+&author=P+Ruggenenti&author=I+Iliev&author=M+Filipponi&author=S+Tadini&author=A+Perna&author=M+Ganeva&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0006"> <div class="reference-title-banner"> <h4 class="title">Chase {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0028"> <div class="citation-journal">Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL. <span class="citation-title">Angiotensin‐converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two‐year trial</span>. <span class="citation"> Annals of Ophthalmology </span><span class="pubYear">1993</span>;<span class="volume">25</span>(8):284‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8239321" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Angiotensin%E2%80%90converting+enzyme+inhibitor+treatment+for+young+normotensive+diabetic+subjects:+a+two%E2%80%90year+trial+&author=HP+Chase&author=SK+Garg&author=S+Harris&author=S+Hoops&author=WE+Jackson&author=DL+Holmes&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0007"> <div class="reference-title-banner"> <h4 class="title">DEMAND {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0029"> <div class="citation-journal">Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S. <span class="citation-title">Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) randomized clinical trial</span>. <span class="citation"> Hypertension </span><span class="pubYear">2011</span>;<span class="volume">58</span>(5):776‐83. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21931073" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+manidipine+and+delapril+in+hypertensive+patients+with+type+2+diabetes+mellitus:+the+Delapril+and+Manidipine+for+Nephroprotection+in+Diabetes+(DEMAND)+randomized+clinical+trial+&author=P+Ruggenenti&author=G+Lauria&author=IP+Iliev&author=A+Fassi&author=AP+Ilieva&author=S+Rota&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0008"> <div class="reference-title-banner"> <h4 class="title">DIRECT Prevent 1 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0030"> <div class="citation-journal">Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. <span class="citation-title">Effect of candesartan on prevention (DIRECT‐Prevent 1) and progression (DIRECT‐Protect 1) of retinopathy in type 1 diabetes: randomised, placebo‐controlled trials</span>. <span class="citation"> Lancet </span><span class="pubYear">2008</span>;<span class="volume">372</span>(9647):1394‐402. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18823656" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+candesartan+on+prevention+(DIRECT%E2%80%90Prevent+1)+and+progression+(DIRECT%E2%80%90Protect+1)+of+retinopathy+in+type+1+diabetes:+randomised,+placebo%E2%80%90controlled+trials+&author=N+Chaturvedi&author=M+Porta&author=R+Klein&author=T+Orchard&author=J+Fuller&author=HH+Parving&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0031"> <div class="citation-journal">Chaturvedi N, DIRECT Programme Study Group. <span class="citation-title">The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design</span>. <span class="citation"> Journal of the Renin‐Angiotensin‐Aldosterone System </span><span class="pubYear">2002</span>;<span class="volume">3</span>(4):255‐61. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12584669" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+DIabetic+REtinopathy+Candesartan+Trials+(DIRECT)+Programme,+rationale+and+study+design+&author=N+Chaturvedi&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0032"> <div class="citation-journal">DIRECT Programme Study Group. <span class="citation-title">The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics</span>. <span class="citation"> Journal of the Renin‐Angiotensin‐Aldosterone System </span><span class="pubYear">2005</span>;<span class="volume">6</span>(1):25‐32. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16088848" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0033"> <div class="citation-journal">Sjolie AK, Klien R, Portat M, Orchard T, Fuller J, Parving HH, et al. <span class="citation-title">Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post‐hoc results from the DIRECT Programme</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2011</span>;<span class="volume">28</span>(3):345‐51. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21309844" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Retinal+microaneurysm+count+predicts+progression+and+regression+of+diabetic+retinopathy.+Post%E2%80%90hoc+results+from+the+DIRECT+Programme+&author=AK+Sjolie&author=R+Klien&author=M+Portat&author=T+Orchard&author=J+Fuller&author=HH+Parving&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0009"> <div class="reference-title-banner"> <h4 class="title">DIRECT Protect 1 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0034"> <div class="citation-journal">Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. <span class="citation-title">Effect of candesartan on prevention (DIRECT‐Prevent 1) and progression (DIRECT‐Protect 1) of retinopathy in type 1 diabetes: randomised, placebo‐controlled trials</span>. <span class="citation"> Lancet </span><span class="pubYear">2008</span>;<span class="volume">372</span>(9647):1394‐402. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18823656" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+candesartan+on+prevention+(DIRECT%E2%80%90Prevent+1)+and+progression+(DIRECT%E2%80%90Protect+1)+of+retinopathy+in+type+1+diabetes:+randomised,+placebo%E2%80%90controlled+trials+&author=N+Chaturvedi&author=M+Porta&author=R+Klein&author=T+Orchard&author=J+Fuller&author=HH+Parving&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0035"> <div class="citation-journal">Chaturvedi N, DIRECT Programme Study Group. <span class="citation-title">DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design</span>. <span class="citation"> Journal of the Renin‐Angiotensin‐Aldosterone System </span><span class="pubYear">2002</span>;<span class="volume">3</span>(4):255‐61. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12584669" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=DIabetic+REtinopathy+Candesartan+Trials+(DIRECT)+Programme,+rationale+and+study+design&author=N+Chaturvedi&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0036"> <div class="citation-journal">DIRECT Programme Study Group. <span class="citation-title">DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics</span>. <span class="citation"> Journal of the Renin‐Angiotensin‐Aldosterone System </span><span class="pubYear">2005</span>;<span class="volume">6</span>(1):25‐32. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16088848" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0010"> <div class="reference-title-banner"> <h4 class="title">DIRECT Protect 2 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0037"> <div class="citation-journal">Chaturvedi N, DIRECT Programme Study Group. <span class="citation-title">DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design</span>. <span class="citation"> Journal of the Renin‐Angiotensin‐Aldosterone System </span><span class="pubYear">2002</span>;<span class="volume">3</span>(4):255‐61. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12584669" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=DIabetic+REtinopathy+Candesartan+Trials+(DIRECT)+Programme,+rationale+and+study+design&author=N+Chaturvedi&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0038"> <div class="citation-journal">DIRECT Programme Study Group. <span class="citation-title">DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics</span>. <span class="citation"> Journal of Renin‐Angiotensin‐Aldosterone System </span><span class="pubYear">2005</span>;<span class="volume">6</span>(1):25‐32. <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0039"> <div class="citation-journal">Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. <span class="citation-title">Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT‐Protect 2): a randomised placebo‐controlled trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2008</span>;<span class="volume">372</span>(9647):1385‐93. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18823658" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+candesartan+on+progression+and+regression+of+retinopathy+in+type+2+diabetes+(DIRECT%E2%80%90Protect+2):+a+randomised+placebo%E2%80%90controlled+trial+&author=AK+Sjolie&author=R+Klein&author=M+Porta&author=T+Orchard&author=J+Fuller&author=HH+Parving&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0011"> <div class="reference-title-banner"> <h4 class="title">EUCLID {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0040"> <div class="citation-journal">Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP, et al. <span class="citation-title">Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition</span>. <span class="citation"> Diabetes Medicine </span><span class="pubYear">2001</span>;<span class="volume">18</span>(4):288‐94. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Circulating+plasma+vascular+endothelial+growth+factor+and+microvascular+complications+of+type+1+diabetes+mellitus:+the+influence+of+ACE+inhibition+&author=N+Chaturvedi&author=JH+Fuller&author=F+Pokras&author=R+Rottiers&author=N+Papazoglou&author=LP+Aiello&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0041"> <div class="citation-journal">Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. <span class="citation-title">Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">351</span>(9095):28‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9433426" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+lisinopril+on+progression+of+retinopathy+in+normotensive+people+with+type+1+diabetes+&author=N+Chaturvedi&author=AK+Sjolie&author=JM+Stephenson&author=H+Abrahamian&author=M+Keipes&author=A+Castellarin&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0042"> <div class="citation-journal">EUCLID Study Group. <span class="citation-title">Randomised placebo‐controlled trial of lisinopril in normotensive patients with insulin‐dependent diabetes and normoalbuminuria or microalbuminuria</span>. <span class="citation"> Lancet </span><span class="pubYear">1997</span>;<span class="volume">349</span>(9068):1787‐92. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9269212" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0043"> <div class="citation-journal">Sjolie AK, Chaturvedi N, Fuller J, EUCLID Study Group. <span class="citation-title">Effect of lisinopril on progression of retinopathy and microalbuminuria in normotensive subjects with insulin‐dependent diabetes mellitus</span> [Effekt af lisinopril på progression af retinopati og mikroalbuminuri hos normotensive personer med insulinafhængig diabetes mellitus]. <span class="citation"> Ugeskrift for Laeger </span><span class="pubYear">1999</span>;<span class="volume">161</span>(7):949‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10051804" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+lisinopril+on+progression+of+retinopathy+and+microalbuminuria+in+normotensive+subjects+with+insulin%E2%80%90dependent+diabetes+mellitus+&author=AK+Sjolie&author=N+Chaturvedi&author=J+Fuller&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0044"> <div class="citation-journal">Sjolie AK, Stephenson J, Aldington S, Kohner E, Janka H, Stevens L, et al. <span class="citation-title">Retinopathy and vision loss in insulin‐dependent diabetes in Europe. The EURODIAB IDDM Complications Study</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1997</span>;<span class="volume">104</span>(2):252‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9052629" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Retinopathy+and+vision+loss+in+insulin%E2%80%90dependent+diabetes+in+Europe.+The+EURODIAB+IDDM+Complications+Study+&author=AK+Sjolie&author=J+Stephenson&author=S+Aldington&author=E+Kohner&author=H+Janka&author=L+Stevens&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0012"> <div class="reference-title-banner"> <h4 class="title">Pradhan {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0045"> <div class="citation-journal">Pradhan R, Fong D, March C, Jack R, Rezapour G, Norris K, et al. <span class="citation-title">Angiotensin‐converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive type 2 diabetic patients. A pilot study</span>. <span class="citation"> Journal of Diabetes and Its Complications </span><span class="pubYear">2002</span>;<span class="volume">16</span>(6):377‐81. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12477620" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Angiotensin%E2%80%90converting+enzyme+inhibition+for+the+treatment+of+moderate+to+severe+diabetic+retinopathy+in+normotensive+type+2+diabetic+patients.+A+pilot+study+&author=R+Pradhan&author=D+Fong&author=C+March&author=R+Jack&author=G+Rezapour&author=K+Norris&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0013"> <div class="reference-title-banner"> <h4 class="title">RASS {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0046"> <div class="citation-journal">Klein R, Moss SE, Sinaiko AR, Zinman B, Gardiner R, Suissa S, et al. <span class="citation-title">The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus. The Renin‐Angiotensin System Study</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2006</span>;<span class="volume">113</span>(12):2231‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16996597" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+relation+of+ambulatory+blood+pressure+and+pulse+rate+to+retinopathy+in+type+1+diabetes+mellitus.%C2%A0The+Renin%E2%80%90Angiotensin+System+Study+&author=R+Klein&author=SE+Moss&author=AR+Sinaiko&author=B+Zinman&author=R+Gardiner&author=S+Suissa&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0047"> <div class="citation-journal">Klein R, Zinman B, Gardiner R, Suissa S, Donnelly SM, Sinaiko AR, et al. <span class="citation-title">The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients. The Renin‐Angiotensin System Study</span>. <span class="citation"> Diabetes </span><span class="pubYear">2005</span>;<span class="volume">54</span>(2):527‐33. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15677511" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+relationship+of+diabetic+retinopathy+to+preclinical+diabetic+glomerulopathy+lesions+in+type+1+diabetic+patients.+The+Renin%E2%80%90Angiotensin+System+Study+&author=R+Klein&author=B+Zinman&author=R+Gardiner&author=S+Suissa&author=SM+Donnelly&author=AR+Sinaiko&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0048"> <div class="citation-journal">Mauer M, Zinman B, Gardiner R, Drummond KN, Suissa S, Donnelly SM, et al. <span class="citation-title">ACE‐I and ARBs in early diabetic retinopathy</span>. <span class="citation"> Journal of the Renin‐Angiotensin‐Aldosterone System </span><span class="pubYear">2002</span>;<span class="volume">3</span>(4):262‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12584670" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=ACE%E2%80%90I+and+ARBs+in+early+diabetic+retinopathy&author=M+Mauer&author=B+Zinman&author=R+Gardiner&author=KN+Drummond&author=S+Suissa&author=SM+Donnelly&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0049"> <div class="citation-journal">Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. <span class="citation-title">Renal and retinal effects of enalapril and losartan in type 1 diabetes</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">2009</span>;<span class="volume">361</span>(1):40‐51. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19571282" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Renal+and+retinal+effects+of+enalapril+and+losartan+in+type+1+diabetes&author=M+Mauer&author=B+Zinman&author=R+Gardiner&author=S+Suissa&author=A+Sinaiko&author=T+Strand&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0014"> <div class="reference-title-banner"> <h4 class="title">Steno‐2 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0050"> <div class="citation-journal">Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. <span class="citation-title">Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">2003</span>;<span class="volume">348</span>(5):383‐93. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12556541" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Multifactorial+intervention+and+cardiovascular+disease+in+patients+with+type+2+diabetes&author=P+Gaede&author=P+Vedel&author=N+Larsen&author=GVH+Jensen&author=HH+Parving&author=O+Pedersen&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0051"> <div class="citation-journal">Gaede P, Vedel P, Parving HH, Pedersen O. <span class="citation-title">Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study</span>. <span class="citation"> Lancet </span><span class="pubYear">1999</span>;<span class="volume">353</span>(9153):617‐22. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10030326" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensified+multifactorial+intervention+in+patients+with+type+2+diabetes+mellitus+and+microalbuminuria:+the+Steno+type+2+randomised+study+&author=P+Gaede&author=P+Vedel&author=HH+Parving&author=O+Pedersen&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0052"> <div class="citation-journal">Vaag AA. <span class="citation-title">Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study</span>. <span class="citation"> Endocrine Practice </span><span class="pubYear">2006</span>;<span class="volume">12</span>(Suppl 1):89‐92. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16627389" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glycemic+control+and+prevention+of+microvascular+and+macrovascular+disease+in+the+Steno+2+study+&author=AA+Vaag&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD006127-bbs2-0015"> <div class="reference-title-banner"> <h4 class="title">UKPDS/HDS {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0053"> <div class="citation-journal">Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR, et al. <span class="citation-title">Cost‐utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2005</span>;<span class="volume">48</span>(5):868‐77. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15834550" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cost%E2%80%90utility+analyses+of+intensive+blood+glucose+and+tight+blood+pressure+control+in+type+2+diabetes+(UKPDS+72)+&author=PM+Clarke&author=AM+Gray&author=A+Briggs&author=RJ+Stevens&author=DR+Matthews&author=RR+Holman&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0054"> <div class="citation-journal">Gray A, Clarke P, Farmer A, Holman R. <span class="citation-title">Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63)</span>. <span class="citation"> BMJ </span><span class="pubYear">2002</span>;<span class="volume">325</span>(7369):860. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12386035" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Implementing+intensive+control+of+blood+glucose+concentration+and+blood+pressure+in+type+2+diabetes+in+England:+cost+analysis+(UKPDS+63)+&author=A+Gray&author=P+Clarke&author=A+Farmer&author=R+Holman&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0055"> <div class="citation-journal">Gray A, Clarke P, Raikou M, Adler A, Stevens R, Neil A, et al. <span class="citation-title">An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54)</span>. <span class="citation"> Diabetes Medicine </span><span class="pubYear">2001</span>;<span class="volume">18</span>(6):438‐44. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=An+economic+evaluation+of+atenolol+vs.+captopril+in+patients+with+type+2+diabetes+(UKPDS+54)+&author=A+Gray&author=P+Clarke&author=M+Raikou&author=A+Adler&author=R+Stevens&author=A+Neil&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0056"> <div class="citation-journal">Holman RR, Paul SK, Bethel MA, Andrew H, Neil W, Matthews DR. <span class="citation-title">Long‐term follow‐up after tight control of blood pressure in type 2 diabetes</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">2008</span>;<span class="volume">359</span>(15):1565‐76. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18784091" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+follow%E2%80%90up+after+tight+control+of+blood+pressure+in+type+2+diabetes&author=RR+Holman&author=SK+Paul&author=MA+Bethel&author=H+Andrew&author=W+Neil&author=DR+Matthews&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0057"> <div class="citation-journal">Hypertension in Diabetes Study Group. <span class="citation-title">Hypertension in Diabetes Study III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and ß‐blockade</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">1994</span>;<span class="volume">11</span>(8):773‐82. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7851072" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0058"> <div class="citation-journal">Hypertension in Diabetes Study Group. <span class="citation-title">Hypertension in Diabetes Study IV.  Therapeutic requirements to maintain tight blood pressure control</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1996</span>;<span class="volume">39</span>(12):1554‐61. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8960842" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0059"> <div class="citation-journal">Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR, UK Prospective Diabetes Study Group. <span class="citation-title">Microaneurysms in the development of diabetic retinopathy (UKPDS 42)</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1999</span>;<span class="volume">42</span>(9):1107‐12. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10447523" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Microaneurysms+in+the+development+of+diabetic+retinopathy+(UKPDS+42)&author=EM+Kohner&author=IM+Stratton&author=SJ+Aldington&author=RC+Turner&author=DR+Matthews&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0060"> <div class="citation-journal">Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. <span class="citation-title">UKPDS 50: Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2001</span>;<span class="volume">44</span>(2):156‐63. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11270671" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=UKPDS+50:+Risk+factors+for+incidence+and+progression+of+retinopathy+in+type+II+diabetes+over+6+years+from+diagnosis+&author=IM+Stratton&author=EM+Kohner&author=SJ+Aldington&author=RC+Turner&author=RR+Holman&author=SE+Manley&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0061"> <div class="citation-journal">UK Prospective Diabetes Study (UKPDS) Group. <span class="citation-title">Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">352</span>(9131):837‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9742976" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0062"> <div class="citation-journal">UK Prospective Diabetes Study Group. <span class="citation-title">Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40</span>. <span class="citation"> BMJ </span><span class="pubYear">1998</span>;<span class="volume">317</span>(7160):720‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9732339" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0063"> <div class="citation-journal">UK Prospective Diabetes Study Group. <span class="citation-title">Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39</span>. <span class="citation"> BMJ </span><span class="pubYear">1998</span>;<span class="volume">317</span>(7160):713‐20. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9732338" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0064"> <div class="citation-journal">UK Prospective Diabetes Study Group. <span class="citation-title">Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37)</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1999</span>;<span class="volume">22</span>(7):1125‐36. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10388978" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0065"> <div class="citation-journal">UK Prospective Diabetes Study Group. <span class="citation-title">Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus. UKPDS 69</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2004</span>;<span class="volume">122</span>(11):1631‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15534123" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0066"> <div class="citation-journal">UK Prospective Diabetes Study Group. <span class="citation-title">Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38</span>. <span class="citation"> BMJ </span><span class="pubYear">1998</span>;<span class="volume">317</span>(7160):703‐13. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9732337" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0067"> <div class="citation-journal">UK Prospective Diabetes Study Group. <span class="citation-title">UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1991</span>;<span class="volume">34</span>(12):877‐90. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1778353" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD006127-bbs1-0002"> <h3 class="title">References to studies excluded from this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006127-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0016"> <div class="reference-title-banner"> <h4 class="title">Araki 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0068"> <div class="citation-journal">Araki A, Iimuro S, Sakurai T, Umegaki H, Iijima K, Nakano H, et al. <span class="citation-title">Long‐term multiple risk factor interventions in Japanese elderly diabetic patients: the Japanese Elderly Diabetes Intervention Trial‐study design, baseline characteristics and effects of intervention</span>. <span class="citation"> Geriatrics and Gerontology International </span><span class="pubYear">2012</span>;<span class="volume">12 Suppl 1</span>:7‐17. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22435936" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+multiple+risk+factor+interventions+in+Japanese+elderly+diabetic+patients:+the+Japanese+Elderly+Diabetes+Intervention+Trial%E2%80%90study+design,+baseline+characteristics+and+effects+of+intervention+&author=A+Araki&author=S+Iimuro&author=T+Sakurai&author=H+Umegaki&author=K+Iijima&author=H+Nakano&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0017"> <div class="reference-title-banner"> <h4 class="title">Auyanet 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0069"> <div class="citation-other">Auyanet I, Rodriguez LJ, Esparza N, Cabrera F, Rossique P, Suria S, et al. <span class="citation-title">Does carvedilol minimize the requirements for laser photocoagulation in diabetic retinopathy?</span> [Minimiza el carvedilol los requerimientos de fotocoagulacion laser en la retinopatia diabetica?]. Nefrologia<span class="pubYear">2010</span>; Vol. 30, issue 4:473‐4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Does+carvedilol+minimize+the+requirements+for+laser+photocoagulation+in+diabetic+retinopathy?&author=I+Auyanet&author=LJ+Rodriguez&author=N+Esparza&author=F+Cabrera&author=P+Rossique&author=S+Suria&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0018"> <div class="reference-title-banner"> <h4 class="title">CALM‐II {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0070"> <div class="citation-journal">Andersen NH, Knudsen ST, Poulsen PL, Poulsen SH, Helleberg K, Eiskjaer H, et al. <span class="citation-title">Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design</span>. <span class="citation"> Journal of the Renin‐Angiotensin‐Aldosterone System </span><span class="pubYear">2003</span>;<span class="volume">4</span>(2):96‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12806591" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dual+blockade+with+candesartan+cilexetil+and+lisinopril+in+hypertensive+patients+with+diabetes+mellitus:+rationale+and+design+&author=NH+Andersen&author=ST+Knudsen&author=PL+Poulsen&author=SH+Poulsen&author=K+Helleberg&author=H+Eiskjaer&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0071"> <div class="citation-journal">Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW, et al. <span class="citation-title">Long‐term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2005</span>;<span class="volume">28</span>(2):273‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15677778" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+dual+blockade+with+candesartan+and+lisinopril+in+hypertensive+patients+with+diabetes:+the+CALM+II+study+&author=NH+Andersen&author=PL+Poulsen&author=ST+Knudsen&author=SH+Poulsen&author=H+Eiskjaer&author=KW+Hansen&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0019"> <div class="reference-title-banner"> <h4 class="title">Chang 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0072"> <div class="citation-journal">Chang CH, Chuang LM. <span class="citation-title">Effects of medical therapies on retinopathy progression in type 2 diabetes: Is blood pressure control the lower the better?</span>. <span class="citation"> Journal of Diabetes Investigation </span><span class="pubYear">2011</span>;<span class="volume">2</span>(2):101‐3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24843468" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+medical+therapies+on+retinopathy+progression+in+type+2+diabetes:+Is+blood+pressure+control+the+lower+the+better?+&author=CH+Chang&author=LM+Chuang&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0020"> <div class="reference-title-banner"> <h4 class="title">DCCT {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0073"> <div class="citation-journal">Genuth S, Lipps J, Lorenzi G, Nathan DM, Davis MD, Lachin JM, et al. <span class="citation-title">Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus</span>. <span class="citation"> JAMA </span><span class="pubYear">2002</span>;<span class="volume">287</span>(19):2563‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12020338" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+therapy+on+the+microvascular+complications+of+type+1+diabetes+mellitus+&author=S+Genuth&author=J+Lipps&author=G+Lorenzi&author=DM+Nathan&author=MD+Davis&author=JM+Lachin&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0074"> <div class="citation-journal">The Diabetes Control and Complications Trial Research Group. <span class="citation-title">Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">1995</span>;<span class="volume">75</span>(14):894‐903. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7732997" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0075"> <div class="citation-journal">The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. <span class="citation-title">Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long‐term follow‐up of the Diabetes Control and Complications Trial cohort</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1999</span>;<span class="volume">22</span>(1):99‐111. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10333910" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0021"> <div class="reference-title-banner"> <h4 class="title">Durruty 2000 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0076"> <div class="citation-journal">Durruty P, Carpentier C, Krause P, Garcia de los Rios M. <span class="citation-title">Evaluation of retinal involvement in type 2 diabetics with microalbuminuria</span> [Evaluacion del compromiseo retinal en diabeticos tipo 2 microalbuminuricos]. <span class="citation"> Revista Medica de Chile </span><span class="pubYear">2000</span>;<span class="volume">128</span>(10):1085‐92. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11349506" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Evaluation+of+retinal+involvement+in+type+2+diabetics+with+microalbuminuria&author=P+Durruty&author=C+Carpentier&author=P+Krause&author=M+GarciadelosRios&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0022"> <div class="reference-title-banner"> <h4 class="title">Faguer de Moustier 1989 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0077"> <div class="citation-journal">Faguer de Moustier B, Paoli V, Tchobroutsky G. <span class="citation-title">Metabolic controlled trial of nicardipine in type 2 diabetic patients with slight hypertension</span>. <span class="citation"> Current Therapeutic Research, Clinical and Experimental </span><span class="pubYear">1989</span>;<span class="volume">45</span>(4):690‐704. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Metabolic+controlled+trial+of+nicardipine+in+type+2+diabetic+patients+with+slight+hypertension+&author=B+FaguerdeMoustier&author=V+Paoli&author=G+Tchobroutsky&publication_year=1989&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0023"> <div class="reference-title-banner"> <h4 class="title">Harrold 1969 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0078"> <div class="citation-journal">Harrold BP, Marmion VJ, Gough KR. <span class="citation-title">A double‐blind controlled trial of clofibrate in the treatment of diabetic retinopathy</span>. <span class="citation"> Diabetes </span><span class="pubYear">1969</span>;<span class="volume">18</span>(5):285‐91. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/4894161" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+double%E2%80%90blind+controlled+trial+of+clofibrate+in+the+treatment+of+diabetic+retinopathy&author=BP+Harrold&author=VJ+Marmion&author=KR+Gough&publication_year=1969&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0024"> <div class="reference-title-banner"> <h4 class="title">Jackson 1992 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0079"> <div class="citation-journal">Jackson WE, Holmes DL, Garg SK, Harris S, Chase HP. <span class="citation-title">Angiotensin‐converting enzyme inhibitor therapy and diabetic retinopathy</span>. <span class="citation"> Annals of Ophthalmology </span><span class="pubYear">1992</span>;<span class="volume">24</span>(3):99‐103. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1570931" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Angiotensin%E2%80%90converting+enzyme+inhibitor+therapy+and+diabetic+retinopathy&author=WE+Jackson&author=DL+Holmes&author=SK+Garg&author=S+Harris&author=HP+Chase&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0025"> <div class="reference-title-banner"> <h4 class="title">JDCS 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0080"> <div class="citation-journal">Kawasaki R, Tanaka S, Tanaka S, Yamamoto T, Sone H, Ohashi Y, et al. <span class="citation-title">Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow‐up study of the Japan Diabetes Complications Study (JDCS)</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2011</span>;<span class="volume">54</span>(9):2288‐94. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21630126" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Incidence+and+progression+of+diabetic+retinopathy+in+Japanese+adults+with+type+2+diabetes:+8+year+follow%E2%80%90up+study+of+the+Japan+Diabetes+Complications+Study+(JDCS)+&author=R+Kawasaki&author=S+Tanaka&author=S+Tanaka&author=T+Yamamoto&author=H+Sone&author=Y+Ohashi&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0081"> <div class="citation-journal">Sone H, Tanaka S, Iimuro S, Tanaka S, Oida K, Yamasaki Y, et al. <span class="citation-title">Long‐term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study)</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2010</span>;<span class="volume">53</span>(3):419‐28. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20054522" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+lifestyle+intervention+lowers+the+incidence+of+stroke+in+Japanese+patients+with+type+2+diabetes:+a+nationwide+multicentre+randomised+controlled+trial+(the+Japan+Diabetes+Complications+Study)+&author=H+Sone&author=S+Tanaka&author=S+Iimuro&author=S+Tanaka&author=K+Oida&author=Y+Yamasaki&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0026"> <div class="reference-title-banner"> <h4 class="title">Larsen 1990 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0082"> <div class="citation-journal">Larsen M, Hommel E, Parving HH, Lund‐Andersen H. <span class="citation-title">Protective effect of captopril on the blood‐retina barrier in normotensive insulin‐dependent diabetic patients with nephropathy and background retinopathy</span>. <span class="citation"> Graefe's Archive of Clinical and Experimental Ophthalmology </span><span class="pubYear">1990</span>;<span class="volume">228</span>(6):505‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Protective+effect+of+captopril+on+the+blood%E2%80%90retina+barrier+in+normotensive+insulin%E2%80%90dependent+diabetic+patients+with+nephropathy+and+background+retinopathy+&author=M+Larsen&author=E+Hommel&author=HH+Parving&author=H+Lund%E2%80%90Andersen&publication_year=1990&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0027"> <div class="reference-title-banner"> <h4 class="title">Lehsten 1996 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0083"> <div class="citation-journal">Lehsten K, Becker B, Michaelis D, Eggert HJ, Rjasanowski I, Salzsieder E. <span class="citation-title">On the prospective significance of age at onset of diabetes, metabolic control, and hypertension for the development of diabetic retinopathy in patients with IDDM</span>. <span class="citation"> Diabetes und Stoffwechsel </span><span class="pubYear">1996</span>;<span class="volume">5</span>(1):18‐25. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=On+the+prospective+significance+of+age+at+onset+of+diabetes,+metabolic+control,+and+hypertension+for+the+development+of+diabetic+retinopathy+in+patients+with+IDDM+&author=K+Lehsten&author=B+Becker&author=D+Michaelis&author=HJ+Eggert&author=I+Rjasanowski&author=E+Salzsieder&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0028"> <div class="reference-title-banner"> <h4 class="title">Malik 1998 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0084"> <div class="citation-journal">Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, et al. <span class="citation-title">Effect of angiotensin‐converting‐enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double‐blind controlled trial</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">352</span>(9145):1978‐81. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9872248" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+angiotensin%E2%80%90converting%E2%80%90enzyme+(ACE)+inhibitor+trandolapril+on+human+diabetic+neuropathy:%C2%A0randomised+double%E2%80%90blind+controlled+trial+&author=RA+Malik&author=S+Williamson&author=C+Abbott&author=AL+Carrington&author=J+Iqbal&author=W+Schady&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0029"> <div class="reference-title-banner"> <h4 class="title">MCSG 1995 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0085"> <div class="citation-journal">Microalbuminuria Collaborative Study Group. <span class="citation-title">Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria</span>. <span class="citation"> BMJ </span><span class="pubYear">1995</span>;<span class="volume">311</span>(7011):973‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7580637" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0030"> <div class="reference-title-banner"> <h4 class="title">Mehlsen 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0086"> <div class="citation-journal">Mehlsen J, Jeppesen P, Erlandsen M, Poulsen PL, Bek T. <span class="citation-title">Lack of effect of short‐term treatment with amlodipine and lisinopril on retinal autoregulation in normotensive patients with type 1 diabetes and mild diabetic retinopathy</span>. <span class="citation"> Acta Ophthalmologica </span><span class="pubYear">2011</span>;<span class="volume">89</span>(8):764‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20346089" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Lack+of+effect+of+short%E2%80%90term+treatment+with+amlodipine+and+lisinopril+on+retinal+autoregulation+in+normotensive+patients+with+type+1+diabetes+and+mild+diabetic+retinopathy+&author=J+Mehlsen&author=P+Jeppesen&author=M+Erlandsen&author=PL+Poulsen&author=T+Bek&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0031"> <div class="reference-title-banner"> <h4 class="title">Newsom 1991 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0087"> <div class="citation-journal">Newsom RS, Rassam SM, Kohner EM. <span class="citation-title">The effect of beta blockers on retinal blood flow in diabetic patients</span>. <span class="citation"> European Journal of Ophthalmology </span><span class="pubYear">1991</span>;<span class="volume">1</span>(3):131‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1841669" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+beta+blockers+on+retinal+blood+flow+in+diabetic+patients&author=RS+Newsom&author=SM+Rassam&author=EM+Kohner&publication_year=1991&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0032"> <div class="reference-title-banner"> <h4 class="title">Patel 1998 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0088"> <div class="citation-journal">Patel V, Rassam SM, Chen HC, Jones M, Kohner EM. <span class="citation-title">Effect of angiotensin‐converting enzyme inhibition with perindopril and beta‐blockade with atenolol on retinal blood flow in hypertensive diabetic subjects</span>. <span class="citation"> Metabolism: Clinical and Experimental </span><span class="pubYear">1998</span>;<span class="volume">47</span>(12 Suppl 1):28‐33. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9867068" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+angiotensin%E2%80%90converting+enzyme+inhibition+with+perindopril+and+beta%E2%80%90blockade+with+atenolol+on+retinal+blood+flow+in+hypertensive+diabetic+subjects+&author=V+Patel&author=SM+Rassam&author=HC+Chen&author=M+Jones&author=EM+Kohner&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0033"> <div class="reference-title-banner"> <h4 class="title">Porush 2000 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0089"> <div class="citation-journal">Porush JG. <span class="citation-title">The benefits of angiotensin II receptor antagonists in high‐risk hypertensive patients with diabetes</span>. <span class="citation"> European Heart Journal Supplements </span><span class="pubYear">2000</span>;<span class="volume">2</span>(B):B22‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+benefits+of+angiotensin+II+receptor+antagonists+in+high%E2%80%90risk+hypertensive+patients+with+diabetes+&author=JG+Porush&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0034"> <div class="reference-title-banner"> <h4 class="title">Rachmani 2000 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0090"> <div class="citation-journal">Rachmani R, Lidar M, Levy Z, Ravid M. <span class="citation-title">Effect of enalapril on the incidence of retinopathy in normotensive patients with type 2 diabetes</span>. <span class="citation"> European Journal of Internal Medicine </span><span class="pubYear">2000</span>;<span class="volume">11</span>(1):48‐50. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+enalapril+on+the+incidence+of+retinopathy+in+normotensive+patients+with+type+2+diabetes+&author=R+Rachmani&author=M+Lidar&author=Z+Levy&author=M+Ravid&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0035"> <div class="reference-title-banner"> <h4 class="title">Rachmani 2002 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0091"> <div class="citation-journal">Rachmani R, Levi Z, Slavachevski I, Avin M, Ravid M. <span class="citation-title">Teaching patients to monitor their risk factors retards the progression of vascular complications in high‐risk patients with type 2 diabetes mellitus‐a randomized prospective study</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2002</span>;<span class="volume">19</span>(5):385‐92. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12027926" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Teaching+patients+to+monitor+their+risk+factors+retards+the+progression+of+vascular+complications+in+high%E2%80%90risk+patients+with+type+2+diabetes+mellitus%E2%80%90a+randomized+prospective+study+&author=R+Rachmani&author=Z+Levi&author=I+Slavachevski&author=M+Avin&author=M+Ravid&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0036"> <div class="reference-title-banner"> <h4 class="title">Rassam 1997 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0092"> <div class="citation-other">Rassam SMB, Patel VJ, Kohner E. <span class="citation-title">Effect of ACE‐inhibitors on retinopathy score and retinal hemodynamics in normotensive diabetic subjects</span>. American Academy of Ophthalmology. <span class="pubYear">1997</span>:207. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+ACE%E2%80%90inhibitors+on+retinopathy+score+and+retinal+hemodynamics+in+normotensive+diabetic+subjects+&author=SMB+Rassam&author=VJ+Patel&author=E+Kohner&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0037"> <div class="reference-title-banner"> <h4 class="title">Schwartz 1998 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0093"> <div class="citation-journal">Schwartz MM, Lewis EJ, Leonard‐Martin T, Lewis JB, Batlle D, The Collaborative Study Group. <span class="citation-title">Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy</span>. <span class="citation"> Nephrology Dialysis Transplantation </span><span class="pubYear">1998</span>;<span class="volume">13</span>(10):2547‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Renal+pathology+patterns+in+type+II+diabetes+mellitus:+relationship+with+retinopathy&author=MM+Schwartz&author=EJ+Lewis&author=T+Leonard%E2%80%90Martin&author=JB+Lewis&author=D+Batlle&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD006127-bbs2-0038"> <div class="reference-title-banner"> <h4 class="title">Wang 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0094"> <div class="citation-journal">Wang N, Zheng Z, Jin HY, Xu X. <span class="citation-title">Treatment effects of captopril on non‐proliferative diabetic retinopathy</span>. <span class="citation"> Chinese Medical Journal </span><span class="pubYear">2012</span>;<span class="volume">125</span>(2):287‐92. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22340561" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Treatment+effects+of+captopril+on+non%E2%80%90proliferative+diabetic+retinopathy&author=N+Wang&author=Z+Zheng&author=HY+Jin&author=X+Xu&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD006127-bbs1-0003"> <h3 class="title">References to studies awaiting assessment</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006127-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD006127-bbs2-0039"> <div class="reference-title-banner"> <h4 class="title">ABCD‐2V {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0095"> <div class="citation-journal">Bedigian M. <span class="citation-title">Improving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor block (ARB) therapy</span>. <span class="citation"> Journal of the Renin‐Angiotensin‐Aldosterone System </span><span class="pubYear">2000</span>;<span class="volume">1</span>(Suppl 2):25‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improving+the+prognosis+of+diabetic+patients:+evaluating+the+role+of+intensive+versus+moderate+blood+pressure+control+with+selective+angiotensin+II+receptor+block+(ARB)+therapy+&author=M+Bedigian&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0096"> <div class="citation-journal">Bedigian MP, Estacio RO, Jefferes BW, Biggerstaff S, Schrier RW. <span class="citation-title">Baseline characteristics of the hypertensive cohort of the appropriate blood pressure control in diabetes trial ‐ part 2 with valsartan (ABCD‐2V)</span>. <span class="citation"> American Journal of Hypertension </span><span class="pubYear">2000</span>;<span class="volume">13</span>(4 Pt 2):56A‐7A. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Baseline+characteristics+of+the+hypertensive+cohort+of+the+appropriate+blood+pressure+control+in+diabetes+trial+%E2%80%90+part+2+with+valsartan+(ABCD%E2%80%902V)+&author=MP+Bedigian&author=RO+Estacio&author=BW+Jefferes&author=S+Biggerstaff&author=RW+Schrier&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0097"> <div class="citation-journal">Estacio RO, Coll JR, Tran ZV, Schrier RW. <span class="citation-title">Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes</span>. <span class="citation"> American Journal of Hypertension </span><span class="pubYear">2006</span>;<span class="volume">19</span>(12):1241‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17161769" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+intensive+blood+pressure+control+with+valsartan+on+urinary+albumin+excretion+in+normotensive+patients+with+type+2+diabetes+&author=RO+Estacio&author=JR+Coll&author=ZV+Tran&author=RW+Schrier&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD006127-bib-0098"> <div class="citation-journal">Shrier RW, Estacio RO, Jeffers BW, Biggerstaff S, Krinsk E, Pincus JR, et al. <span class="citation-title">ABCD‐2V: Appropriate blood pressure control in diabetes ‐ part 2 with valsartan</span>. <span class="citation"> American Journal of Hypertention </span><span class="pubYear">1999</span>;<span class="volume">12</span>(4 Pt 2):141A. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=ABCD%E2%80%902V:+Appropriate+blood+pressure+control+in+diabetes+%E2%80%90+part+2+with+valsartan&author=RW+Shrier&author=RO+Estacio&author=BW+Jeffers&author=S+Biggerstaff&author=E+Krinsk&author=JR+Pincus&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD006127-bbs2-0040"> <div class="reference-title-banner"> <h4 class="title">ADDITION 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0099"> <div class="citation-journal">Sandbæk A, Griffin SJ, Sharp SJ, Simmons RK, Borch‐Johnsen K, Rutten GE, et al. <span class="citation-title">Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen‐detected diabetes: a randomized controlled trial: The ADDITION‐Europe Study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(7):2015‐23. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24784827" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+early+multifactorial+therapy+compared+with+routine+care+on+microvascular+outcomes+at+5+years+in+people+with+screen%E2%80%90detected+diabetes:+a+randomized+controlled+trial:+The+ADDITION%E2%80%90Europe+Study+&author=A+Sandb%C3%A6k&author=SJ+Griffin&author=SJ+Sharp&author=RK+Simmons&author=K+Borch%E2%80%90Johnsen&author=GE+Rutten&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD006127-bbs2-0041"> <div class="reference-title-banner"> <h4 class="title">ROADMAP {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0100"> <div class="citation-journal">Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, et al. <span class="citation-title">Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study</span>. <span class="citation"> Journal of Hypertension </span><span class="pubYear">2006</span>;<span class="volume">24</span>(2):403‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16508590" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Preventing+microalbuminuria+in+patients+with+diabetes:+rationale+and+design+of+the+Randomised+Olmesartan+and+Diabetes+Microalbuminuria+Prevention+(ROADMAP)+study+&author=H+Haller&author=GC+Viberti&author=A+Mimran&author=G+Remuzzi&author=AJ+Rabelink&author=E+Ritz&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD006127-bbs1-0004"> <h3 class="title">References to ongoing studies</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006127-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006127-bbs2-0042"> <div class="reference-title-banner"> <h4 class="title">AdDIT {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0101"> <div class="citation-journal">AdDIT Research Group. <span class="citation-title">Adolescent type 1 diabetes cardio‐renal intervention trial (AdDIT)</span>. <span class="citation"> BMC Pediatrics </span><span class="pubYear">2009</span>;<span class="volume">9</span>:79. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20017932" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006127-bbs2-0043"> <div class="reference-title-banner"> <h4 class="title">NCT00134160 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0102"> <div class="citation-other">NCT00134160. <span class="citation-title">The study comparing the incidence of cardiovascular events between high‐dose ARB monotherapy and combination therapy with ARB and calcium channel blocker in Japanese elderly hypertensive patients at high cardiovascular risk</span>. clinicaltrials.gov/ct2/show/NCT00134160 (accessed 30 July 2013). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD006127-bbs2-0044"> <div class="reference-title-banner"> <h4 class="title">NCT00300976 {published data only} </h4> </div> <div class="bibliography-section" id="CD006127-bib-0103"> <div class="citation-other">NCT00300976. <span class="citation-title">A randomized controlled study of the intensive therapy and the conventional therapy for the suppression of the vascular complications in the type 2 diabetic patients</span>. clinicaltrials.gov/ct2/show/NCT00300976 (accessed 30 July 2013). <ul class="citation-link-group"> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD006127-bbs1-0005"> <h3 class="title">Additional references</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006127-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0045"> <div class="reference-title-banner"> <h4 class="title">ADA 1998</h4> </div> <div class="bibliography-section" id="CD006127-bib-0104"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Diabetic retinopathy</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1998</span>;<span class="volume">21</span>(1):157‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9538987" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0046"> <div class="reference-title-banner"> <h4 class="title">Buch 2004</h4> </div> <div class="bibliography-section" id="CD006127-bib-0105"> <div class="citation-journal">Buch H. <span class="citation-title">Prevalence and causes of visual impairment and blindness among Scandinavian adults: the Copenhagen City Eye Study</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2004</span>;<span class="volume">111</span>(1):53‐61. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/14711714" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevalence+and+causes+of+visual+impairment+and+blindness+among+Scandinavian+adults:+the+Copenhagen+City+Eye+Study+&author=H+Buch&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0047"> <div class="reference-title-banner"> <h4 class="title">CDC 2011</h4> </div> <div class="bibliography-section" id="CD006127-bib-0106"> <div class="citation-other">Centers for Disease Control and Prevention. <span class="citation-title">National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011</span>. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0048"> <div class="reference-title-banner"> <h4 class="title">Chew 1996</h4> </div> <div class="bibliography-section" id="CD006127-bib-0107"> <div class="citation-journal">Chew E. <span class="citation-title">Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">1996</span>;<span class="volume">114</span>(9):1079‐84. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8790092" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Association+of+elevated+serum+lipid+levels+with+retinal+hard+exudates+in+diabetic+retinopathy.+Early+Treatment+Diabetic+Retinopathy+Study+(ETDRS)+Report+22+&author=E+Chew&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0049"> <div class="reference-title-banner"> <h4 class="title">Cushman 2007</h4> </div> <div class="bibliography-section" id="CD006127-bib-0108"> <div class="citation-journal">Cushman WC, Grimm RH, Cutler JA, Evans GW, Capes S, Corson MA, et al. <span class="citation-title">Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2007</span>;<span class="volume">99</span>(12A):44i‐55i. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17599425" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Rationale+and+design+for+the+blood+pressure+intervention+of+the+Action+to+Control+Cardiovascular+Risk+in+Diabetes+(ACCORD)+trial+&author=WC+Cushman&author=RH+Grimm&author=JA+Cutler&author=GW+Evans&author=S+Capes&author=MA+Corson&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0050"> <div class="reference-title-banner"> <h4 class="title">DCCT 1993</h4> </div> <div class="bibliography-section" id="CD006127-bib-0109"> <div class="citation-journal">The Diabetes Control and Complications Trial Research Group. <span class="citation-title">The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">1993</span>;<span class="volume">329</span>(14):977‐86. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8366922" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0051"> <div class="reference-title-banner"> <h4 class="title">Desai 2001</h4> </div> <div class="bibliography-section" id="CD006127-bib-0110"> <div class="citation-journal">Desai M, Pratt LA, Lentzner H, Robinson KN. <span class="citation-title">Trends in vision and hearing among older Americans</span>. <span class="citation"> Aging Trends </span><span class="pubYear">2001</span>, (2):1‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11894223" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Trends+in+vision+and+hearing+among+older+Americans&author=M+Desai&author=LA+Pratt&author=H+Lentzner&author=KN+Robinson&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0052"> <div class="reference-title-banner"> <h4 class="title">DRCR.net 2010</h4> </div> <div class="bibliography-section" id="CD006127-bib-0111"> <div class="citation-journal">Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Diabetic Retinopathy Clinical Research Network. <span class="citation-title">Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">117</span>(6):1064‐77. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20427088" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Randomized+trial+evaluating+ranibizumab+plus+prompt+or+deferred+laser+or+triamcinolone+plus+prompt+laser+for+diabetic+macular+edema+&author=MJ+Elman&author=LP+Aiello&author=RW+Beck&author=NM+Bressler&author=SB+Bressler&author=AR+Edwards&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0053"> <div class="reference-title-banner"> <h4 class="title">DRS10 1985</h4> </div> <div class="bibliography-section" id="CD006127-bib-0112"> <div class="citation-journal">Rand LI, Prud'homme GJ, Ederer F, Canner PL. <span class="citation-title">Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) report number 10</span>. <span class="citation"> Investigative Ophthalmology and Visual Science </span><span class="pubYear">1985</span>;<span class="volume">26</span>(7):983‐91. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2409053" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Factors+influencing+the+development+of+visual+loss+in+advanced+diabetic+retinopathy.+Diabetic+Retinopathy+Study+(DRS)+report+number+10+&author=LI+Rand&author=GJ+Prud'homme&author=F+Ederer&author=PL+Canner&publication_year=1985&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0054"> <div class="reference-title-banner"> <h4 class="title">DRS2 1978</h4> </div> <div class="bibliography-section" id="CD006127-bib-0113"> <div class="citation-journal">The Diabetes Retinopathy Study Research Group. <span class="citation-title">Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1978</span>;<span class="volume">85</span>(1):82‐106. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/345173" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0055"> <div class="reference-title-banner"> <h4 class="title">DRS5 1981</h4> </div> <div class="bibliography-section" id="CD006127-bib-0114"> <div class="citation-journal">The Diabetic Retinopathy Study Research Group. <span class="citation-title">Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic Retinopathy Study report number 5</span>. <span class="citation"> Developments in Ophthalmology </span><span class="pubYear">1981</span>;<span class="volume">2</span>:248‐56. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7262408" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0056"> <div class="reference-title-banner"> <h4 class="title">DRS8 1981</h4> </div> <div class="bibliography-section" id="CD006127-bib-0115"> <div class="citation-journal">The Diabetic Retinopathy Study Research Group. <span class="citation-title">Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings. DRS report number 8</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1981</span>;<span class="volume">88</span>(7):583‐600. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7196564" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0057"> <div class="reference-title-banner"> <h4 class="title">EDPRG 2004a</h4> </div> <div class="bibliography-section" id="CD006127-bib-0116"> <div class="citation-journal">The Eye Diseases Prevalence Research Group. <span class="citation-title">Causes and prevalence of visual impairment among adults in the United States</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2004</span>;<span class="volume">122</span>(4):477‐85. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15078664" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0058"> <div class="reference-title-banner"> <h4 class="title">EDPRG 2004b</h4> </div> <div class="bibliography-section" id="CD006127-bib-0117"> <div class="citation-journal">The Eye Diseases Prevalence Research Group. <span class="citation-title">The prevalence of diabetic retinopathy among adults in the United States</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2004</span>;<span class="volume">122</span>(4):552‐63. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15078674" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0059"> <div class="reference-title-banner"> <h4 class="title">EDPRG 2004c</h4> </div> <div class="bibliography-section" id="CD006127-bib-0118"> <div class="citation-journal">The Eye Diseases Prevalence Research Group. <span class="citation-title">The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2004</span>;<span class="volume">122</span>(4):546‐51. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15078673" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0060"> <div class="reference-title-banner"> <h4 class="title">ETDRS1 1985</h4> </div> <div class="bibliography-section" id="CD006127-bib-0119"> <div class="citation-journal">Early Treatment Diabetic Retinopathy Study Research Group. <span class="citation-title">Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">1985</span>;<span class="volume">103</span>(12):1796‐806. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2866759" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0061"> <div class="reference-title-banner"> <h4 class="title">ETDRS10 1991</h4> </div> <div class="bibliography-section" id="CD006127-bib-0120"> <div class="citation-journal">Early Treatment Diabetic Retinopathy Study Research Group. <span class="citation-title">Grading diabetic retinopathy from stereoscopic color fundus photographs‐‐an extension of the modified Airlie House classification. ETDRS report number 10</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1991</span>;<span class="volume">98</span>(5 Suppl):786‐806. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2062513" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0062"> <div class="reference-title-banner"> <h4 class="title">ETDRS12 1991</h4> </div> <div class="bibliography-section" id="CD006127-bib-0121"> <div class="citation-journal">Early Treatment Diabetic Retinopathy Study Research Group. <span class="citation-title">Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1991</span>;<span class="volume">98</span>(5 Suppl):823‐33. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2062515" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0063"> <div class="reference-title-banner"> <h4 class="title">ETDRS18 1998</h4> </div> <div class="bibliography-section" id="CD006127-bib-0122"> <div class="citation-journal">Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, et al. <span class="citation-title">Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report number 18</span>. <span class="citation"> Investigative Ophthalmology and Visual Science </span><span class="pubYear">1998</span>;<span class="volume">39</span>(2):233‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9477980" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+factors+for+high%E2%80%90risk+proliferative+diabetic+retinopathy+and+severe+visual+loss:+Early+Treatment+Diabetic+Retinopathy+Study+report+number+18+&author=MD+Davis&author=MR+Fisher&author=RE+Gangnon&author=F+Barton&author=LM+Aiello&author=EY+Chew&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0064"> <div class="reference-title-banner"> <h4 class="title">ETDRS9 1991</h4> </div> <div class="bibliography-section" id="CD006127-bib-0123"> <div class="citation-journal">Early Treatment Diabetic Retinopathy Study Research Group. <span class="citation-title">Early photocoagulation for diabetic retinopathy. ETDRS report number 9</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1991</span>;<span class="volume">98</span>(5 Suppl):766‐85. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2062512" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0065"> <div class="reference-title-banner"> <h4 class="title">Ferris 1993</h4> </div> <div class="bibliography-section" id="CD006127-bib-0124"> <div class="citation-journal">Ferris FL. <span class="citation-title">How effective are treatments for diabetic retinopathy?</span>. <span class="citation"> JAMA </span><span class="pubYear">1993</span>;<span class="volume">269</span>(10):1290‐1. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8437309" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=How+effective+are+treatments+for+diabetic+retinopathy?&author=FL+Ferris&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0066"> <div class="reference-title-banner"> <h4 class="title">Fong 2004</h4> </div> <div class="bibliography-section" id="CD006127-bib-0125"> <div class="citation-journal">Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. <span class="citation-title">Retinopathy in diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2004</span>;<span class="volume">27</span>(Suppl 1):S84‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/14693935" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Retinopathy+in+diabetes&author=DS+Fong&author=L+Aiello&author=TW+Gardner&author=GL+King&author=G+Blankenship&author=JD+Cavallerano&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0067"> <div class="reference-title-banner"> <h4 class="title">Frank 2004</h4> </div> <div class="bibliography-section" id="CD006127-bib-0126"> <div class="citation-journal">Frank RN. <span class="citation-title">Medical progress: diabetic retinopathy</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">2004</span>;<span class="volume">350</span>(1):48‐58. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/14702427" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Medical+progress:+diabetic+retinopathy&author=RN+Frank&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0068"> <div class="reference-title-banner"> <h4 class="title">Gillow 1999</h4> </div> <div class="bibliography-section" id="CD006127-bib-0127"> <div class="citation-journal">Gillow JT, Gibson JM, Dodson PM. <span class="citation-title">Hypertension and diabetic retinopathy‐‐what's the story?</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">1999</span>;<span class="volume">83</span>(9):1083‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10460781" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Hypertension+and+diabetic+retinopathy%E2%80%90%E2%80%90what's+the+story?&author=JT+Gillow&author=JM+Gibson&author=PM+Dodson&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0069"> <div class="reference-title-banner"> <h4 class="title">Giuffre 2004</h4> </div> <div class="bibliography-section" id="CD006127-bib-0128"> <div class="citation-journal">Giuffre G, Lodato G, Dardanoni G. <span class="citation-title">Prevalence and risk factors of diabetic retinopathy in adult and elderly subjects: The Castedaccia Eye Study</span>. <span class="citation"> Graefe's Archives of Clinical and Experimental Ophthalmology </span><span class="pubYear">2004</span>;<span class="volume">242</span>(7):535‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevalence+and+risk+factors+of+diabetic+retinopathy+in+adult+and+elderly+subjects:+The+Castedaccia+Eye+Study+&author=G+Giuffre&author=G+Lodato&author=G+Dardanoni&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0070"> <div class="reference-title-banner"> <h4 class="title">Glanville 2006</h4> </div> <div class="bibliography-section" id="CD006127-bib-0129"> <div class="citation-journal">Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. <span class="citation-title">How to identify randomized controlled trials in MEDLINE: ten years on</span>. <span class="citation"> Journal of the Medical Library Association </span><span class="pubYear">2006</span>;<span class="volume">94</span>(2):130‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16636704" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=How+to+identify+randomized+controlled+trials+in+MEDLINE:+ten+years+on&author=JM+Glanville&author=C+Lefebvre&author=JN+Miles&author=J+Camosso%E2%80%90Stefinovic&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0071"> <div class="reference-title-banner"> <h4 class="title">Grey 1989</h4> </div> <div class="bibliography-section" id="CD006127-bib-0130"> <div class="citation-journal">Grey RHB. <span class="citation-title">Blind and partial sight registration in Avon</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">1989</span>;<span class="volume">73</span>(2):88‐94. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2930763" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Blind+and+partial+sight+registration+in+Avon&author=RHB+Grey&publication_year=1989&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0072"> <div class="reference-title-banner"> <h4 class="title">Hansson 1998</h4> </div> <div class="bibliography-section" id="CD006127-bib-0131"> <div class="citation-journal">Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. <span class="citation-title">Effects of intensive blood‐pressure lowering and low‐dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">351</span>(9118):1755‐62. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9635947" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+intensive+blood%E2%80%90pressure+lowering+and+low%E2%80%90dose+aspirin+in+patients+with+hypertension:+principal+results+of+the+Hypertension+Optimal+Treatment+(HOT)+randomised+trial.+HOT+Study+Group+&author=L+Hansson&author=A+Zanchetti&author=SG+Carruthers&author=B+Dahlof&author=D+Elmfeldt&author=S+Julius&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0073"> <div class="reference-title-banner"> <h4 class="title">Harris 1998</h4> </div> <div class="bibliography-section" id="CD006127-bib-0132"> <div class="citation-journal">Harris MI, Klein R, Cowie CC, Rowland M, Byrd‐Holt DD. <span class="citation-title">Is the risk of diabetic retinopathy greater in non‐Hispanic blacks and Mexican Americans than in non‐Hispanic whites with type‐2 diabetes? A US population study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1998</span>;<span class="volume">21</span>(8):1230‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9702425" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Is+the+risk+of+diabetic+retinopathy+greater+in+non%E2%80%90Hispanic+blacks+and+Mexican+Americans+than+in+non%E2%80%90Hispanic+whites+with+type%E2%80%902+diabetes?+A+US+population+study+&author=MI+Harris&author=R+Klein&author=CC+Cowie&author=M+Rowland&author=DD+Byrd%E2%80%90Holt&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0074"> <div class="reference-title-banner"> <h4 class="title">Hayward 2002</h4> </div> <div class="bibliography-section" id="CD006127-bib-0133"> <div class="citation-journal">Hayward LM. <span class="citation-title">What is the prevalence of visual impairment in the general and diabetic populations: are there ethnic and gender differences?</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2002</span>;<span class="volume">19</span>(1):27‐34. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11869300" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=What+is+the+prevalence+of+visual+impairment+in+the+general+and+diabetic+populations:+are+there+ethnic+and+gender+differences?+&author=LM+Hayward&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0075"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011</h4> </div> <div class="bibliography-section" id="CD006127-bib-0134"> <div class="citation-other">Higgins JPT, Altman DG (editors). <span class="citation-title">Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</span>. Available from www.cochrane‐handbook.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0076"> <div class="reference-title-banner"> <h4 class="title">HOPESI 2000</h4> </div> <div class="bibliography-section" id="CD006127-bib-0135"> <div class="citation-journal">Heart Outcomes Prevention Evaluation Study Investigators. <span class="citation-title">Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO‐HOPE sub‐study</span>. <span class="citation"> Lancet </span><span class="pubYear">2000</span>;<span class="volume">355</span>(9200):253‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10675071" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0077"> <div class="reference-title-banner"> <h4 class="title">Keen 2001</h4> </div> <div class="bibliography-section" id="CD006127-bib-0136"> <div class="citation-journal">Keen H. <span class="citation-title">The appearance of retinopathy and progression to proliferative retinopathy: the WHO multinational study of vascular disease in diabetes</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2001</span>;<span class="volume">44</span>(Suppl 2):S22‐30. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11587046" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+appearance+of+retinopathy+and+progression+to+proliferative+retinopathy:+the+WHO+multinational+study+of+vascular+disease+in+diabetes+&author=H+Keen&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0078"> <div class="reference-title-banner"> <h4 class="title">Klein 1984a</h4> </div> <div class="bibliography-section" id="CD006127-bib-0137"> <div class="citation-journal">Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. <span class="citation-title">The Wisconsin Epidemiologic Study of Diabetic Retinopathy II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">1984</span>;<span class="volume">102</span>(4):520‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/6367724" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Wisconsin+Epidemiologic+Study+of+Diabetic+Retinopathy+II.+Prevalence+and+risk+of+diabetic+retinopathy+when+age+at+diagnosis+is+less+than+30+years+&author=R+Klein&author=BE+Klein&author=SE+Moss&author=MD+Davis&author=DL+DeMets&publication_year=1984&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0079"> <div class="reference-title-banner"> <h4 class="title">Klein 1984b</h4> </div> <div class="bibliography-section" id="CD006127-bib-0138"> <div class="citation-journal">Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. <span class="citation-title">The Wisconsin Epidemiologic Study of Diabetic Retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">1984</span>;<span class="volume">102</span>(4):527‐32. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/6367725" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Wisconsin+Epidemiologic+Study+of+Diabetic+Retinopathy+III.+Prevalence+and+risk+of+diabetic+retinopathy+when+age+at+diagnosis+is+30+or+more+years+&author=R+Klein&author=BE+Klein&author=SE+Moss&author=MD+Davis&author=DL+DeMets&publication_year=1984&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0080"> <div class="reference-title-banner"> <h4 class="title">Klein 1988</h4> </div> <div class="bibliography-section" id="CD006127-bib-0139"> <div class="citation-journal">Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. <span class="citation-title">Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy</span>. <span class="citation"> JAMA </span><span class="pubYear">1988</span>;<span class="volume">260</span>(19):2864‐71. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3184351" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glycosylated+hemoglobin+predicts+the+incidence+and+progression+of+diabetic+retinopathy&author=R+Klein&author=BE+Klein&author=SE+Moss&author=MD+Davis&author=DL+DeMets&publication_year=1988&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0081"> <div class="reference-title-banner"> <h4 class="title">Klein 1989a</h4> </div> <div class="bibliography-section" id="CD006127-bib-0140"> <div class="citation-journal">Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. <span class="citation-title">The Wisconsin Epidemiologic Study of Diabetic Retinopathy XI. The incidence of macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1989</span>;<span class="volume">96</span>(10):1501‐10. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2587045" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Wisconsin+Epidemiologic+Study+of+Diabetic+Retinopathy+XI.+The+incidence+of+macular+edema+&author=R+Klein&author=SE+Moss&author=BE+Klein&author=MD+Davis&author=DL+DeMets&publication_year=1989&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0082"> <div class="reference-title-banner"> <h4 class="title">Klein 1989b</h4> </div> <div class="bibliography-section" id="CD006127-bib-0141"> <div class="citation-journal">Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. <span class="citation-title">Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?</span>. <span class="citation"> Archives of Internal Medicine </span><span class="pubYear">1989</span>;<span class="volume">149</span>(11):2427‐32. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2684072" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Is+blood+pressure+a+predictor+of+the+incidence+or+progression+of+diabetic+retinopathy?&author=R+Klein&author=BE+Klein&author=SE+Moss&author=MD+Davis&author=DL+DeMets&publication_year=1989&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0083"> <div class="reference-title-banner"> <h4 class="title">Klein 2002a</h4> </div> <div class="bibliography-section" id="CD006127-bib-0142"> <div class="citation-journal">Klein R, Klein BE. <span class="citation-title">Blood pressure control and diabetic retinopathy</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">2002</span>;<span class="volume">86</span>(4):365‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11914198" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Blood+pressure+control+and+diabetic+retinopathy&author=R+Klein&author=BE+Klein&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0084"> <div class="reference-title-banner"> <h4 class="title">Klein 2002b</h4> </div> <div class="bibliography-section" id="CD006127-bib-0143"> <div class="citation-journal">Klein R. <span class="citation-title">The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2002</span>;<span class="volume">109</span>(7):1225‐34. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12093643" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+association+of+atherosclerosis,+vascular+risk+factors,+and+retinopathy+in+adults+with+diabetes:+the+atherosclerosis+risk+in+communities+study+&author=R+Klein&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0085"> <div class="reference-title-banner"> <h4 class="title">Krakoff 2003</h4> </div> <div class="bibliography-section" id="CD006127-bib-0144"> <div class="citation-journal">Krakoff J, Lindsay RS, Looker HC, Nelson RG, Hanson RL, Knowler WC. <span class="citation-title">Incidence of retinopathy and nephropathy in youth‐onset compared with adult‐onset type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2003</span>;<span class="volume">26</span>(1):76‐81. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12502661" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Incidence+of+retinopathy+and+nephropathy+in+youth%E2%80%90onset+compared+with+adult%E2%80%90onset+type+2+diabetes+&author=J+Krakoff&author=RS+Lindsay&author=HC+Looker&author=RG+Nelson&author=RL+Hanson&author=WC+Knowler&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0086"> <div class="reference-title-banner"> <h4 class="title">Krumpaszky 1999</h4> </div> <div class="bibliography-section" id="CD006127-bib-0145"> <div class="citation-journal">Krumpaszky HG. <span class="citation-title">Blindness incidence in Germany. A population‐based study from Wurttemberg‐Hohenzollern</span>. <span class="citation"> Ophthalmologica </span><span class="pubYear">1999</span>;<span class="volume">213</span>(3):176‐82. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10202291" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Blindness+incidence+in+Germany.+A+population%E2%80%90based+study+from+Wurttemberg%E2%80%90Hohenzollern&author=HG+Krumpaszky&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0087"> <div class="reference-title-banner"> <h4 class="title">Kullberg 2002</h4> </div> <div class="bibliography-section" id="CD006127-bib-0146"> <div class="citation-journal">Kullberg CE, Abrahamsson M, Arnqvist HJ, Finnstrom K, Ludvigsson J, VISS Study Group. <span class="citation-title">Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with type 1 diabetes</span>. <span class="citation"> Diabetes Medicine </span><span class="pubYear">2002</span>;<span class="volume">19</span>(11):924‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevalence+of+retinopathy+differs+with+age+at+onset+of+diabetes+in+a+population+of+patients+with+type+1+diabetes+&author=CE+Kullberg&author=M+Abrahamsson&author=HJ+Arnqvist&author=K+Finnstrom&author=J+Ludvigsson&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0088"> <div class="reference-title-banner"> <h4 class="title">Leske 2003</h4> </div> <div class="bibliography-section" id="CD006127-bib-0147"> <div class="citation-journal">Leske C. <span class="citation-title">Incidence of diabetic retinopathy in the Barbados Eye Studies</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2003</span>;<span class="volume">110</span>(5):941‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12750094" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Incidence+of+diabetic+retinopathy+in+the+Barbados+Eye+Studies&author=C+Leske&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0089"> <div class="reference-title-banner"> <h4 class="title">Mangione 2001</h4> </div> <div class="bibliography-section" id="CD006127-bib-0148"> <div class="citation-journal">Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, et al. <span class="citation-title">Development of the 25‐item National Eye Institute Visual Function Questionnaire</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2001</span>;<span class="volume">119</span>(7):1050‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11448327" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Development+of+the+25%E2%80%90item+National+Eye+Institute+Visual+Function+Questionnaire&author=CM+Mangione&author=PP+Lee&author=PR+Gutierrez&author=K+Spritzer&author=S+Berry&author=RD+Hays&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0090"> <div class="reference-title-banner"> <h4 class="title">Mohamed 2007</h4> </div> <div class="bibliography-section" id="CD006127-bib-0149"> <div class="citation-journal">Mohamed Q, Gillies MC, Wong TY. <span class="citation-title">Management of diabetic retinopathy. A systematic review</span>. <span class="citation"> JAMA </span><span class="pubYear">2007</span>;<span class="volume">298</span>(8):902‐16. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17712074" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Management+of+diabetic+retinopathy.+A+systematic+review&author=Q+Mohamed&author=MC+Gillies&author=TY+Wong&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0091"> <div class="reference-title-banner"> <h4 class="title">Moss 1996</h4> </div> <div class="bibliography-section" id="CD006127-bib-0150"> <div class="citation-journal">Moss S, Klein R, Klein BE. <span class="citation-title">Cigarette smoking and ten‐year progression in diabetic retinopathy</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1996</span>;<span class="volume">103</span>(9):1438‐42. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8841303" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cigarette+smoking+and+ten%E2%80%90year+progression+in+diabetic+retinopathy&author=S+Moss&author=R+Klein&author=BE+Klein&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0092"> <div class="reference-title-banner"> <h4 class="title">Porta 2001</h4> </div> <div class="bibliography-section" id="CD006127-bib-0151"> <div class="citation-journal">Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Veglio M, et al. <span class="citation-title">Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2001</span>;<span class="volume">44</span>(12):2203‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11793022" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+factors+for+progression+to+proliferative+diabetic+retinopathy+in+the+EURODIAB+Prospective+Complications+Study+&author=M+Porta&author=AK+Sjoelie&author=N+Chaturvedi&author=L+Stevens&author=R+Rottiers&author=M+Veglio&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0093"> <div class="reference-title-banner"> <h4 class="title">PPP 2012</h4> </div> <div class="bibliography-section" id="CD006127-bib-0152"> <div class="citation-book">American Academy of Ophthalmology Retina Panel. <span class="citation">Preferred Practice Patterns® Guidelines. Diabetic Retinopathy</span>. San Francisco, CA: American Academy of Ophthalmology, 2008 (4th printing 2012) Available at: www.aao.org/ppp. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0094"> <div class="reference-title-banner"> <h4 class="title">RevMan 2014 [Computer program]</h4> </div> <div class="bibliography-section" id="CD006127-bib-0153"> <div class="citation-other">The Nordic Cochrane Center, The Cochrane Collaboration. <span class="citation-title">Review Manager (RevMan)</span>. Version 5.3. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, <span class="pubYear">2014</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0095"> <div class="reference-title-banner"> <h4 class="title">Rosenberg 1996</h4> </div> <div class="bibliography-section" id="CD006127-bib-0154"> <div class="citation-journal">Rosenberg T, Klie F. <span class="citation-title">Current trends in newly registered blindness in Denmark</span>. <span class="citation"> Acta Ophthalmologica Scandinavica </span><span class="pubYear">1996</span>;<span class="volume">74</span>(4):395‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8883558" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Current+trends+in+newly+registered+blindness+in+Denmark&author=T+Rosenberg&author=F+Klie&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0096"> <div class="reference-title-banner"> <h4 class="title">Sivaprasad 2012</h4> </div> <div class="bibliography-section" id="CD006127-bib-0155"> <div class="citation-journal">Sivaprasad S, Gupta B, Crosby‐Nwaobi R, Evans J. <span class="citation-title">Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective</span>. <span class="citation"> Survey of Opthalmology </span><span class="pubYear">2012</span>;<span class="volume">57</span>(4):347‐70. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevalence+of+diabetic+retinopathy+in+various+ethnic+groups:+a+worldwide+perspective&author=S+Sivaprasad&author=B+Gupta&author=R+Crosby%E2%80%90Nwaobi&author=J+Evans&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0097"> <div class="reference-title-banner"> <h4 class="title">Sjølie 2011</h4> </div> <div class="bibliography-section" id="CD006127-bib-0156"> <div class="citation-journal">Sjølie AK, Dodson P, Hobbs FR. <span class="citation-title">Does renin‐angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2011</span>;<span class="volume">65</span>(2):148‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21235695" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Does+renin%E2%80%90angiotensin+system+blockade+have+a+role+in+preventing+diabetic+retinopathy?+A+clinical+review+&author=AK+Sj%C3%B8lie&author=P+Dodson&author=FR+Hobbs&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0098"> <div class="reference-title-banner"> <h4 class="title">Smith 2011</h4> </div> <div class="bibliography-section" id="CD006127-bib-0157"> <div class="citation-journal">Smith JM, Steel DHW. <span class="citation-title">Anti‐vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2011</span>, Issue 5. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD008214.pub2" target="_blank"><span>10.1002/14651858.CD008214.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Anti%E2%80%90vascular+endothelial+growth+factor+for+prevention+of+postoperative+vitreous+cavity+haemorrhage+after+vitrectomy+for+proliferative+diabetic+retinopathy+&author=JM+Smith&author=DHW+Steel&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0099"> <div class="reference-title-banner"> <h4 class="title">Tapp 2003</h4> </div> <div class="bibliography-section" id="CD006127-bib-0158"> <div class="citation-journal">Tapp RJ, Shaw JE, Harper CA, Courten MP, Balkau B, McCarty DJ, et al. <span class="citation-title">The prevalence of and factors associated with diabetic retinopathy in the Australian population</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2003</span>;<span class="volume">26</span>(6):1731‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12766102" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+prevalence+of+and+factors+associated+with+diabetic+retinopathy+in+the+Australian+population+&author=RJ+Tapp&author=JE+Shaw&author=CA+Harper&author=MP+Courten&author=B+Balkau&author=DJ+McCarty&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0100"> <div class="reference-title-banner"> <h4 class="title">Thomas 2014</h4> </div> <div class="bibliography-section" id="CD006127-bib-0159"> <div class="citation-journal">Thomas RL, Dunstan FD, Luzio SD, Chowdhury SR, North RV, Hale SL, et al. <span class="citation-title">Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">2015</span>;<span class="volume">99</span>(1):64‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25091950" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevalence+of+diabetic+retinopathy+within+a+national+diabetic+retinopathy+screening+service+&author=RL+Thomas&author=FD+Dunstan&author=SD+Luzio&author=SR+Chowdhury&author=RV+North&author=SL+Hale&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0101"> <div class="reference-title-banner"> <h4 class="title">UKPDS33 1998</h4> </div> <div class="bibliography-section" id="CD006127-bib-0160"> <div class="citation-journal">UK Prospective Diabetes Study Group. <span class="citation-title">Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">352</span>(9131):837‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9742976" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0102"> <div class="reference-title-banner"> <h4 class="title">UKPDS38 1998</h4> </div> <div class="bibliography-section" id="CD006127-bib-0161"> <div class="citation-journal">UK Prospective Diabetes Study Group. <span class="citation-title">Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)</span>. <span class="citation"> BMJ </span><span class="pubYear">1998</span>;<span class="volume">317</span>(7160):703‐13. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9732337" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0103"> <div class="reference-title-banner"> <h4 class="title">van Leiden 2002</h4> </div> <div class="bibliography-section" id="CD006127-bib-0162"> <div class="citation-journal">Leiden HA. <span class="citation-title">Blood pressure, lipids, and obesity are associated with retinopathy: The Hoorn Study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2002</span>;<span class="volume">25</span>(8):1320‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12145228" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Blood+pressure,+lipids,+and+obesity+are+associated+with+retinopathy:+The+Hoorn+Study&author=HA+Leiden&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0104"> <div class="reference-title-banner"> <h4 class="title">van Leiden 2003</h4> </div> <div class="bibliography-section" id="CD006127-bib-0163"> <div class="citation-journal">Leiden HA. <span class="citation-title">Risk factors for incident retinopathy in a diabetic and non‐diabetic population: The Hoorn Study</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2003</span>;<span class="volume">121</span>(2):245‐51. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12583792" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+factors+for+incident+retinopathy+in+a+diabetic+and+non%E2%80%90diabetic+population:+The+Hoorn+Study+&author=HA+Leiden&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0105"> <div class="reference-title-banner"> <h4 class="title">Virgili 2014</h4> </div> <div class="bibliography-section" id="CD006127-bib-0164"> <div class="citation-journal">Virgili G, Parravano M, Menchini F, Evans JR. <span class="citation-title">Anti‐vascular endothelial growth factor for diabetic macular oedema</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2014</span>, Issue 10. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD007419.pub4" target="_blank"><span>10.1002/14651858.CD007419.pub4</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Anti%E2%80%90vascular+endothelial+growth+factor+for+diabetic+macular+oedema&author=G+Virgili&author=M+Parravano&author=F+Menchini&author=JR+Evans&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0106"> <div class="reference-title-banner"> <h4 class="title">Wild 2004</h4> </div> <div class="bibliography-section" id="CD006127-bib-0165"> <div class="citation-journal">Wild S, Roglic G, Green A, Sicree R, King H. <span class="citation-title">Global prevalence of diabetes: estimates for the year 2000 and projections for 2030</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2004</span>;<span class="volume">27</span>(5):1047‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15111519" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Global+prevalence+of+diabetes:+estimates+for+the+year+2000+and+projections+for+2030&author=S+Wild&author=G+Roglic&author=A+Green&author=R+Sicree&author=H+King&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0107"> <div class="reference-title-banner"> <h4 class="title">Zhang 2001</h4> </div> <div class="bibliography-section" id="CD006127-bib-0166"> <div class="citation-journal">Zhang L, Krzentowski G, Albert A, Lefebvre PJ. <span class="citation-title">Risk of developing retinopathy in Diabetes Control and Complication Trial type 1 diabetic patients with good or poor metabolic control</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2001</span>;<span class="volume">24</span>(7):1275‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11423515" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+of+developing+retinopathy+in+Diabetes+Control+and+Complication+Trial+type+1+diabetic+patients+with+good+or+poor+metabolic+control+&author=L+Zhang&author=G+Krzentowski&author=A+Albert&author=PJ+Lefebvre&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD006127-bbs2-0108"> <div class="reference-title-banner"> <h4 class="title">Zhang 2010</h4> </div> <div class="bibliography-section" id="CD006127-bib-0167"> <div class="citation-journal">Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al. <span class="citation-title">Prevalence of diabetic retinopathy in the United States, 2005‐2008</span>. <span class="citation"> JAMA </span><span class="pubYear">2010</span>;<span class="volume">304</span>(6):649‐56. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20699456" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevalence+of+diabetic+retinopathy+in+the+United+States,+2005%E2%80%902008&author=X+Zhang&author=JB+Saaddine&author=CF+Chou&author=MF+Cotch&author=YJ+Cheng&author=LS+Geiss&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD006127-bbs1-0006"> <h3 class="title">References to other published versions of this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD006127-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD006127-bbs1-0005">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_otherVersions" id="CD006127-bbs2-0109"> <div class="reference-title-banner"> <h4 class="title">Sleilati 2009</h4> </div> <div class="bibliography-section" id="CD006127-bib-0168"> <div class="citation-journal">Sleilati G, Frank RN, Mathew MC. <span class="citation-title">Blood pressure control for diabetic retinopathy</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2006</span>, Issue 3. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD006127" target="_blank"><span>10.1002/14651858.CD006127</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Blood+pressure+control+for+diabetic+retinopathy&author=G+Sleilati&author=RN+Frank&author=MC+Mathew&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> </section> <section class="characteristicStudies" id="characteristicStudies"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title"> Characteristics of studies <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="characteristicIncludedStudiesContent" lang=""> <div class="section-header" id="CD006127-sec2-0025"> <h3 class="title">Characteristics of included studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD006127-sec2-0026" class="jump-to">excluded studies</a></li> <li><a href="#CD006127-sec2-0027" class="jump-to">awaiting classification</a></li> <li><a href="#CD006127-sec2-0028" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">ABCD (1) </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> 1 of 2 parallel group RCTs conducted within ABCD </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 950 </p> <p><b>Per group:</b> 480 normotensive patients: 237 to intensive therapy and 243 to moderate therapy </p> <p><b>Sample size calculation</b>: sample size calculation was based on glomerular filtration rate; power was not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> USA </p> <p><b>Study period:</b> accrual: March 1991 to May 1993; follow‐up planned for 5 to 7 years after March 1991 </p> <p><b>Age:</b> mean (SD) was 58.5 (9.2) years in intensive therapy group and 59.1 (7.8) in moderate therapy group </p> <p><b>Gender:</b> 47% in intensive therapy group and 44% in moderate therapy group were women </p> <p><b>Race/ethnicity:</b> 74.1% non‐Hispanic white; 7% African‐American; 16.6% Hispanic; 0.8% Asian; 1.2% other </p> <p><b>Inclusion criteria:</b> patients with type 2 diabetes diagnosed by WHO criteria aged 40 to 74 years at study enrollment, willing to participate in study, and likely to complete 5 to 7 years of study </p> <p><b>Exclusion criteria:</b> pregnant or lactating women, allergies to study medications, heart disease including uncorrected heart block, myocardial infarction, angina or heart failure, malignant hypertension, peripheral vascular disease, aortic dissection, on dialysis or other kidney disease, liver disease </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> mean (SD) SBP was 135.6 (12.3) mmHg, DBP was 84.4 (3.1) mmHg in intensive therapy group; SBP was 137.2 (14.0) mmHg, DBP was 84.4 (3.1) mmHg in moderate therapy group </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> mean (SD) was 11.5 (3.1) in intensive therapy group and 11.6 (3.1) in moderate therapy group </p> <p><b>Severity of retinopathy:</b> 47.9% no retinopathy; 44% NPDR; 4% PDR; 4% ungradable </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> intensive blood pressure control </p> <p>Goal DBP 10 mmHg below baseline</p> <p>Participants were randomized to either nisoldipine 10 mg/day, titrated to 20, 40, and then 60 mg/day (plus placebo for enalapril), or enalapril 5 mg/day titrated to 10, 20, and then 40 mg/day (plus placebo for nisoldipine) as the initial anti‐hypertensive medication. Additional anti‐hypertensive medications were added in an open‐label fashion in a step‐wise manner initially with metoprolol, then hydrochlorothiazide, and then until the target blood pressure was achieved. Addition of medications was at the discretion of the medical director, but the additional medications could not include calcium channel blockers or ACE inhibitors. </p> <p><b>Intervention 2:</b> moderate blood pressure control </p> <p>Goal DBP 80 to 89 mmHg; randomized to nisoldipine or enalapril if DBP ≤ 90 mmHg</p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 5 to 7 years</p> <p>Actual: 4.7 years mean</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> retinopathy: using modified Airlie House classification as adapted from <a href="references#CD006127-bbs2-0020">DCCT</a> at 2 and 5 years follow‐up, graded by the Wisconsin Retinal Reading Center; overall retinopathy according to ETDRS interim scale‐‐23 steps to represent overall extent of retinopathy in both eyes; progression of retinopathy defined as a 2‐step worsening from baseline based on 7‐field stereoscopic fundus photographs. Progression was not reported separately from incidence for normotensives or hypertensives; incidence was not reported for hypertensives. </p> <p><b>Secondary outcomes, as specified for this review:</b> visual acuity and incidence of CSME not reported </p> <p><b>Eye examined for the outcome:</b> both eyes </p> <p><b>Intervals at which outcomes were assessed:</b> retinal photographs taken at 2‐ and 5‐years follow‐up </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> <p><b>Other outcomes reported from the study:</b> glomerular filtration rate, urinary albumin excretion, left ventricular hypertrophy, neuropathy, and cardiovascular events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Source of funding:</b> industry and government </p> <p><b>Declaration of interest:</b> not reported </p> <p><b>Run‐in length:</b> 7 to 11 weeks on placebo </p> <p><b>Class(es) of anti‐hypertensive agents:</b> calcium channel blocker, ACE inhibitor </p> <p><b>Degrees of blood pressure control:</b> intensive therapy and moderate therapy had goals described above in the interventions section; however, both groups achieved blood pressure control targets for intensive control group </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Randomization using permuted block randomization within strata was used to ensure equal sample sizes within all arms of the study.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“The random assignment to intensive versus moderate treatment with either active nisoldipine coat‐core or enalapril medication was made by telephone by the Data Coordinating Center and the Clinical Coordinating Center.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“The drugs and placebos were administered in a double‐blind manner. If the single study medication assigned did not achieve the target blood pressure, then open‐label antihypertensive medications were added in a stepwise fashion until the target blood pressure was achieved.” </p> <p>“All retinal films are interpreted and staged at the Wisconsin Retinal Reading Center without knowledge of the group to which the patient has been randomized.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No specific information on withdrawals, exclusions, or losses to follow‐up were reported. However, figures in each report of outcomes show numbers of participants at each examination through 5 years that suggest ˜40% of those enrolled were lost to follow‐up sometime during the 5‐year period. No analysis to account for attrition. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear with available information. Percentages reported without explicit denominators for outcomes over 5 years. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Financial support was provided by Bayer Pharmaceutical Company.”</p> <p>“Supported by the Bayer Pharmaceutical Company and by a grant (DK50298‐02) from the National Institute of Diabetes and Digestive and Kidney Diseases." </p> <p>“We are indebted to the members of the Data and Safety Monitoring Committee for their guidance: Paul W. Whelton, M.D., Tulane University, New Orleans; . . . and Kevin Higgins, M.D., Bayer Pharmaceuticals, West Haven, Conn.” </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">ABCD (2) </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> 1 of 2 parallel group RCTs conducted within ABCD </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 950 </p> <p><b>Per group:</b> 470 hypertensive participants; 237 to intensive therapy and 233 to moderate therapy. </p> <p><b>Sample size calculation</b>: sample size calculation was based on glomerular filtration rate; power was not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> USA </p> <p><b>Study period:</b> accrual: March 1991 to May 1993; follow‐up planned for 5 to 7 years after March 1991 </p> <p><b>Age:</b> mean (SD) was 58.0 (8.4) years in intensive therapy group and 57.7 (8.3) years in moderate therapy group </p> <p><b>Gender:</b> 33% in intensive therapy group and 32% in moderate therapy group were women </p> <p><b>Race/ethnicity:</b> 66.3% non‐Hispanic white; 17% African‐American; 13.4% Hispanic; 1.9% Asian; 1% other </p> <p><b>Inclusion criteria:</b> patients with type 2 diabetes diagnosed by WHO criteria aged 40 to 74 years at study enrollment, willing to participate in study, and likely to complete 5 to 7 years of study </p> <p><b>Exclusion criteria:</b> pregnant or lactating women, allergies to study medications, heart disease including uncorrected heart block, myocardial infarction, angina or heart failure, malignant hypertension, peripheral vascular disease, aortic dissection, on dialysis or other kidney disease, liver disease </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> mean (SD) SBP was 156 (16.1) mmHg, DBP was 98 (6.4) mmHg in intensive therapy group; SBP 154 (16.9) mmHg and DBP 98 (6.4) mmHg in moderate therapy group </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> mean (SD) was 11.6 (3.2) in intensive therapy group and 11.5 (3.5) in moderate therapy group </p> <p><b>Severity of retinopathy:</b> 38.5% no retinopathy; 52.5% NPDR; 4.5% PDR; 4.5% ungradable </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> intensive blood pressure control </p> <p>Goal DBP 75 mmHg</p> <p>Participants were randomized to either nisoldipine 10 mg/day, titrated to 20, 40, and then 60 mg/day (plus placebo for enalapril), or enalapril 5 mg/day titrated to 10, 20, and then 40 mg/day (plus placebo for nisoldipine) as the initial anti‐hypertensive medication. Additional anti‐hypertensive medications were added in an open‐label fashion in a step‐wise manner initially with metoprolol, then hydrochlorothiazide, and then until the target blood pressure was achieved. Addition of medications was at the discretion of the medical director, but the additional medications could not include calcium channel blockers or ACE inhibitors. </p> <p><b>Intervention 2:</b> moderate blood pressure control </p> <p>Goal DBP 89 mmHg</p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 5 to 7 years</p> <p>Actual: 4.7 years mean</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> retinopathy: using modified Airlie House classification as adapted from <a href="references#CD006127-bbs2-0020">DCCT</a> at 2 and 5 years follow‐up, graded by the Wisconsin Retinal Reading Center; overall retinopathy according to ETDRS interim scale‐‐23 steps to represent overall extent of retinopathy in both eyes; progression of retinopathy defined as a 2‐step worsening from baseline based on 7‐field stereoscopic fundus photographs. Progression was not reported separately from incidence for normotensives or hypertensives; incidence was not reported for hypertensives. </p> <p><b>Secondary outcomes, as specified for this review:</b> visual acuity and incidence of PDR or CSME not reported </p> <p><b>Eye examined for the outcome:</b> both eyes </p> <p><b>Intervals at which outcomes were assessed:</b> retinal photographs taken at 2‐ and 5‐years follow‐up </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> <p><b>Other outcomes reported from the study:</b> glomerular filtration rate, urinary albumin excretion, left ventricular hypertrophy, neuropathy, and cardiovascular events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Source of funding:</b> industry and government </p> <p><b>Declaration of interest:</b> not reported </p> <p><b>Run‐in length:</b> 7 to 11 weeks on placebo </p> <p><b>Class(es) of anti‐hypertensive agents:</b> calcium channel blocker, ACE inhibitor </p> <p><b>Degrees of blood pressure control:</b> intensive therapy and moderate therapy had goals described above in the interventions section; however, both groups achieved blood pressure control targets for intensive control group </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Randomization using permuted block randomization within strata was used to ensure equal sample sizes within all arms of the study.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“The random assignment to intensive versus moderate treatment with either active nisoldipine coat‐core or enalapril medication was made by telephone by the Data Coordinating Center and the Clinical Coordinating Center.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“The drugs and placebos were administered in a double‐blind manner. If the single study medication assigned did not achieve the target blood pressure, then open‐label antihypertensive medications were added in a stepwise fashion until the target blood pressure was achieved.” </p> <p>“All retinal films are interpreted and staged at the Wisconsin Retinal Reading Center without knowledge of the group to which the patient has been randomized.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No specific information on withdrawals, exclusions, or losses to follow‐up were reported. However, figures in each report of outcomes show numbers of participants at each examination through 5 years that suggest ˜40% of those enrolled were lost to follow‐up sometime during the 5‐year period. No analysis to account for attrition. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear with available information. Percentages reported without explicit denominators for outcomes over 5 years. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Financial support was provided by Bayer Pharmaceutical Company.”</p> <p>“Supported by the Bayer Pharmaceutical Company and by a grant (DK50298‐02) from the National Institute of Diabetes and Digestive and Kidney Diseases." </p> <p>“We are indebted to the members of the Data and Safety Monitoring Committee for their guidance: Paul W. Whelton, M.D., Tulane University, New Orleans; . . . and Kevin Higgins, M.D., Bayer Pharmaceuticals, West Haven, Conn.” </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">ACCORD EYE </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> substudy of ACCORD – a 2x2 factorial RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 10,251 in ACCORD; 3537 enrolled in the <a href="references#CD006127-bbs2-0003">ACCORD EYE</a> study and 1590 in the ACCORD EYE blood pressure trial; 1263 participants in the blood pressure trial with 4‐year follow‐up data were analyzed for diabetic retinopathy outcomes in <a href="references#CD006127-bbs2-0003">ACCORD EYE</a> </p> <p><b>Per group:</b> blood pressure trial (n = 1263): 647 (intensive) and 616 (standard) analyzed for diabetic retinopathy outcomes. Visual acuity outcomes analyzed for 1546 participants: 798 (intensive) and 748 (standard). </p> <p><b>Sample size calculation:</b> target of 4065, which would have given 80% power to detect a 20% relative reduction with intensive blood pressure control as compared with standard blood‐pressure control (power of 77% for the blood pressure question for ACCORD EYE with 1263 enrolled participants, per ad hoc calculation) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> USA and Canada </p> <p><b>Study period:</b> protocol developed October 1999; randomization in ACCORD began January 2001 (for Vanguard centers) and restarted February 2003; accrual ended October 2005; follow‐up completed June 2009 </p> <p><b>Age:</b> mean (SD) was 61.3 ± 6.1 (intensive) and 61.5 ± 6.6 (standard) <a href="references#CD006127-bbs2-0003">ACCORD EYE</a> blood pressure trial </p> <p><b>Gender:</b> 48% in intensive therapy group and 45% in standard therapy group were women </p> <p><b>Race/ethnicity:</b> 31.4% non‐white participants in intensive group and 32.6% non‐white participants in standard group of the ACCORD EYE blood pressure trial </p> <p><b>Inclusion criteria:</b> type 2 diabetes (&gt; 3 months); HbA1c level of ≥ 7.5%; and high risk for cardiovascular disease (established cardiovascular disease or had known risk factors) </p> <p><b>Exclusion criteria:</b> history of proliferative diabetic retinopathy that had been treated with laser photocoagulation or vitrectomy </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> mean 138 ± 17/76 ± 10 (intensive), 139 ± 15/77 ± 10 (standard) </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> 8.4 ± 1.1 (intensive) and 8.2 ± 1.0 (standard) </p> <p><b>Severity of retinopathy:</b> intensive group: 50.9% none; 16.3% mild; 30.2% moderate NPDR; 0.5% severe NPDR; 2.2% PDR </p> <p>Standard group: 47.9% none; 19.0% mild; 32.1% moderate NPDR; 0.2% severe NPDR; 0.8% PDR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> intensive blood pressure control (intervention) arm targeted SBP &lt; 120 mmHg. The recommendation was to start with a combination of a diuretic and either an ACE inhibitor or a beta‐blocker at randomization. Drug doses were increased or additional anti‐hypertensive medications were added, or both, at each subsequent visit in the intensive group until goal was reached. </p> <p><b>Intervention 2:</b> the standard blood pressure control arm targeted SBP &lt; 140 mmHg. Medication dose titration or the addition of another drug was indicated whenever SBP was ≥ 160 mmHg at a single visit or ≥ 140 mmHg at 2 successive visits. </p> <p>Both the intensive and standard treatment groups in the blood pressure trial were factorial with intensive glycemic control (maintain an HbA1c level &lt; 6.0%) and standard (targets an HbA1c range of 7.0% to 7.9%) </p> <p><b>Length of follow‐up</b> in <a href="references#CD006127-bbs2-0003">ACCORD EYE</a>: </p> <p>Planned: 4 years</p> <p>Actual: 4 years</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> progression of diabetic retinopathy by at least 3 steps on the ETDRS severity scale. Incidence and progression reported in combination, not separately. </p> <p><b>Secondary outcomes, as specified for this review:</b> development of proliferative diabetic retinopathy necessitating photocoagulation therapy or vitrectomy; development or progression of macular edema; change in visual acuity at 4 years compared with baseline: moderate vision loss (i.e. loss of ≥ 3 lines on the logMAR visual acuity charts) </p> <p><b>Other diabetic retinopathy outcomes:</b> legal blindness (20/160 or worse), severe vision loss (5/200) </p> <p><b>Eye examined for the outcome:</b> average of both eyes </p> <p><b>Intervals at which outcomes were assessed:</b> visual acuity assessment at baseline, years 2, 4, 6, and 8 or at the study closeout visit; retinopathy assessed at 4 years </p> <p><b>Cost of the intervention:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Sources of funding:</b> government and industry‐donated study medications, equipment, and supplies </p> <p><b>Declaration of interest:</b> several authors declared interests related to pharmaceutical companies </p> <p><b>Class(es) of anti‐hypertensive agents compared:</b> not specified </p> <p><b>Degree of blood pressure control:</b> intensive: median &lt; 120 mmHg (115 to 120); standard: median &lt; 140 mmHg (135 to 140) </p> <p><b>Concomitant treatment:</b> participants were also randomized to intensive (maintenance of HbA1c &lt; 6.0%) or standard (HbA1c 7.0% to 7.9%) glycemic control </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“An Internet‐based, web browser randomization procedure will be employed in ACCORD” (protocol). Algorithm used to generate random sequence was not clearly described. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Randomization was performed centrally on the study's web site with the use of permuted blocks to maintain concealment of future study‐group assignments" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The blood pressure component of ACCORD was an unmasked, open‐label randomized trial.</p> <p>"The fundus photographs were evaluated by trained graders, who were unaware of the treatment assignments . . ." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Did not report whether visual acuity assessors and ophthalmologists were masked to interventions. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>291 of 1263 participants (23%) in the <a href="references#CD006127-bbs2-0003">ACCORD EYE</a> blood pressure trial: 155 (intensive blood pressure) and 136 (standard blood pressure) </p> <p>"there was no evidence of significant differences regarding the amount of missing data, and the results of sensitivity analyses supported those of the primary analyses." Used logistic regression methods for multiple imputation. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>see above</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Progression to PDR and/or CSME not reported.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65 of 3537 (1.8%) of randomized participants enrolled in <a href="references#CD006127-bbs2-0003">ACCORD EYE</a> were subsequently excluded from the trial due to detection of exclusion criteria after randomization. ". . . baseline fundus photographs could not be obtained within four months of randomization." </p> <p>Conflicts of interests for the Data and Safety Monitoring Board members are unclear.</p> <p>"For the Eye Substudy (in a subset of 4065 participants), the baseline eye exam/fundus photography can be performed up to 2 months post‐randomization." (protocol) </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">ADVANCE/AdRem </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> substudy of ADVANCE – a 2x2 factorial RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 11,140 in ADVANCE; 2130 enrolled in <a href="references#CD006127-bbs2-0004">ADVANCE/AdRem;</a> 1982 had baseline photographs received, but only 1602 had valid baseline photographs; 1241 with gradeable baseline and final photographs were included in the AdRem analysis </p> <p><b>Per group:</b> 623 to perindopril‐indapamide; 618 to placebo </p> <p><b>Sample size calculation:</b> target of 2000 was estimated to provide 85% power to detect an absolute reduction of 6.2% in the primary outcome event rate, assuming an event rate 27.8% over 6 years and a type I error of 0.05. "The main limitation of this study is the lower than planned sample size." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> 14 countries in Asia, Australia, Europe, and North America </p> <p><b>Study period:</b> baseline photographs: August 2002 to January 2004 </p> <p><b>Age:</b> mean (SD) was 65.6 (5.8) years in the perindopril‐indapamide group and 65.6 (5.9) years in the placebo group; 65.6 (5.8) overall </p> <p><b>Gender:</b> 38.7% overall were women; 40.3% in the perindopril‐indapamide group and 37.1% in the placebo group </p> <p><b>Race/ethnicity:</b> perindopril‐indapamide group: 48.5% white, 37.9% Chinese, 8.5% South Asian; placebo group: 47% white, 38.3% Chinese, 9.6% South Asian </p> <p><b>Inclusion criteria:</b> all participants in ADVANCE (55 years or older at recruitment; diagnosed with type 2 diabetes at age 30 years or older; history of at least one of the following conditions: major cardiovascular disease, risk factors including history of major microvascular disease, current cigarette smoking, elevated total cholesterol (&gt; 6.0 mmol/L), low HDL cholesterol (&lt; 1.0 mmol/L), microalbuminuria, diagnosed with type 2 diabetes 10 years or more preceding entry into the study or age 65 years or older at recruitment; an indication for an ACE inhibitor) who enrolled at centers with retinal cameras were eligible to participate in <a href="references#CD006127-bbs2-0004">ADVANCE/AdRem</a> </p> <p><b>Exclusion criteria:</b> for ADVANCE: definite indication or contraindication for the active study treatments or a definite indication for a HbA1c target of ≤ 6.5%, long‐term insulin therapy at study entry, or participating in a different clinical trial; in addition for AdRem: previous ophthalmological intervention or inability to obtain good quality photographs due to either severe cataract or inadequate pupil dilation (&lt; 4 mm) </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> mean (SD): perindopril‐indapamide group 142.3/79.2 (22.0/11.2) mmHg; placebo 143.1/79.5 (21.4/10.5) mmHg; overall 142.7/79.3 (21.7/10.8) </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> mean (SD): perindopril‐indapamide group 7.5 (1.5); placebo 7.3 (1.4); overall 7.4 (1.5) </p> <p><b>Severity of diabetic retinopathy:</b> 40.9% in placebo group and 39.3% in perindopril‐indapamide group for ETDRS grade ≥ 20 (microaneurysms only; mild, moderate, moderately severe, or severe non‐proliferative diabetic retinopathy; or proliferative diabetic retinopathy) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> perindopril (2 mg) plus indapamide (0.625 mg) daily at randomization and doubled to perindopril (4 mg) plus indapamide (1.25 mg)&nbsp;after 3 months </p> <p><b>Intervention 2:</b> placebo </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 5.5 years</p> <p>Actual: 4.1 years (median)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> progression of diabetic retinopathy ≥ 2 steps in ETDRS classification </p> <p><b>Secondary outcome, as specified for this review:</b> visual acuity and progression to PDR or CSME not reported </p> <p><b>Other diabetic retinopathy outcomes:</b> ≥ 1 and ≥ 3 steps of progression and individual diabetic retinopathy lesion development </p> <p><b>Eye examined for outcome:</b> participant's worse eye </p> <p><b>Intervals at which outcomes were assessed:</b> within 3 months after randomization (photographs taken within 3 months following ADVANCE randomization were considered “baseline” photographs), at 2 years, and at final follow‐up examination; retinal photographs taken at 2‐year follow‐up were used when photographs at final follow‐up were not available </p> <p><b>Cost of the interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Source of funding:</b> institutional and government support </p> <p><b>Declaration of interest:</b> two authors declared interests related to pharmaceutical companies </p> <p><b>Run‐in length:</b> 6 weeks on “active blood pressure lowering treatment and usual glucose lowering treatment” </p> <p><b>Class(es) of anti‐hypertensive agents compared:</b> ACE inhibitor plus diuretic </p> <p><b>Degree of blood pressure control:</b> drug treatment yielded mean decrease of 6.1 mmHg in SBP and 2.3 mmHg in DBP </p> <p><b>Concomitant treatment:</b> standard and intensive glucose therapy as randomized </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Randomisation was stratified by study centre, history of macrovascular disease, and background use of perindopril at baseline." </p> <p>"A central computer‐based randomization service will assign patients to treatments . . ." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Study treatments were allocated using a central, computer‐based randomization service accessible by internet, telephone, and facsimile." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“The two main effects comparisons were a double‐blind comparison of blood pressure‐lowering vs placebo . . . blinded endpoint evaluation design.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"All analyses were based on the intention‐to‐treat principle (1,241 patients with gradeable baseline and final photographs)." Participants with missing retinal photographs at baseline or follow‐up were excluded from the analyses. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes in published results consistent with outcomes pre‐specified in design paper.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Baseline photographs were taken after the randomization visit, "preferably within 3 months after"; median of 2 months (IQR 1 to 6 months). </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">BENEDICT </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 550 with available fundus photographs at baseline (of 1209 total number of people randomized in <a href="references#CD006127-bbs2-0005">BENEDICT</a>) </p> <p><b>Per group:</b> number of participants was not reported for the four individual treatment groups; 279 assigned to non‐ACE inhibitor; 271 assigned to ACE inhibitor </p> <p><b>Sample size calculation:</b> none; authors stated “at the time the present analyses were planned, no data were available on the regression of retinopathy in hypertensive patients with type 2 diabetes on intensified BP and metabolic control . . . ." For the <a href="references#CD006127-bbs2-0005">BENEDICT</a> trial, based on time to persistent albuminuria at 3‐years follow‐up with evidence of 9.5% in the placebo group and 3.1% in the treatment group, estimated 225 per group to provide 80% power at 2‐sided alpha = 0.05; adjusted for attrition to 300 per group. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> Italy&nbsp; </p> <p><b>Study period:</b> not reported; design and number enrolled published in 2003. </p> <p><b>Age:</b> mean (SD): 61.6 (8.1) years in the trandolapril group; 62.5 (8.2) years in the verapamil group; 62.7 (7.7) years in the VeraTran group; and 62.6 (8.2) years in the placebo group </p> <p>Retina subgroup (n = 550): 62.0 (7.8) years overall</p> <p><b>Gender:</b> 48% in trandolapril group; 46% in verapamil group; 45% in combination (VeraTran) group; and 50% in placebo group were women </p> <p>Retina subgroup (n = 550): 256 (46%) were women</p> <p><b>Race/ethnicity:</b> 99.8% white in <a href="references#CD006127-bbs2-0005">BENEDICT</a> overall </p> <p><b>Inclusion criteria:</b> hypertensive type 2 diabetics &lt; 25 years duration; urinary albumin excretion rate &lt; 20 μg/min in 2 of 3 overnight urine collections; serum creatinine &lt; 1.5 mg/dL; hypertension defined as previous anti‐hypertensive therapy or SBP/DBP &gt; 130/85 mmHg; for retina subgroup fundus exam/photos at baseline </p> <p><b>Exclusion criteria:</b> concomitant nondiabetic renal disease; HbA1c &gt; 11%; specific indications or contraindications for study drugs </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> retina subgroup (n = 550): SBP 151.6 ± 14.3 mmHg; DBP 88.8 ± 8.3 mmHg </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> retina subgroup (n = 550): mean (SD): 5.9 (1.5) </p> <p><b>Severity of diabetic retinopathy:</b> 82 of 90 with retinopathy (out of 550) had pre‐proliferative retinopathy at baseline (microaneurysms, hemorrhage, vitreous coagulation, hard exudates, CWS, IRMA) and 8 had PDR (NV, glial proliferation (i.e. sheathing), preretinal hemorrhage, vitreous hemorrhage, photocoagulation scars, and/or RD) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> non‐dihydropyridine CCB verapamil SR, 240 mg/day </p> <p><b>Intervention 2:</b> ACE inhibitor: trandolapril 2 mg/day </p> <p><b>Intervention 3:</b> fixed‐dose combination of verapamil SR, 180 mg/day, plus trandolapril&nbsp;2 mg/day (VeraTran) </p> <p><b>Intervention 4:</b> placebo </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 3 years</p> <p>Actual: median 3.6 years (IQR: 1.3 to 4.3); 35.9 months (IQR: 12.4 to 60.7)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> pre‐specified in <a href="references#CD006127-bbs2-0005">BENEDICT</a> protocol to be new‐onset retinopathy in participants free of retinopathy at baseline </p> <p><b>Secondary outcomes, as specified for this review:</b> visual acuity and progression to PDR or CSME not reported </p> <p><b>Other diabetic retinopathy outcomes</b>: regression of retinopathy; regression of retinal changes in participants with baseline retinopathy defined as "a persistent (up to the final visit) change in the stage of retinal involvement from proliferative to pre‐proliferative retinopathy, or from pre‐proliferative retinopathy to no retinal involvement"; "pre‐proliferative retinopathy was defined by the presence of microaneurysms, hemorrhages, hard exudates, venous congestion, cotton wool spots, or intraretinal microvascular abnormalities"; "proliferative retinopathy was diagnosed when new vessels, glial proliferation, preretinal hemorrhage, vitreous hemorrhage, scars of photocoagulation (known to have been directed at new vessels), and/or retinal detachment were found" </p> <p><b>Eye examined for the outcome:</b> both eyes were examined and the eye with the more severe involvement was used to categorize retinal involvement </p> <p><b>Intervals at which outcomes were assessed:</b> baseline; yearly thereafter; and at the final visit </p> <p><b>Cost of the interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> <p><b>Other outcomes reported from the study:</b> progression to micro‐ and macroabuminuria, increase in albuminuria, rate of glomerular filtration rate decline, incidence of major cardiovascular events, overall and cardiovascular mortality </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Source of funding:</b> partial support from industry </p> <p><b>Declaration of interest:</b> not reported </p> <p><b>Run‐in length: "</b>At the first visit of the study, patients on ACE inhibitor and conventional antihypertensive treatment withdraw previous antihypertensive medications and are randomized after at least 6‐ and 3‐week washout, respectively." </p> <p><b>Classes of anti‐hypertensive agents compared:</b> 1) ACE inhibitors to no ACE inhibitors; 2) non‐dihydropyridine CCB to no non‐dihydropyridine CCB </p> <p><b>Degree of blood pressure control:</b> not reported for the retina subgroup; in <a href="references#CD006127-bbs2-0005">BENEDICT</a>, similar for all arms at 3 years, SBP/DBP about 135/75 </p> <p><b>Concomitant treatment:</b> "Other antihypertensive drugs (with the exception of RAS inhibitors and ndCCBs different from the study drugs) could be used to achieve and maintain target BP according to predefined guidelines." </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"The unblinded data centre receives the randomization code from the sponsor."</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No description provided.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inadequate information provided for incident diabetic retinopathy.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Of the 1209 patients randomized in the original <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/sections/documents/view?version=z1309131500388138314073588185815%26format=REVMAN#STD-BENEDICT" target="_blank">BENEDICT</a> cohort, 583 patients were referred to the two centers involved in the present study. Five hundred‐fifty patients had a baseline funduscopy evaluation" </p> <p>1209 randomized while 1204 were analyzed in parent study: 4 never took study medication; 1 ineligible. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The protocol states: "The retinopathy grading score used makes it possible to quantify the progression of the retinal changes. Worsening of the disease is defined as progression from a less‐severe to a more‐severe class during follow‐up." </p> <p>However, the results were reported as: "...regression of retinopathy...". Progression cannot be derived from regression without data regarding stabilization. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Support in part by Abbott (pharmaceutical company) where Abbott representatives "reviewed the paper" [<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/sections/documents/view?version=z1309131500388138314073588185815%26format=REVMAN#STD-BENEDICT" target="_blank">BENEDICT</a> paper]. No mention of such support/review was made in the article describing retinopathy outcomes. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Chase </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 16 </p> <p><b>Per group:</b> 7 to captopril; 9 to placebo </p> <p><b>Sample size calculation:</b> none reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> USA </p> <p><b>Age:</b> mean (SD): 22 (8.4) years in the captopril group and 19.9 (4.4) years in the placebo group </p> <p><b>Gender:</b> none in captopril group and 4 (44%) in placebo group were women </p> <p><b>Race/ethnicity:</b> not reported </p> <p><b>Inclusion criteria:</b> insulin‐dependent type 1 diabetes, with an albumin excretion rate of 20 to 200 µg/min on 3 of 4 overnight urine collections </p> <p><b>Exclusion criteria:</b> not otherwise reported </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> captopril: 118/78 mmHg (10.2/6.1); placebo: 113/78 mmHg (10.2/7.2) </p> <p><b>Type of diabetes:</b> type 1 </p> <p><b>HbA1c categories/levels:</b> mean (SD): 8.8 (1.6) captopril; 8.0 (1.1) placebo </p> <p><b>Severity of diabetic retinopathy:</b> based on modified Airlie House system‐‐1 (no microaneurysm or other diabetic retinopathy lesion) to 6 (PDR); captopril group: 0 with grade 1; 1 with grade 2; 2 with grade 3; 3 with grade 4 </p> <p>Placebo group: 3 with grade 1; 3 with grade 2; 1 with grade 3; 1 with grade 4, and 1 with grade 6 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> captopril 50 mg twice a day for 2 years </p> <p><b>Intervention 2:</b> placebo for 2 years </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 2 years</p> <p>Actual: 2 years</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as defined for this review:</b> worsening of diabetic retinopathy defined as any change from baseline to 2 years by 1 or more grades using the modified Airlie House classification based on 7‐field color photographs </p> <p><b>Secondary outcomes, as specified for this review:</b> visual acuity and progression to CSME not reported; grade 6 represented PDR </p> <p><b>Other diabetic retinopathy outcomes:</b> improvement of diabetic retinopathy by 1 or more grades </p> <p><b>Eye examined for the outcome:</b> participant's worse eye </p> <p><b>Intervals at which outcomes were assessed:</b> 6‐ to 12‐month intervals </p> <p><b>Cost of the interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> <p><b>Other outcomes reported from the study:</b> albumin excretion rate and creatinine clearance rate </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Sources of funding:</b> partial support from industry, foundation, and government </p> <p><b>Declaration of interest:</b> not reported </p> <p><b>Class(es) of anti‐hypertensive agents compared:</b> ACE inhibitor only </p> <p><b>Degree of blood pressure control:</b> no target blood pressure reported; 2‐year follow‐up blood pressure was similar to baseline blood pressure </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“The subjects were randomized in a double‐blind study design.”</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not mentioned.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“double‐blind study design”</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Data reported for all 16 participants.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear with available information.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Supported in part by Bristol‐Myers Squibb Company.” Too little information reported regarding methods to classify as "low risk." </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">DEMAND </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 380; 258 consented to central funduscopy </p> <p><b>Per group</b>: 90 to manidipine + delapril; 81 to delapril; and 87 to placebo </p> <p><b>Sample size calculation:</b> target of 342 which would give 80% power with 20% "nonassessable" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> Italy and Slovenia </p> <p><b>Study period:</b> May 2002 to June 2005 </p> <p><b>Age:</b> mean (SD): 60.2 (7.8) years in the manidipine + delapril group; 61.9 (7.8) years in the delapril group; and 60.4 (7.5) years in the placebo group </p> <p><b>Gender:</b> 38% in the manidipine + delapril group; 35% in the delapril group; and 31% in the placebo group were women </p> <p><b>Race/ethnicity:</b> not reported </p> <p><b>Inclusion criteria:</b> &gt; 40 years of age with hypertension and known history of type 2 diabetes (WHO criteria); &lt; 25 years of duration, with urinary albumin excretion &lt; 200 µg/min in &gt; 2 of 3 consecutive, sterile overnight samples, and serum creatinine &lt; 1.5 mg/dL; hypertension was defined as untreated SBP/DBP &gt;130/85 mmHg or concomitant anti‐hypertensive therapy </p> <p><b>Exclusion criteria:</b> HbA1c &gt; 11%, ischemic kidney disease, urinary tract obstruction, or urinary abnormalities suggestive for primary glomerular disease, or specific indications or contraindications to ACE inhibitor or calcium channel blocker therapy </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> Target: SBP/DBP &lt; 120/80 mmHg </p> <p>Manidipine + delapril: 148 ± 15/87 ± 9 mmHg</p> <p>Delapril: 147 ± 14/87 ± 8 mmHg</p> <p>Placebo: 147 ± 14/88 ± 10 mmHg</p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> 6.2 to 6.3 (1.7) </p> <p><b>Severity of diabetic retinopathy:</b> 208 without diabetic retinopathy at baseline who also had fundoscopy follow‐up </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> manidipine (10 mg/day) + delapril (30 mg/day) </p> <p><b>Intervention 2:</b> delapril (30 mg/day) </p> <p><b>Intervention 3:</b> placebo </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 3 years (last randomized patient followed for 3 years)</p> <p>Actual: 3.8 years (median) (IQR: 3.1 to 4.7 years)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> new onset or progression of retinopathy: retinal involvement was graded from no apparent retinopathy to mild, moderate, or severe pre‐proliferative retinopathy and to PDR; new‐onset retinopathy was diagnosed when any grade of retinopathy was observed in 2 consecutive evaluations in eyes with no retinopathy at baseline. Only the combined outcome of new onset or progression of retinopathy was reported as a hazard ratio. </p> <p><b>Secondary outcome, as specified for this review:</b> visual acuity and progression to PDR or CSME not reported </p> <p><b>Other diabetic retinopathy outcomes:</b> regression of retinopathy, both arms combined; regression was diagnosed when no retinal changes were observed in 2 consecutive evaluations in eyes with retinopathy at baseline </p> <p><b>Eye examined for the outcome:</b> eye with the higher retinopathy grade was considered for analysis </p> <p><b>Intervals at which outcomes were assessed:</b> retinal changes were assessed at baseline and every year after randomization </p> <p><b>Cost of the interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> <p><b>Other outcomes reported from the study:</b> rate of glomerular filtration rate decline, composite end point of all‐cause and cardiovascular mortality, and nonfatal myocardial infarction or stroke, coronary revascularization, amputation, or vascular surgery for peripheral atherosclerotic artery disease, new onset, progression, or regression of peripheral neuropathy </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Source of funding:</b> partial support from industry: "Chiesi Farmaceutici SpA (Parma, Italy) funded the study and provided the experimental drugs but had no involvement in the study conduct and data handling, analyses, and reporting." </p> <p><b>Declaration of interest:</b> authors declared that they had nothing to disclose </p> <p><b>Classes of anti‐hypertensive agents compared:</b> combination of calcium channel blocker (manidipine) and ACE inhibitor (delapril) vs. ACE inhibitor alone </p> <p><b>Degree of blood pressure control</b>: means during study 137.2 ± 10/80.5 ± 6 mmHg </p> <p><b>Concomitant treatment:</b> additional anti‐hypertensive drugs were allowed to achieve target blood pressure in the following steps: 1) hydrochlorothiazide, indapamide, or furosemide; 2) beta‐ or alpha‐blockers; 3) doxazosis, prazosin, clonidine hydrochloride, or alpha‐methyldopa </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"The Chiesi Farmaceutici Statistical Unit created a computer generated randomization list with a block of 6 patients assigned to each therapy with a 1:1:1 ratio." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Randomization numbers were blindly assigned by the treatment assignment secretariat at the Mario Negri Institute (Ranica, Italy). . . . Individual sealed envelopes containing the randomized treatment code were provided to each centre and could be broken for safety reasons after discussion with the study coordinator." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Study treatments were externally nondistinguishable orange, rounded tablets containing either delapril 15 mg plus manidipine 5 mg, delapril 15 mg, or placebo . . . Patients and investigators were all blinded throughout the study." "All of the end points were adjudicated at the blind review by a clinical end point committee unaware of the treatment assignments." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Among the 192 subjects [out of 208] without retinopathy at inclusion and with fundoscopy available on follow‐up . . ." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incidence and progression not reported separately.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants who discontinued medication were excluded from the final analysis; pharmaceutical company sponsor. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">DIRECT Prevent 1 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT conducted as part of DIRECT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 1421 </p> <p><b>Per group:</b> 711 to candesartan; 710 to placebo </p> <p><b>Sample size calculation:</b> target of 1300 which would give 80% power to detect a 5% significance for treatment effect of 23% </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> 30 countries: Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, New Zealand, Poland, Portugal, Romania, Russian Federation, South Africa, Spain, Sweden, Turkey, United Kingdom </p> <p><b>Study period:</b> August 2001 to February 2004 (end of randomization) with follow‐up through March 2008 </p> <p><b>Age:</b> 29.6 years in candesartan group; 29.9 years in placebo group </p> <p><b>Gender:</b> 42% in candesartan group and 45% in placebo group were women </p> <p><b>Race/ethnicity:</b> 97% white </p> <p><b>Inclusion criteria:</b> type 1 diabetics without retinopathy: age 18 to 50 years, no restriction on gender, younger than 36 years of age at diagnosis of diabetes, 5 to 15 years duration, continuous insulin use within a year of diagnosis, no microalbuminuria, SBP ≤ 130 mmHg and DBP ≤ 85 mmHg and a retinal grading level of 10/10 on the ETDRS scale with 7‐field stereo retinal photographs </p> <p><b>Exclusion criteria:</b> eye conditions precluding capture of gradable retinal photographs (open‐angle glaucoma, cataracts obscuring view of retina); valvular stenosis; history of heart attack or stroke; pregnant or lactating women; renal impairment defined as serum creatinine ≥ 110 µmol/L for women and ≥ 130 µmol/L for men </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> normotensive patients (≤ 130/≤ 85 mmHg) </p> <p>SBP at baseline: mean (SD): 116 (9.5) mmHg in candesartan group and 116 (9.6) mmHg in placebo group </p> <p>DBP at baseline: mean (SD): 72 (6.9) mmHg in candesartan group and 72 (7.3) mmHg in placebo group </p> <p><b>Type of diabetes:</b> type 1 </p> <p><b>HbA1c categories/levels:</b> mean (SD): 8.0 (1.7) in candesartan group; 8.2 (1.7) in placebo group </p> <p><b>Severity of diabetic retinopathy:</b> all participants had ETDRS grade 10/10 (no retinopathy present) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> candesartan cilexetil 16 mg (ARB); increased in dose up to 32 mg once a day after one month based on tolerability </p> <p><b>Intervention 2:</b> placebo </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 3 years</p> <p>Actual: 4.7 years (median; IQR 4.2 to 5.2 years)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> incidence of retinopathy defined as "a two‐step progression from 10/10 on the ETDRS scale"; "two steps are defined as either a 1‐step change in each eye or as a 2‐step change in one eye only" </p> <p><b>Secondary outcomes, as specified for this review:</b> PDR, CSME, and visual acuity not mentioned or reported </p> <p><b>Eye examined for the outcome:</b> both eyes; see primary outcome description above </p> <p><b>Intervals at which outcomes were assessed:</b> 6 months and then yearly until at least 4 years for diabetic retinopathy outcomes </p> <p><b>Cost of the interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> <p><b>Other outcomes reported from the study:</b> change in albumin excretion rate, serum total and HDL cholesterol, and glycemic control </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Source of funding:</b> industry </p> <p><b>Declaration of interest:</b> all authors declared interests related to pharmaceutical companies </p> <p><b>Class(es) of anti‐hypertensive agents compared:</b> angiotensin receptor antagonist only </p> <p><b>Degree of blood pressure control:</b> no target blood pressure levels mentioned </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Randomisation is performed centrally by a computerized system.”</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Random assignment was done centrally, using an interactive voice‐response system. Both investigators and participants were unaware of the treatment allocation status.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Participants were initially assigned to candesartan 16 mg once a day or matching placebo.” </p> <p>“Two independent observers, a primary and secondary grader, constituting a team, were assigned to each patient for the duration of the study at the Retinopathy Grading Centre, Imperial College, London, UK. The team assessed the photographs for diabetic retinopathy and clinically significant macular oedema; they were unaware of the treatment the patients were assigned to.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Intention‐to‐treat analysis for all participants randomized. Reasons and percent discontinued similar in both treatment groups. Imputation used from previous photographs when photographs missed. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk for retinopathy outcomes.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"This study was jointly funded by AstraZeneca and Takeda."</p> <p>"The sponsors did the statistical analysis, with validation by an independent statistician.” No further details on independent validation. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">DIRECT Protect 1 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT conducted as part of DIRECT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 1905 </p> <p><b>Per group:</b> 951 to candesartan and 954 to placebo </p> <p><b>Sample size calculation:</b> target of 1850 which would give 80% power to detect a 5% significance for treatment effect of 25% </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> 30 countries; Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, New Zealand, Poland, Portugal, Romania, Russian Federation, South Africa, Spain, Sweden, Turkey, United Kingdom </p> <p><b>Study period:</b> August 2001 to February 2004 (end of randomization) with follow‐up through March 2008 </p> <p><b>Age:</b> 31.5 years in candesartan group and 31.9 years in placebo group </p> <p><b>Gender:</b> 43% in candesartan group and 42% in placebo group were women </p> <p><b>Race/ethnicity:</b> 98% white </p> <p><b>Inclusion criteria:</b> age 18 to 55 years, no restriction on gender, younger than 36 years of age when type 1 diabetes diagnosed, duration of 1 to 20 years, continuously used insulin within a year of diagnosis, no microalbuminuria, SBP ≤ 130 mmHg and DBP ≤ 85 mmHg and a diabetic retinopathy grading ≥ 20/10 (mild, non‐proliferative), up to ≤ 47/47 (moderately severe non‐proliferative) on the ETDRS scale based on 7‐field stereo retinal photographs </p> <p><b>Exclusion criteria:</b> eye conditions precluding capture of gradable retinal photographs (open‐angle glaucoma, cataracts obscuring view of retina), patients with valvular stenosis, history of heart attack or stroke, pregnant or lactating women, patients with renal impairment defined as serum creatinine ≥ 110 µmol/L for women and ≥ 130 µmol/L for men </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> normotensive patients (&lt; 130/&lt; 85 mmHg) </p> <p>SBP at baseline: mean (SD): 117 (9.6) mmHg in candesartan group and 117 (9.8) mmHg in placebo group </p> <p>DBP at baseline: mean (SD): 74 (6.5) mmHg in candesartan group and 73 (6.9) mmHg in placebo group </p> <p><b>Type of diabetes at baseline:</b> type 1 </p> <p><b>HbA1c categories/levels:</b> mean (SD) was 8.5 (1.6) in candesartan group and placebo group </p> <p><b>Severity of diabetic retinopathy (worse eye):</b> in the candesartan group 49% with ETDRS grade of 20 (microaneurysms only), 41% with grade of 35 (mild NPDR), and 10% with grade &gt; 35 to 47 (moderate, moderately severe, or severe NPDR); in the placebo group 49% with grade of 20, 43% with grade &gt; 35 to 47, and 8% had grades &gt; 35 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> candesartan cilexetil 16 mg (ARB); increased in dose up to 32 mg once a day after one month based on tolerability </p> <p><b>Intervention 2:</b> placebo </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 3 years</p> <p>Actual: 4.8 years (median; IQR 4.4 to 5.3 years)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> progression of retinopathy defined as a 3‐step change or more in ETDRS levels, e.g. at least 2 steps in 1 eye and 1 step in the other or at least 3 steps in 1 eye </p> <p><b>Secondary outcomes, as specified for this review:</b> incidence of CSME and/or PDR per the ETDRS protocol </p> <p><b>Eye examined for the outcome:</b> both eyes; see primary outcome description above </p> <p><b>Intervals at which outcomes were assessed:</b> 6 months and yearly thereafter for at least 4 years for retinopathy outcomes </p> <p><b>Cost of the interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> <p><b>Other outcomes reported from the study:</b> change in albumin excretion rate, serum total and HDL cholesterol, and glycemic control </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Sources of funding:</b> industry </p> <p><b>Declaration of interest:</b> all authors declared interests related to pharmaceutical companies </p> <p><b>Class(es) of anti‐hypertensive agents compared:</b> angiotensin receptor antagonist only </p> <p><b>Degree of blood pressure control:</b> no target blood pressure levels mentioned </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Randomisation is performed centrally by a computerized system.”</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Random assignment was done centrally, using an interactive voice‐response system. Both investigators and participants were unaware of the treatment allocation status.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Participants were initially assigned to candesartan 16 mg once a day or matching placebo.” </p> <p>“Two independent observers, a primary and secondary grader, constituting a team, were assigned to each patient for the duration of the study at the Retinopathy Grading Centre, Imperial College, London, UK. The team assessed the photographs for diabetic retinopathy and clinically significant macular oedema; they were unaware of the treatment the patients were assigned to.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Same as above.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Intention‐to‐treat analysis reported for all participants randomized. Reasons and percent discontinued similar in both treatment groups. Imputation for missed photographs based on previous photograph. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Intention‐to‐treat analysis with imputation for all participants randomized. Reasons and percent discontinued similar in both treatment groups. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Low risk" for retinopathy outcomes.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"This study was jointly funded by AstraZeneca and Takeda."<br> "The sponsors did the statistical analysis, with validation by an independent statistician.” No further details on independent validation. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">DIRECT Protect 2 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 1905 </p> <p><b>Per group:</b> 951 to candesartan; 954 to placebo </p> <p><b>Sample size calculation:</b> target of 1700 followed at least 3 years which would give 80% power to detect a 5% significance for treatment effect of 27% for 3‐step or more progression </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> 30 countries: Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, New Zealand, Poland, Portugal, Romania, Russian Federation, South Africa, Spain, Sweden, Turkey, United Kingdom </p> <p><b>Study period:</b> August 2001 to February 2004 (end of randomization) and March 2008 (end of follow‐up) </p> <p><b>Age:</b> mean was 56.9 years in candesartan group; 56.8 years in placebo group </p> <p><b>Gender:</b> 51% in candesartan group and 49% in placebo group were women </p> <p><b>Race/ethnicity:</b> 96% white </p> <p><b>Inclusion criteria:</b> age 37 to 75 years, no restriction on gender, onset at 36 years of age or older, type 2 diabetes for 1 to 20 years, no microalbuminuria, SBP ≤ 130 mmHg and DBP ≤ 85 mmHg or treated for hypertension with SBP ≤ 160 mmHg and DBP ≤ 90 mmHg, and a retinopathy grading level from ≥ 20/10 (mild non‐proliferative) up to ≤ 47/47 (moderately severe non‐proliferative) on the ETDRS scale based on 7‐field stereo retinal photographs </p> <p><b>Exclusion criteria:</b> eye conditions precluding capture of gradable retinal photographs (angle closure glaucoma, dense cataracts), valvular stenosis, recent heart attack or stroke, pregnant or lactating women, renal impairment (serum creatinine ≥ 110 µmol/L for women and ≥ 130 µmol/L for men, or taking renin angiotensin system inhibitors) </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> </p> <p><b>Normotensive patients</b>: </p> <p>SBP at baseline: mean (SD): 123 (8.7) mmHg in candesartan group and 123 (9.0) mmHg in placebo group </p> <p>DBP at baseline: mean (SD): 75 (6.4) mmHg in candesartan group and 76 (6.5) mmHg in placebo group </p> <p><b>Treated hypertensive patients</b>: </p> <p>SBP at baseline: mean (SD): 139 (12.7) mmHg in candesartan group and 139 (12.0) mmHg in placebo group </p> <p>DBP at baseline: mean (SD): 79 (6.9) mmHg in candesartan group and 80 (7.1) mmHg in placebo group </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> mean (SD) was 8.2 (1.6) overall </p> <p><b>Severity of diabetic retinopathy:</b> </p> <p>ETDRS scale (overall %): diabetic retinopathy absent, 10 (0.3); microaneurysms only, 20 (25.6); mild NPDR, 35 (54.3); mild, moderate, moderately severe NPDR, &gt; 35 to 47 (16.9) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> candesartan cilexetil 16 mg (ARB) increased in dose up to 32 mg once a day after one month based on tolerability </p> <p><b>Intervention 2:</b> placebo </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 3 or more years</p> <p>Actual: 4.7 years (median)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> progression of retinopathy defined as a 3‐step change or more in ETDRS levels, e.g. at least 2 steps in 1 eye and 1 step in the other or at least 3 steps in 1 eye; overall change in retinopathy levels from baseline to final visit </p> <p><b>Secondary outcomes, as specified for this review:</b> incidence of CSME and/or PDR per the ETDRS protocol; visual acuity not reported </p> <p><b>Eye examined for the outcome:</b> both eyes; see primary outcome description above </p> <p><b>Intervals at which outcomes were assessed:</b> retinal photographs at 6 months, 1 year, and every year thereafter </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> <p><b>Other outcomes reported from the study:</b> change in albumin excretion rate, serum total and HDL cholesterol, and glycemic control </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Sources of funding:</b> industry </p> <p><b>Declaration of interest:</b> all authors declared interests related to pharmaceutical companies </p> <p><b>Class(es) of anti‐hypertensive agents compared:</b> angiotensin receptor antagonist only </p> <p><b>Degree of blood pressure control:</b> reduction in blood pressure in both groups; mean changes were 4.3/2.5 mmHg in the candesartan group and 2.9/1.3 mmHg in the placebo group </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Randomisation is performed centrally by a computerized system.”</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Random assignment was done centrally, using an interactive voice‐response system. Both investigators and participants were unaware of the treatment allocation status.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Participants were initially assigned to candesartan 16 mg once a day or matching placebo.” </p> <p>“Two grading teams of independent observers, each consisting of a primary and a secondary grader, were assigned to each patient for the duration of the study at the Retinopathy Grading Centre, Imperial College London, UK. Graders, who were unaware of treatment allocation, assessed all photographs for retinopathy." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Same as for primary outcome.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Intent‐to‐treat analysis for all randomized participants. Reasons for discontinuation and percent discontinued were similar in the two groups. Time‐to‐event analysis. Missed photograph grades imputed from previous photograph grades. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Intent‐to‐treat analysis done on all randomized patients. Reasons for discontinuation and percent discontinued seem similar in the two groups. Time‐to‐event analysis. Imputation for retinopathy outcomes. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk for retinopathy outcomes.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"This study was jointly funded by AstraZeneca and Takeda."</p> <p>“The sponsors did the statistical analysis, with validation by an independent statistician." The authors had full access to all data and were free to interpret data and draw conclusions. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">EUCLID </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 530; 409 had gradable baseline photographs; 354 had baseline and follow‐up retinal photographs </p> <p><b>Per group:</b> 265 to each group (lisinopril and placebo); for retinopathy outcomes: 202 lisinopril, 207 placebo, in which 175 in the lisinopril group and 179 in the placebo group were analyzed </p> <p><b>Sample size calculation:</b> target of 580 (500 with follow‐up) which would give 80% power to detect a 28% reduction in retinopathy progression </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Countries:</b> Austria, Belgium, Croatia, Finland, Greece, Hungary, Ireland, Italy, Luxembourg, Poland, Romania, United Kingdom </p> <p><b>Study period:</b> not reported </p> <p><b>Age:</b> mean (SD) of 34 (9) years in lisinopril group, 35 (8) years in placebo group </p> <p><b>Gender:</b> 36.7% in lisinopril group and 33% in placebo group were women </p> <p><b>Race/ethnicity:</b> not reported </p> <p><b>Inclusion criteria:</b> men and women (on contraception or postmenopausal) aged 20 to 59 years, IDDM defined as diagnosis before 36 years of age and continuous insulin required within 1 year of diagnosis, resting DBP 75 to 90 mmHg, SBP ≤ 155 mmHg </p> <p><b>Exclusion criteria:</b>&nbsp;renal artery stenosis, cardiac valve obstruction, accelerated hypertension, recent myocardial infarction, CABG, stroke, CHF, abnormal renal function (creatinine &gt; 1.8 mg/dL), postural hypotension, or idiosyncratic reactions to ACE inhibitors </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> mean (SD): SBP 123 (10) mmHg in lisinopril group, 123 (11) mmHg in placebo group; DBP 81 (5) mmHg in both lisinopril and placebo groups </p> <p><b>Type of diabetes:</b> type 1 </p> <p><b>HbA1c categories/levels:</b> median (IQR): 6.9 (1.9) for lisinopril and 7.3 (1.9) for placebo group </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> 10 mg/day lisinopril, which could be increased to 20 mg/day at 3 months and at subsequent visits to achieve a target DBP &lt; 75 mmHg </p> <p><b>Intervention 2:</b> placebo </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 2 years</p> <p>Actual: 2 years for those analyzed</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> incidence of retinopathy and retinopathy progression by at least 2 levels; retinal photographs at baseline and 24 months; classification was on a 5‐level scale, using the EURODIAB diabetic retinopathy classification from photos </p> <p><b>Secondary outcomes, as specified for this review:</b> progression to PDR; CSME and visual acuity not reported </p> <p><b>Other diabetic retinopathy outcomes:</b> retinopathy progression by 1 level </p> <p><b>Eyes examined for the outcome:</b> both eyes, but whether average of two eyes was analyzed or whether two eyes were analyzed separately was unclear </p> <p><b>Intervals at which outcomes were assessed:</b> retinal photographs taken at baseline and at 24 months; unclear whether photographs were taken at other follow‐up visits </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> <p><b>Other outcomes reported from the study:</b> change in albumin excretion rate and HbA1c </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Sources of funding:</b> industry </p> <p><b>Declaration of interest:</b> not reported </p> <p><b>Run‐in length:</b> 1 month run‐in on placebo; 70% adherence required for eligibility </p> <p><b>Class(es) of anti‐hypertensive agents compared:</b> ACE inhibitor only </p> <p><b>Degree of blood pressure control:</b> mean DBP near target in lisinopril group </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Randomisation was stratified by centre and albuminuric status.”</p> <p>“Patients were randomly assigned to lisinopril or placebo with a block size of four. Separate schemes were created for each stratum (microalbuminuric and normoalbuminuric), with a FORTRAN computer program validated against the SAS RANUNI random‐number generator. This scheme was generated by Zeneca Pharmaceuticals, so that both the coordinating centre and the local investigators were unaware of the allocation.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Local investigators telephoned the coordinating centre with the provisional albuminuric status, and were given an identification number that matched numbers on pill boxes.”<br> “This scheme was generated by Zeneca Pharmaceuticals, so that both the coordinating centre and the local investigators were unaware of the allocation. Sealed envelopes were supplied to each centre and the coordinating centre so that the code could be broken in an emergency.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“AKS assessed all photographs according to the EURODIAB protocol, based on the modified Airlie House classification. She had no access to information about patients, except study number.” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Same as above.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Analysis based on 325 participants who had 2‐year photographs of 409 randomized participants. Reasons for missed photographs were similar in 2 groups. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Same as above.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear with available information.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“This study was supported by a grant from Zeneca Pharmaceuticals, who also provided the lisinopril and placebo tablets.” Also, the company generated the randomization scheme. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Pradhan </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 40 (35 included in the analysis) </p> <p><b>Per group:</b> 18 to enalapril; 17 to multivitamin </p> <p><b>Sample size calculation:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> USA </p> <p><b>Study period:</b> April 1997 through June 1998 </p> <p><b>Age:</b> mean: 49.3 years in enalapril group; 53.4 years in multivitamin group </p> <p><b>Gender:</b> 50% in enalapril group and 58.8% in placebo group were women </p> <p><b>Race/ethnicity:</b> not reported </p> <p><b>Inclusion criteria:</b> type 2 diabetes, normotensive (&lt; 140/90 mmHg), not on any ACE inhibitors or anti‐hypertensive agents, moderate or severe NPDR identified and graded as ≥ 40 to 50 level of modified Airlie House classification (ETDRS), 7‐field stereoscopic photos to confirm diabetic retinopathy severity </p> <p><b>Exclusion criteria:</b> abnormal serum creatinine, visual acuity &lt; 20/50, dipstick proteinuria more than trace, treatment with ACE inhibitors or other anti‐hypertensive medications </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> all were &lt; 140/90; mean arterial pressures were 91.3 in enalapril group and 89.1 in multivitamin group </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> mean was 10.6 for both groups </p> <p><b>Retinopathy status:</b> all had moderate or severe NPDR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> 5 mg enalapril daily </p> <p><b>Intervention 2:</b> multivitamin placebo daily </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 2 years</p> <p>Actual: 7.1 months (mean; range: 3 to 15 months)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> neither incidence nor progression of diabetic retinopathy reported </p> <p><b>Secondary outcomes, as specified for this review:</b> progression to PDR or macular edema requiring laser treatment based on slit‐lamp examination; PDR, when detected ophthalmoscopically, was documented by 7‐field photos; visual acuity measured but not reported </p> <p><b>Intervals at which outcomes were assessed:</b> all participants had retinal photographs taken at 1 and 2 years; slit‐lamp assessment every 3 months </p> <p><b>Eyes examined for outcome:</b> both eyes, but whether average of two eyes was analyzed or whether two eyes were analyzed separately not stated </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Source of funding:</b> government agency </p> <p><b>Declaration of interest:</b> not reported </p> <p><b>Class(es) of anti‐hypertensive agents compared:</b> ACE inhibitors only </p> <p><b>Degree of blood pressure control:</b> not reported </p> <p><b>Other:</b> terminated with mean follow‐up less than 1 year for “unlikelihood” of demonstrating a significant difference between ACE inhibitor and placebo in the study cohort </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“After randomization to either a multivitamin (MVI) placebo or an ACE‐I . . .”; details of sequence generation not reported. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>PDR and CSME reported at 3‐month intervals based on slit‐lamp examination by ophthalmologist for whom masking was not mentioned. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"One woman had an allergic reaction and was dropped from the study. Four patients did not return for the 3‐month evaluation and were also dropped from the study since they could not be contacted." Treatment arm not specified for dropouts. Also, study terminated early for futility. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear from available information, but visual acuity measured at 3‐month intervals and not reported. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Terminated prematurely for futility; less than 1‐year follow‐up inadequate to assess diabetic retinopathy outcomes in so few participants. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">RASS </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 285 in the trial; 223 analyzed for retinopathy outcome </p> <p><b>Per group:</b> 94 to enalapril, 96 to losartan, 95 to placebo; 77 enalapril, 72 losartan, 74 placebo analyzed for retinopathy </p> <p><b>Sample size calculation:</b> target of 95 participants per each of 3 arms which would give 80% power to detect a two‐sided 5% significance for treatment effect of 50% decrease in rate of change in mesangial fractional volume per glomerulus with 10% dropout; "RASS trial may not have adequate statistical power to detect small effects of RAS blockade on DR" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> Canada and the USA </p> <p><b>Study period:</b> not reported; design published in 2002 </p> <p><b>Age:</b> mean (SD): 30.6 (10) years in enalapril group; 29.3 (10.2) years in losartan group; 29.1 (9.1) years in placebo group </p> <p><b>Gender:</b> 52% in enalapril group; 54% in losartan group; 55% in placebo group were women </p> <p><b>Race/ethnicity:</b> 98% white<br> <b>Inclusion criteria:</b> age 18 years or older; type 1 diabetes defined as onset before the patient's 45th birthday; BMI &lt; 26 kg/m<sup>2</sup> along with a positive glutamate decarboxylase or islet cell antibody test at time of diagnosis if between 31 and 40 years of age; no evidence of renal disease; participants who did not have PDR at baseline and who had fundus photographs at both baseline (defined as within 1 year after randomization) were included in analyses for diabetic retinopathy </p> <p><b>Exclusion criteria:</b> evidence of renal disease; blood pressure &gt; 135/85 mmHg or requiring anti‐hypertensive medications; albumin excretion rate &gt; 20 μg/min; pregnancy; failure to take at least 85% of placebo pills during a 2‐week run‐in period; and glomerular filtration rate &lt; 90 mL/min/1.73 m<sup>2</sup> of body surface area </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> </p> <p>Mean (SD) of SBP at baseline: 120 (13) mmHg in enalapril group; 120 (11) mmHg in losartan group; 119 (11) mmHg in placebo group </p> <p>Mean (SD) of DBP at baseline: 71 (8) mmHg in enalapril group; 70 (8) mmHg in losartan group; 70 (8) mmHg in placebo group </p> <p><b>Type of diabetes:</b> type 1 </p> <p><b>HbA1c categories/levels:</b> mean (SD): 8.6 (1.6) in enalapril group; 8.7 (1.7) in losartan group; 8.3 (1.4) in placebo group </p> <p><b>Severity of retinopathy (worse eye):</b> no retinopathy (10): 34%; minimal NPDR (21): 40%; early NPDR (31‐37): 18%; moderate/severe NPDR (43‐53): 9% </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> enalapril (ACE inhibitor) 10 mg + 'losartan' placebo daily </p> <p><b>Intervention 2:</b> losartan (ARB) 50 mg + 'enalapril' placebo daily </p> <p><b>Intervention 3:</b> 'enalapril' and 'losartan' placebos daily </p> <p>40 months after first randomization, doses for the interventions were doubled owing to evidence suggesting that the reduction in proteinuria was greater with higher doses of study treatments; the treatments were increased to 20 mg enalapril and 100 mg losartan by doubling the number of pills taken each day </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 5 years</p> <p>Actual: 5 years</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> retinopathy progression by 2 steps; diabetic retinopathy grade "derived by concatenating the grades of the two eyes in which the eye with the higher grade given greater weight"; only the combined outcome of incidence and progression reported </p> <p><b>Secondary outcomes, as specified for this review:</b> as above for PDR and CSME; visual acuity not reported </p> <p><b>Other diabetic retinopathy outcomes:</b> incidence of diabetic retinopathy by 3 steps </p> <p><b>Eye examined for outcome:</b> participant's worse eye </p> <p><b>Intervals at which outcomes were assessed:</b> retinal photographs taken at baseline, midpoint, and conclusion of the study </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> <p><b>Other outcomes reported from the study:</b> change in mesangial fractional volume, albumin excretion rate, and glomerular filtration rate </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Sources of funding:</b> industry and government </p> <p><b>Declaration of interest:</b> several authors declared interests related to pharmaceutical companies </p> <p><b>Run‐in length:</b> 2 weeks on placebo </p> <p><b>Class(es) of anti‐hypertensive agents compared:</b> ACE inhibitor and ARB </p> <p><b>Degree of blood pressure control:</b> &lt; 120/80 during follow‐up </p> <p><b>Other:</b> only 223 participants were analyzed for retinopathy outcomes; 28 with no baseline photographs, 4 with baseline PDR, 30 with no 5‐year photographs were excluded from analysis for retinopathy outcomes </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Patients were randomly assigned to one of three groups with the use of computer‐generated blocks of six and stratified according to centre and sex . . ." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"These [stereoscopic fundus photographs] were graded by observers, unaware of the study‐drug assignments, at the University of Wisconsin Ocular Epidemiology Reading Center who used the modified Airlie House . . ." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Same as above.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>". . . use of multiple imputation techniques to assess effects of patients excluded for not having both the baseline and 5‐year . . . diabetic retinopathy grades, respectively." Patients without baseline photographs were excluded from the analyses. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See above for details of multiple imputation for missing retinal photographs at 5‐year follow‐up. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear from available information. Retinopathy assessment is the only pertinent outcome described in Mauer 2002 paper. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Partially supported by industry.</p> <p>Baseline retinal photographs were taken after randomization for 45.3% of the participants (mean time to baseline photographs was 4.8 ± 4.8 months after randomization for these participants). 32 participants were excluded: 4 with baseline PDR and 28 (of 285) without baseline photographs within 1 year after randomization. Not stated, but 30 more not analyzed for retinopathy, presumably because follow‐up photographs not taken. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Steno‐2 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 160 </p> <p><b>Per group:</b> 80 per group </p> <p><b>Sample size calculation:</b> target of 128 which would give 90% power to detect a 5% significance for treatment effect of 23% difference in urinary albumin excretion rate </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> Denmark </p> <p><b>Study period:</b> enrollment 1992 to 1993; total study period 1992 to 1997 </p> <p><b>Age:</b> mean (SD) 54.9 (7.2) years in intensive therapy and 55.2 (7.2) years in standard therapy </p> <p><b>Gender:</b> 21% in intensive therapy and 30% in standard therapy were women </p> <p><b>Race/ethnicity:</b> not reported </p> <p><b>Inclusion criteria:</b> albumin excretion rate 30 mg to 300 mg in 4 of 6 24‐hour overnight samples, type 2 diabetes diagnosed by 1985 WHO criteria, age between 40 and 65 years </p> <p><b>Exclusion criteria:</b> simulated serum C peptide concentration &lt; 600 pmol/L 6 minutes after 1 m IV glucagon injection, pancreatic insufficiency, diabetes secondary to pancreatitis, alcohol abuse, non‐diabetic kidney disease, malignancy or life‐threatening disease probable within 4 years </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> mean (SD): SBP 146 (20) mmHg in intensive therapy and 149 (19) mmHg in standard therapy; DBP 85 (10) mmHg in intensive therapy and 86 (11) mmHg in standard therapy </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels at baseline:</b> mean (SD) 8.4 (1.6) intensive therapy and 8.8 (1.7) standard therapy </p> <p><b>Severity of retinopathy:</b> </p> <p>NPDR: 22% intensive therapy and 20% in standard therapy</p> <p>PDR/photocoagulation: 4% intensive therapy and 8% standard therapy</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> multifactorial; all participants in intensive therapy group received ACE inhibitor equivalent to 50 mg two times a day captopril irrespective of blood pressure with additional intensive therapy for hypertension for a goal SBP &lt; 140 and DBP &lt; 85; vitamin C 250 mg/day for nonsmokers and 1250 mg/day for smokers; vitamin E 100 mg/day for nonsmokers and 500 mg/day for smokers; aspirin 150 mg/day; instructions to limit daily fat intake to &lt; 30% and saturated fat intake to &lt; 10%; light to moderate exercise for 30 minutes, 5 times a week; smoking cessation; metformin 1 g twice a day if BMI &gt; 25; NPH insulin if HbA1c &gt; 7%. Anti‐hypertensive therapy was initiated in a stepwise fashion starting with ACE inhibitors, progressing to AT‐2 blockers, thiazides, calcium antagonists, and beta‐blockers as needed. </p> <p><b>Intervention 2:</b> standard treatment by participants' medical practitioners based on 1998 Danish guidelines with goal SBP &lt; 160 mmHg and DBP &lt; 95 mmHg </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 4 years</p> <p>Actual: 3.8 years mean (SD = 0.3 year)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> incidence of retinopathy; progression of retinopathy defined as at least 1 level in either eye; retinal photographs of 2 45<sup>o</sup> to 50<sup>o</sup> fields (macula‐temporal and disc‐nasal) of each eye with pupils dilated and graded according to EURODIAB 6‐level grading scale </p> <p><b>Secondary outcomes, as specified for this review:</b> progression to PDR or maculopathy </p> <p><b>Other diabetic retinopathy outcomes:</b> blindness in 1 eye by WHO criteria or worse than 6/60 </p> <p><b>Eye examined for outcome:</b> both eyes, but whether average of two eyes was analyzed or whether two eyes were analyzed separately was not stated </p> <p><b>Intervals at which outcomes were assessed:</b> retinopathy assessed at baseline and every 2 years </p> <p><b>Cost of interventions:</b> EUR2538 per quality adjusted life expectancy with multifactorial intensive treatment </p> <p><b>Quality of life:</b> not reported </p> <p><b>Other outcomes reported from the study:</b> urinary albumin excretion </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Sources of funding:</b> unclear; the cost‐effectiveness analysis was supported by the Steno Diabetes Center and Novo Nordisk A/S </p> <p><b>Declaration of interest:</b> not reported </p> <p><b>Class(es) of anti‐hypertensive agents compared:</b> not applicable </p> <p><b>Degree of blood pressure control:</b> blood pressure in intensive therapy group dropped by 14 (2)/12 (2) mmHg by "end of study" compared with 3 (3)/8 (2) mmHg in conventional therapy group </p> <p><b>Other:</b> denominators for retinopathy analysis unclear given some PDR and photocoagulation at baseline </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Concealed randomisation was done in groups of four with two in each treatment arm and thus allowed a maximum difference of two patients per group per stratum." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"Concealed randomisation . . . ," but treatments not masked so some assignments in each block of 4 could be known. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions compared in the trial do not allow masking of participants and personnel; however, the "photographs were graded by two independent ophthalmologists, masked to treatment allocation . . ." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“The photographs were graded by two independent ophthalmologists, masked to treatment allocation . . .” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Analyzed as randomized but withdrawals and deaths excluded from analyses. No imputation or accounting for censoring. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Analyzed as randomized but withdrawals and deaths excluded from analyses. No imputation or accounting for censoring. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear with available information.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Sources of funding not reported.</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">UKPDS/HDS </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 1148 for TBP control policy versus LTBP control policy </p> <p><b>Per group:</b> 758 to TBP control policy (400 to captopril and 358 to atenolol as main therapy), 390 to LTBP control policy </p> <p><b>Sample size calculation:</b> none found in more than 50 study publications for TBP control versus LTBP control or captopril versus atenolol </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> United Kingdom </p> <p><b>Study period:</b> enrollment 1987 to 1991 </p> <p><b>Age:</b> mean (SD) of 56.4 (8.1) years in TBP control group and 56.5 (8.1) in LTBP control group; mean (SD) of 56.3 (8.1) years in captopril group and 56 (8.2) years in atenolol group </p> <p><b>Gender:</b> 46% in TBP control group and 42% in LTBP control group were women; 49% in captopril group and 43% in atenolol group were women </p> <p><b>Race/ethnicity:</b> 87% white; 5% Asian; 8% Afro‐Carribean </p> <p><b>Inclusion criteria:</b> type 2 diabetes and participating in the UKPDS with the mean of blood pressure readings from 3 consecutive visits &gt; 160 mmHg SBP and/or a DBP &gt; 90 mmHg when not receiving treatment for hypertension or an SBP &gt; 150 mmHg and/or a DBP &gt; 85 mmHg when already receiving treatment for hypertension; participants with SBP ≥ 200 mmHg and/or DBP ≥ 105 mmHg on any single occasion were eligible for randomization; the mean of subsequent 3 consecutive readings after discarding the first was used </p> <p><b>Exclusion criteria:</b> requirement for strict blood pressure control due to a previous stroke, accelerated hypertension, ketonuria &gt; 3 mmol/L; cardiac or renal failure; those who required beta‐blockade (myocardial infarction in the previous year or current angina); severe vascular disease with more than one major vascular episode; contraindication to beta‐blockade (with conditions such as asthma, intermittent claudication, foot ulcers or amputations); and severe concurrent illness </p> <p><b>Participants’ status at baseline:</b> </p> <p><b>Blood pressure control:</b> </p> <p><b>TBP control vs. LTBP control (UKPDS 38):</b> mean SBP and DBP similar in both groups; treated stratum blood pressure ≥ 150/85; untreated stratum blood pressure ≥ 160/90 </p> <p><b>ACE inhibitor vs. beta‐blocker (UKPDS 39):</b> mean SBP and DBP similar in both groups; a similar proportion of patients were on anti‐hypertensive therapy before randomization. </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels at baseline:</b> no categories reported, mean levels similar in both groups </p> <p><b>Severity of retinopathy:</b> in TBP group 23% with 20 or worse (microaneurysms only; mild, moderate, moderately severe, or severe NPDR; or PDR) and 7% with 35 or worse (severe NPDR or PDR); in LTBP group 29% with 20 or worse and 10% with 35 or worse </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>TBP control vs. LTBP control</b> </p> <p><b>Intervention 1:</b> TBP control policy aiming for blood pressure &lt; 150/85 mmHg with a random allocation to either an ACE inhibitor or a beta‐blocker </p> <p> <ul id="CD006127-lst1-0008"> <li> <p>captopril (ACE inhibitor) starting at 25 mg twice daily, increasing to 50 mg twice daily </p> </li> <li> <p>atenolol (beta‐blocker) starting at 50 mg daily, increasing to 100 mg daily</p> </li> </ul> </p> <p><b>Intervention 2:</b> LTBP control policy aiming for blood pressure ≤ 180/105 mmHg but avoiding therapy with ACE inhibitors or beta‐blockers. In both groups, if blood pressure control criteria were not met, other agents were added, including (recommended sequence): furosemide 20 mg (maximum 40 mg) twice a day, slow‐release nifedipine 10 mg (maximum 40 mg) twice a day, methyldopa 250 mg (maximum 500 mg) twice a day, and prazosin 1 mg (maximum 5 mg) three times a day </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: unclear</p> <p>Actual: 9.3 years (median)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome, as specified for this review:</b> progression of retinopathy defined as a 2‐step or greater change in ETDRS grading (both eyes 1 step or 1 eye 2 steps) with a worse eye/better eye </p> <p><b>Secondary outcomes, as specified for this review:</b> visual loss defined as the best vision in either eye, deteriorating by 3 lines or more on the ETDRS chart (clinical records); retinopathy grading scale included retinal photocoagulation or vitreous hemorrhage (for PDR) as the most serious grade </p> <p><b>Other diabetic retinopathy outcomes:</b> incidence of retinopathy defined as 1 or more microaneurysms in 1 eye or worse (changed to 5 or more microaneurysms after UKPDS 50 analysis); vitreous hemorrhage; blindness in 1 eye </p> <p><b>Eye examined for outcome:</b> both eyes; see primary outcome description above </p> <p><b>Intervals at which outcomes were assessed:</b> baseline data from retinal photographs taken up to 3 years prior to randomization within the hypertension study component of UKPDS; analyses reported at mean intervals of 1.5, 4.5, and 7.5 years from randomization </p> <p><b>Cost of interventions:</b> reported in UKPDS 40 and UKPDS 54 publications </p> <p><b>Quality of life:</b> UKPDS 37: cross‐sectional comparison of TBP control with LTBP control </p> <p><b>Other outcomes reported from the study:</b> occurrence of 1) first clinical end point related to diabetes (sudden death, death from hyper‐ or hypoglycemia, fatal or nonfatal myocardial infarction, angina, heart failure, stroke, renal failure, amputation, vitreous hemorrhage, retinal photocoagulation, blindness in 1 eye, or cataract extraction, 2) death related to diabetes due to myocardial infarction, sudden death, stroke, peripheral vascular disease, renal disease, hyper‐ or hypoglycemia, (3) death from all causes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Sources of funding:</b> government agencies, industry, and foundations </p> <p><b>Declaration of interest:</b> not reported </p> <p><b>Class(es) of anti‐hypertensive agents compared:</b> ACE inhibitor (captopril) vs. beta‐blocker (atenolol) </p> <p><b>Degree of blood pressure control:</b> TBP control resulted in mean blood pressure decrease 140/80 mmHg compared to LTBP 150/90 mmHg </p> <p><b>Concomitant treatments:</b> all participants also participating in UKPDS RCT of control of blood glucose levels </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Cited UKPDS 33, in which randomization was described as follows:</p> <p>“Randomisation was by means of centrally produced, computer‐generated therapy allocations in sealed, opaque envelopes which were opened in sequence.” </p> <p>“The trial was open once patients were randomised.”</p> <p>“The randomization was stratified for those with or without previous therapy for hypertension.”</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Sealed opaque envelopes were used and checked as described for the UK Prospective Diabetes Study.” </p> <p>The reference was to UKPDS 33 in which randomization was described as above.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Primary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Retinal photographs, masked for all patient‐identifying details and assigned a unique identification number, were assessed initially by two independent, experienced readers for quality and adherence to protocol as well as the presence of any diabetic retinal lesions.” </p> <p>“Retinopathy requiring photocoagulation or vitreous hemorrhage was independently assessed and recorded throughout the study” UKPDS 69. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Masking (performance bias and detection bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>As above for PDR and CSME. Unclear from report for UKPDS 69 and UKPDS VIII whether visual acuity examiners were masked. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Primary outcome </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“Survival function estimates were calculated using the product limit (Kaplan‐Meier) method.” Participants were kept in assigned group but outcomes reported only for available cases. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> Secondary outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Same as above</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None for retinopathy outcomes.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“To form the baseline data set, we used the retinal photograph taken up to 3 years prior to hypertension randomization.” Partial industry support. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><a href="references#CD006127-bbs2-0001">ABCD (1)</a> Appropriate Blood Pressure Control in Diabetes Trial (2 RCTs)<br> <a href="references#CD006127-bbs2-0003">ACCORD EYE:</a> Action to Control Cardiovascular Risk in Diabetes ‐ Eye Study<br> ACE inhibitors: angiotensin‐converting enzyme inhibitors<br> <a href="references#CD006127-bbs2-0004">ADVANCE/AdRem:</a> Action in Diabetes and Vascular Disease Retinal Measurements Study<br> ARB: angiotensin receptor blocker<br> <a href="references#CD006127-bbs2-0005">BENEDICT:</a> BErgamo NEphrologic DIabetes Complications Trial<br> BMI: body mass index<br> CABG: coronary artery bypass graft surgery<br> CCB: calcium channel blocker<br> CHF: congestive heart failure<br> CSME: clinically significant macular edema<br> CWS: cotton‐wool spots<br> DBP: diastolic blood pressure<br> DCCT: Diabetes Control and Complications Trial<br> <a href="references#CD006127-bbs2-0007">DEMAND:</a> Delapril and Manidipine for Nephroprotection in Diabetes<br> DIRECT: Diabetic Retinopathy Candesartan Trials Programme Prevent 1, Protect 1, Protect 2<br> ETDRS: Early Treatment Diabetic Retinopathy Study<br> <a href="references#CD006127-bbs2-0011">EUCLID:</a> EURODIAB Controlled Trial of Lisinopril in Insulin‐Dependent Diabetes Mellitus study<br> HbA1c: glycated hemoglobin<br> HDL: high‐density lipoprotein<br> IDDM: insulin‐dependent diabetes mellitus<br> IQR: interquartile range<br> IRMA: intraretinal microvascular abnormalities<br> logMAR: logarithm of the minimum angle of resolution<br> LTBP: less tight blood pressure<br> mmHg: millimeter of mercury<br> NPDR: non‐proliferative diabetic retinopathy<br> NV: neovascularization<br> PDR: proliferative diabetic retinopathy<br> <a href="references#CD006127-bbs2-0013">RASS:</a> Renin‐Angiotensin System Study<br> RCT: randomized controlled trial<br> RD: retinal detachment<br> SBP: systolic blood pressure<br> SD: standard deviation<br> TBP: tight blood pressure<br> <a href="references#CD006127-bbs2-0015">UKPDS/HDS:</a> United Kingdom Prospective Diabetes Study/Hypertension in Diabetes Study<br> WHO: World Health Organization </p> <p>Declaration of interest information was sought from the primary reference of each study. For UKPDS, we did not specify any one article as the primary reference. We used information from UKPDS 33 and UKPDS 40 because we extracted most of the numbers we used in our analyses from these reports. </p> </div> </div> </p> </section> <section class="characteristicsOfExcludedStudies" lang=""> <div class="section-header" id="CD006127-sec2-0026"> <h3 class="title">Characteristics of excluded studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD006127-sec2-0025" class="jump-to">included studies</a></li> <li><a href="#CD006127-sec2-0027" class="jump-to">awaiting classification</a></li> <li><a href="#CD006127-sec2-0028" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reason for exclusion</p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0016">Araki 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; RCT of 1173 participants with type 2 diabetes randomized to intensive or conservative treatment. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0017">Auyanet 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an RCT; case‐control study to evaluate whether people with diabetic retinopathy who had or had not received photocoagulation had been treated with carvedilol. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0018">CALM‐II</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; the investigator's response to our query indicated that retinopathy data from this trial had not been analyzed; RCT of 75 participants with type 1 or type 2 diabetes randomized to lisinopril alone or dual‐blockade treatment with candesartan and lisinopril. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0019">Chang 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an RCT; commentary on an included trial, no new trial data.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0020">DCCT</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an RCT of blood pressure control; RCT of 1441 participants with insulin‐dependent diabetes randomized to intensive or conservative glycemic control treatment. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0021">Durruty 2000</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; we did not receive a response to multiple requests for information regarding outcomes on diabetic retinopathy; RCT of 57 participants with type 2 diabetes and normal blood pressure randomized to enalapril or placebo. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0022">Faguer de Moustier 1989</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; RCT of 20 participants with type 2 diabetes and slight hypertension randomized to nicardipine or placebo. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0023">Harrold 1969</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an RCT of blood pressure control; RCT of 56 participants with diabetic retinopathy randomized to clofibrate (a lipid‐lowering agent) or placebo. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0024">Jackson 1992</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an RCT; retrospective cohort study evaluating people with diabetic retinopathy and use of angiotensin‐converting enzyme (ACE) inhibitors. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0025">JDCS 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an RCT of blood pressure control; RCT of 2205 participants with type 2 diabetes randomized to intensive lifestyle intervention or conventional diabetes treatment; data on diabetic retinopathy outcomes were reported for the entire RCT cohort and not by treatment group. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0026">Larsen 1990</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; RCT of 20 participants with insulin‐dependent diabetes and normal blood pressure randomized to captopril or control. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0027">Lehsten 1996</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an RCT; case‐control study to compare prevalence of hypertension in people with or without diabetic retinopathy. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0028">Malik 1998</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; we did not receive a response to our request for information regarding outcomes for diabetic retinopathy; RCT of 41 participants with type 1 or type 2 diabetes and normal blood pressure randomized to trandolapril or placebo. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0029">MCSG 1995</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an RCT of blood pressure control; RCT of 70 participants with insulin‐dependent diabetes randomized to intensive or conventional diabetes treatment. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0030">Mehlsen 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; cross‐over RCT of 25 participants with type 1 diabetes, mild retinopathy, and normal blood pressure randomized to amlodipine followed by lisinopril, or vice versa. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0031">Newsom 1991</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; RCT of 8 participants with insulin‐dependent diabetes and normal blood pressure randomized to propanolol, dilevalol, salbutamol, or placebo. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0032">Patel 1998</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; RCT of 45 participants with type 1 or type 2 diabetes and hypertension randomized to perindopril or atenolol. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0033">Porush 2000</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an RCT; narrative review of multiple RCTs of blood pressure control in diabetic participants with or without diabetic retinopathy; most of the RCTs discussed focused on renal and cardiovascular outcomes and were not included in this review. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0034">Rachmani 2000</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; RCT of 250 participants with type 2 diabetes and normal blood pressure randomized to enalapril or placebo. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0035">Rachmani 2002</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an RCT of blood pressure control; RCT of 165 participants with type 2 diabetes and hypertension randomized to a patient participation program or standard annual consultation. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0036">Rassam 1997</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; RCT of 42 participants with mild diabetic retinopathy and normal blood pressure randomized to perindopril or placebo. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0037">Schwartz 1998</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; RCT of 1715 participants with type 2 diabetes and hypertension randomized to irbesartan or amlodipine. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD006127-bbs2-0038">Wang 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data on diabetic retinopathy were available; RCT of 317 participants with type 2 diabetes randomized to captopril or placebo. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RCT: randomized controlled trial</p> </div> </div> </p> </section> <section class="characteristicsOfAwaitingStudies" lang=""> <div class="section-header" id="CD006127-sec2-0027"> <h3 class="title">Characteristics of studies awaiting assessment [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD006127-sec2-0025" class="jump-to">included studies</a></li> <li><a href="#CD006127-sec2-0026" class="jump-to">excluded studies</a></li> <li><a href="#CD006127-sec2-0028" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">ABCD‐2V </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> randomized controlled trial, single center </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 129 </p> <p><b>Per group:</b> 66 allocated to intensive treatment; 63 allocated to moderate treatment </p> <p><b>Sample size calculation:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> USA </p> <p><b>Study period:</b> not reported </p> <p><b>Age:</b> mean (SD) 56.7 (7.7) years in intensive treatment group and 55.5 (7.7) in moderate treatment group </p> <p><b>Gender:</b> 33.3% in intensive treatment group and 31.7% in moderate treatment group were women </p> <p><b>Race/ethnicity:</b> 71.2% white, 19.7% Hispanic, 9.1% African‐American in intensive treatment group; 76.2% white, 11.1% Hispanic, 6.4% African‐American, and 3.2% Asian in moderate treatment group </p> <p><b>Inclusion criteria:</b> type 2 diabetes, 40 to 81 years of age, with a SBP &lt; 140 mmHg, a DBP between 80 and 90 mmHg, and without evidence of overt albuminuria (&lt; 200 µg/min) </p> <p><b>Exclusion criteria:</b> "pregnant or lactating women, need for any antihypertensive medications, documented myocardial infarction or cerebrovascular accident within the past 6 months, severe peripheral vascular disease, history of bilateral renal artery stenosis or stenosis in a solitary kidney, evidence of severe liver disease, hyperkalemia, or history of active cancer" </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> not reported </p> <p><b>Retinopathy status:</b> both non‐proliferative and proliferative </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> intensive treatment </p> <p><b>Intervention 2:</b> moderate treatment </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 5 years</p> <p>Actual: mean follow‐up was 1.9 ± 1.0 years; ranging from &lt; 1 year to 4 years, with 12 participants having 4 years of follow‐up </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes for this review:</b> progression of diabetic retinopathy </p> <p><b>Secondary outcomes for this review:</b> none mentioned </p> <p><b>Other diabetic retinopathy outcomes:</b> regression of diabetic retinopathy </p> <p><b>Other outcomes:</b> change in creatinine clearance from baseline, proportion with doubling of serum creatinine, and change in log urinary albumin excretion from baseline; progression/regression of neuropathy; incidence of cardiovascular events </p> <p><b>Intervals at which outcomes were assessed:</b> every 6 months </p> <p><b>Eyes examined for outcome:</b> not reported </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Source of funding:</b> Novartis Pharmaceutical Company </p> <p><b>Declaration of interest:</b> not reported </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">ADDITION 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> cluster randomized controlled trial </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> 3057 </p> <p><b>Per group:</b> 1678 allocated to intensive care; 1379 allocated to routine care </p> <p><b>Sample size calculation:</b> Yes; </p> <p>"We calculated that a patient‐level randomised trial would have required enrolment of 2700 individuals (1350 per treatment group) to detect a 30% reduction in the risk of the primary endpoint at a 5% significance level, and with 90% power. This calculation allowed for 10% loss to follow‐up and assumed an event rate in the routine care group of 3% per year, on the basis of the results of the UK Prospective Diabetes Study Group (UKPDS). We expected a minimum effect of clustering within general practice, with the estimated within‐cluster correlation coefficient being 0·01. We assumed that the average number of participants per general practice would be 10 and, therefore, the design effect was 1·09. Thus, we inflated the estimated sample size for this cluster trial to 3000 patients in total." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> Denmark, United Kingdom, the Netherlands </p> <p><b>Study period:</b> September 2008 to the end of December 2009 </p> <p><b>Age:</b> not reported </p> <p><b>Gender:</b> not reported </p> <p><b>Race/ethnicity:</b> not reported </p> <p><b>Inclusion criteria:</b> newly diagnosed type 2 diabetes </p> <p><b>Exclusion criteria:</b> patients had "contraindications to the proposed study medication, an illness with a life expectancy of 12 months, or psychological or psychiatric problems that were likely to invalidate informed consent" </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> not reported </p> <p><b>Retinopathy status:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> intensive treatment </p> <p><b>Intervention 2:</b> routine care </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 5 years</p> <p>Actual: mean (SD) follow‐up period of 5.3 (1.6) years</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes for this review:</b> combined incidence and progression of diabetic retinopathy </p> <p><b>Secondary outcomes for this review:</b> none mentioned </p> <p><b>Other outcomes:</b> neuropathy </p> <p><b>Intervals at which outcomes were assessed:</b> not reported </p> <p><b>Eyes examined for outcome:</b> both eyes, but whether average of two eyes were analyzed or whether two eyes were analyzed separately not stated </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Source of funding:</b> multiple sources from government agencies, foundations, etc. </p> <p><b>Declaration of interest:</b> multiple sources including receiving grants, speaking and travel expenses, advisory board members, etc. </p> <p>Author's contact information: Annelli Sandbæk, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="25444b4b4049494c0b56444b414744404e654449480b44500b414e">[email&#160;protected]</a></p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">ROADMAP </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter, phase III </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> not reported </p> <p><b>Per group:</b> not reported </p> <p><b>Sample size calculation:</b> Yes; </p> <p>The study can "detect a 30% reduction in the risk of microalbuminuria (hazard ratio of 1.433) with 90% power at the 5% significance level . . . Thus, at least 2043 subjects are needed in each treatment arm and 328 events of microalbuminuria are expected to be observed. To compensate for withdrawals, 2200 patients are being recruited and randomized to each of the two treatment arms of the study." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> European countries including Austria, Belgium, Bulgaria, Czech Republic, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Poland, Romania, Russia, Slovak Republic, Spain, the Netherlands, the United Kingdom, and Ukraine </p> <p><b>Study period:</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Gender:</b> not reported </p> <p><b>Race/ethnicity:</b> not reported </p> <p><b>Inclusion criteria:</b> Type 2 diabetics free of signs of urinary albumin excretion who have one additional cardiovascular risk factor; if hypertensive, not taking ACE inhibitors or ARBs; 18 to 75 years of age; HbA1c ≥ 6.5% or are on treatment; hypertensive (SBP ≥ 130 mmHg and/or DBP ≥ 80 mmHg) </p> <p><b>Exclusion criteria:</b> renal and/or renal‐vascular disease (including malignant or severe renal disease); a history of nephrectomy and/or renal transplantation, or if they require dialysis; a recent history (within 6 months of starting the study) of myocardial infarction, stroke, transient ischaemic attack, myocardial revascularization or reperfusion; recent use of (within 6 months of starting the study) ARBs or ACE inhibitors or if they have severe hypertension, defined as SBP &gt; 200 mmHg and/or DBP &gt; 110 mmHg; severe uncontrolled hyperlipidaemia, severe heart failure, bradycardia (&lt; 50 beats/minute at rest), a significant narrowing of the aortic bicuspid valve, a severe obstruction of cardiac outflow (hypertrophic cardiomyopathy, New York Heart Association (NYHA) stage 3–4) </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> not reported </p> <p><b>Retinopathy status:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> 40 mg olmesartan twice daily with water before breakfast </p> <p><b>Intervention 2:</b> placebo tablet twice daily with water before breakfast </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 5 years</p> <p>Actual: not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome for this review:</b> incidence and progression of retinopathy </p> <p><b>Secondary outcomes for this review:</b> none mentioned </p> <p><b>Other outcomes:</b> time to albuminuria, cardiovascular mortality, stroke, cardiovascular morbidity, serum creatinine, hospitalization for various bad outcomes (end‐stage renal disease, worsening glomerular filtration rate) </p> <p><b>Intervals at which outcomes were assessed:</b> week 4, week 12, and month 6 (visits 2, 3, and 4, respectively) and thereafter every 6 months until the end of the study </p> <p><b>Eyes examined for outcome:</b> not reported </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Source of funding:</b> Sankyo </p> <p><b>Declaration of interest:</b> "All steering committee members are consultants for Sankyo for the ROADMAP study." </p> </td> </tr> </tbody> </table> </div> </p> </section> <section class="characteristicsOfOngoingStudies" lang=""> <div class="section-header" id="CD006127-sec2-0028"> <h3 class="title">Characteristics of ongoing studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD006127-sec2-0025" class="jump-to">included studies</a></li> <li><a href="#CD006127-sec2-0026" class="jump-to">excluded studies</a></li> <li><a href="#CD006127-sec2-0027" class="jump-to">awaiting classification</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">AdDIT </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Adolescent type 1 Diabetes cardio‐renal Intervention Trial (AdDIT)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> Multicenter RCT; 2x2 factorial design; randomization with minimization with primary intent‐to‐treat analysis and secondary ‘as treated’ analysis </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> not reported </p> <p><b>Per group:</b> not reported </p> <p><b>Sample size calculation:</b> Yes; </p> <p>"This sample size is informed by the ORPS cohort study (477 participants in the correct age range of recruitment with a mean of 3.5 observations over time)" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> United Kingdom, Australia, and Canada </p> <p><b>Study period:</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Gender:</b> not reported </p> <p><b>Race/ethnicity:</b> not reported </p> <p><b>Inclusion criteria:</b> type 1 diabetics 11 to 16 years of age with albumin/creatinine ratio measured twice from average of 3 early‐morning samples; adjusted for gender, age, and duration of diabetes; eligible whenever “subject’s residual lies above log 1.2” (i.e. higher side); &lt; 1 year since diagnosis or C‐peptide negative </p> <p><b>Exclusion criteria:</b> "the presence of any of the following will prevent patient inclusion: 1) Non T1D, i.e. type 2 diabetes, insulin dependent diabetes related to monogenic disease, secondary<br> diabetes; 2) ACR based on six early morning urines deemed to be at low risk for subsequent development of CVD or DN; 3) Pregnancy or unwillingness to comply with contraceptive advice and regular testing throughout trial; 4) Breast feeding; 5) Severe hyperlipidaemia and family history data to support diagnosis of familial hypercholesterolaemia; 6) Established hypertension unrelated<br> to DN; 7) Prior exposure to the investigational products; 8) Unwillingness/inability to comply with the study protocol; 9) Other co‐morbidities considered unsuitable by the investigator (excluding treated hypothyroidism and celiac disease); 10) Proliferative retinopathy." </p> <p><b>Type of diabetes:</b> type 1 </p> <p><b>HbA1c categories/levels:</b> not reported </p> <p><b>Retinopathy status:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> ACE inhibitor </p> <p><b>Intervention 2:</b> statin </p> <p><b>Intervention 3:</b> combination of ACE inhibitor and statin </p> <p><b>Intervention 4:</b> placebo </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 5 to 10 years</p> <p>Actual: not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary study outcome</b>: reduction in albumin/creatinine ratio (30% assumed; 25% advantage) using the area under the curve of the log albumin/creatinine ratio standardized for gender, age, and duration of diabetes </p> <p><b>Secondary study outcomes</b>: changes in 1) carotid intima‐media thickness, fibromuscular dysplasia, endothelial dysfunction, and pulse wave velocity; 2) arterial blood pressure, lipids, and other lipoproteins, cardiovascular disease risk markers (high‐sensitivity C‐reactive protein and asymmetric dimethylarginine); 3) measure of glomerular filtration rate (plasma symmetric dimethyl arginine, creatinine, and cystatin C); 4) retinopathy scores and retinal microvascular structure; 5) quality of life and health economics </p> <p><b>Intervals at which outcomes were assessed:</b> every 3 months </p> <p><b>Eyes examined for outcome:</b> not reported </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Registered in 2007 and publication expected in 2009</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The Adolescent type 1 Diabetes cardio‐renal Intervention Trial Research Group (<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/NWRXT5DVN67GIZUEGI4VAZ5BNVYGCZ3PPWWB/" target="_blank"><span class="__cf_email__" data-cfemail="593d3b3d6b6c193a383477383a772c32">[email&#160;protected]</span></a>) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Source of funding:</b> Juvenile Diabetes Research Foundation, British Heart Foundation, and Diabetes UK. Study drugs are supplied by Pfizer UK Ltd. The study is also funded in Canada by the Canadian Diabetes Association and the Heart and Stroke Foundation of Canada. </p> <p><b>Declaration of interest:</b> "The author declares that they have no competing interests" </p> <p><b>Target sample size:</b> 500 </p> <p>For retinopathy, expect &gt; 90% power to detect 25% difference in “retinopathy prevalence” using retinal photographs </p> <p><b>EudraCT number:</b> 2007‐001039‐72 </p> <p><b>Trial Registration Number:</b> ISRCTN91419926 </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT00134160 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The Study Comparing the Incidence of Cardiovascular Events Between High‐Dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> Parallel group RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> not reported </p> <p><b>Per group:</b> not reported </p> <p><b>Sample size calculation:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> Japan </p> <p><b>Study period:</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Gender:</b> not reported </p> <p><b>Race/ethnicity:</b> not reported </p> <p><b>Inclusion criteria:</b> individuals aged 65 to 85 years on anti‐hypertensive therapy (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) with either type 2 diabetes, cardiovascular risk factors, elevated serum creatinine, or proteinuria </p> <p><b>Exclusion criteria:</b> "Secondary hypertension or malignant hypertension; Heart failure (NYHA functional classification III or IV); Required treatment for malignant tumor; Serious liver or renal dysfunction (serum creatinine &gt; 2.5 mg/dL or with dialysis treatment); Not appropriate for change to the test drugs from current therapy for hypertension or coronary diseases (i.e. calcium channel blockers, β‐blockers, thiazide diuretics, etc.); History of serious adverse drug reactions to angiotensin II receptor blockers or calcium channel blockers; Patients with other serious reasons (i.e. illness, significant abnormalities, etc.) that investigators judge inappropriate for the study" </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> not reported </p> <p><b>Retinopathy status:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> ARB therapy: olmesartan medoxomil 40 mg/day </p> <p><b>Intervention 2:</b> Combination therapy: ARB and calcium channel blocker (olmesartan medoxomil 20 mg/day and either amlodipine or azelnidipine) </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: 36 months</p> <p>Actual: not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary study outcome:</b> composite fatal and nonfatal cardiovascular events; coronary events; heart failure; vascular events; diabetic complications (nephropathy, retinopathy, neuropathy); renal dysfunction; all‐cause mortality </p> <p><b>Secondary study outcomes:</b> change in blood pressure; serious adverse events not including primary outcomes </p> <p><b>Intervals at which outcomes were assessed:</b> not reported </p> <p><b>Eyes examined for outcome:</b> not reported </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>August 2005</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Kikuo Arakawa, MD<br> Emeritus Professor, Fukuoka University<br> Fukuoka, Japan </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov identifier: NCT00134160</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT00300976 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases (J‐DOIT3) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> Parallel group RCT </p> <p><b>Unit of randomization and analysis:</b> individual </p> <p><b>Number randomized ‐ Total:</b> not reported </p> <p><b>Per group:</b> not reported </p> <p><b>Sample size calculation:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> Japan </p> <p><b>Study period:</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Gender:</b> not reported </p> <p><b>Race/ethnicity:</b> not reported </p> <p><b>Inclusion criteria:</b> Individuals aged 45 to 70 years with type 2 diabetes with 1 of the following: 1) HbA1c ≥ 6.9% despite therapy and lifestyle interventions; 2) SBP ≥ 140 mmHg or DBP ≥ 90 mmHg when not on anti‐hypertensive therapy or SBP of 130 mmHg or DBP of 80 mmHg on ACE inhibitors, ARBs, and/or long‐acting calcium channel blockers; 3) abnormalities in lipid metabolism </p> <p><b>Exclusion criteria:</b> "1. Those with poorly controlled hypertension despite pharmacological therapy (systolic BP 200 mmHg or diastolic BP 120 mmHg) 2. Those on insulin therapy 3. Those with non‐diabetic renal disease 4. Those in whom type 1 and other diabetes due to pathogenic mechanisms other than those associated with type 2 diabetes is strongly suspected 5. Those who tested anti‐GAD antibody*‐positive 6. Those with LDL‐cholesterol 200 mg/dL 7. Those suspected of having secondary hypertension other than renal parenchymal hypertension 8. Those suspected of having hereditary lipid disorder with a strong family history of lipid metabolic disorder 9. Those who were receiving antihypertensive agents other than ARB, ACEI, long‐acting CCB, except where they were receiving these agents for other purposes than blood pressure lowering 10. Those who were receiving 3 or more antihypertensive agents (i.e., ARB, ACEI, and long‐acting CCB), except where they were receiving these agents for other purposes than blood pressure lowering 11. Those with more serious retinopathy than proliferative retinopathy 12. Renal failure (serum Cr: 2.0 mg/dL in men; 1.5 mg/dL in women) 13. Those with a history of cardiac failure or those with cardiac failure 14. Those who were pregnant or potentially pregnant 15. Those who met any of the following criteria and who had BNP 100 pg/mL, Myocardial infarction, Angina pectoris (or a history of disease), History of coronary artery bypass graft (CABG), History of percutaneous coronary angioplasty (PTCA), Other cardiac disease, ECG findings of left ventricular hyperplasia, Abnormal ECG findings (excluding isolated extrasystole or right bundle branch block (RBBB)) 16. Those judged by the physician in charge to be ineligible for study entry" </p> <p><b>Type of diabetes:</b> type 2 </p> <p><b>HbA1c categories/levels:</b> not reported </p> <p><b>Retinopathy status:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1:</b> Intensive therapy: weight control, diet, and exercise through lifestyle consultation; and drug therapy to achieve HbA1c &lt; 6.2%, SBP/DBP &lt; 120/75 mmHg, high‐density lipoprotein cholesterol of 40 mg/dL, low‐density lipoprotein cholesterol &lt; 80 mg/dL, triglycerides &lt; 120 mg/dL </p> <p><b>Intervention 2:</b> Conventional therapy: weight control, diet, and exercise according to standard guidelines </p> <p><b>Length of follow‐up:</b> </p> <p>Planned: not reported; follow up every 6 or 12 months</p> <p>Actual: not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary study outcome</b>: incidence of cardiovascular events </p> <p><b>Secondary study outcomes</b>: incidence or progression of nephropathy, retinopathy, incidence of peripheral vascular events </p> <p><b>Intervals at which outcomes were assessed:</b> every 6 or 12 months </p> <p><b>Eyes examined for outcome:</b> not reported </p> <p><b>Cost of interventions:</b> not reported </p> <p><b>Quality of life:</b> not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>May 2006</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Takashi Kadowaki<br> University of Tokyo </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ClinicalTrials.gov identifier: NCT00300976</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACE: angiotensin‐converting enzyme<br> ARBs: angiotensin II receptor blockers<br> DBP: diastolic blood pressure<br> HbA1c: glycated hemoglobin<br> mg/dL: milligram per deciliter<br> mmHg: millimeter of mercury<br> ORPS: Oxford Regional Prospective Study<br> RCT: randomized controlled trial<br> SBP: systolic blood pressure </p> </div> </div> </p> </section> </section> <section class="dataAndAnalyses" id="dataAndAnalyses"> <section class="dataAndAnalyses" lang="en"> <div class="section-header section-collapse-header" id="CD006127-sec1-0011"> <h2 class="title section-collapse-title">Data and analyses<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <div class="table" id="CD006127-tbl-0002"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of retinopathy at 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3053</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.80 [0.71, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00101"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-01.png?filename=nCD006127-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%201%20Incidence%20of%20retinopathy%20at%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.1</div> </div> <hr class="top"><img data-id="CD006127-fig-00101" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-01.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 1 Incidence of retinopathy at 4 to 5 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 1 Incidence of retinopathy at 4 to 5 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1421</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 [0.69, 0.97]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1632</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.63, 0.96]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Progression of retinopathy at 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4589</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.88 [0.73, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00102"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-02.png?filename=nCD006127-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%202%20Progression%20of%20retinopathy%20at%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.2</div> </div> <hr class="top"><img data-id="CD006127-fig-00102" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-02.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 2 Progression of retinopathy at 4 to 5 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 2 Progression of retinopathy at 4 to 5 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1905</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.03 [0.82, 1.29]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2684</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.81 [0.65, 1.01]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Combined incidence and progression of DR, 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2587</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.63, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00103"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-03.png?filename=nCD006127-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%203%20Combined%20incidence%20and%20progression%20of%20DR%2C%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.3</div> </div> <hr class="top"><img data-id="CD006127-fig-00103" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-03.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 3 Combined incidence and progression of DR, 4 to 5 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 3 Combined incidence and progression of DR, 4 to 5 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2436</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 [0.66, 1.03]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>151</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.55 [0.35, 0.88]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Incidence of PDR/CSME at 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6573</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.95 [0.83, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00104"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-04.png?filename=nCD006127-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%204%20Incidence%20of%20PDR%2FCSME%20at%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.4</div> </div> <hr class="top"><img data-id="CD006127-fig-00104" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-04.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 4 Incidence of PDR/CSME at 4 to 5 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 4 Incidence of PDR/CSME at 4 to 5 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2128</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.03 [0.80, 1.32]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4445</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.89 [0.70, 1.13]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Visual acuity (loss of 3 lines or more), 4 to 5 years in type 2 diabetics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2326</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.06 [0.85, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00105"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-05.png?filename=nCD006127-CMP-001-05.ppt&amp;title=1.5&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%205%20Visual%20acuity%20%28loss%20of%203%20lines%20or%20more%29%2C%204%20to%205%20years%20in%20type%202%20diabetics.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.5</div> </div> <hr class="top"><img data-id="CD006127-fig-00105" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-05.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 5 Visual acuity (loss of 3 lines or more), 4 to 5 years in type 2 diabetics."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 5 Visual acuity (loss of 3 lines or more), 4 to 5 years in type 2 diabetics. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events ‐ All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6709</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.86 [0.64, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00106"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-06.png?filename=nCD006127-CMP-001-06.ppt&amp;title=1.6&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%206%20Adverse%20events%20%E2%80%90%20All%20cause%20mortality.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.6</div> </div> <hr class="top"><img data-id="CD006127-fig-00106" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-06.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 6 Adverse events ‐ All cause mortality."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 6 Adverse events ‐ All cause mortality. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3322</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.08 [0.50, 2.29]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3387</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 [0.60, 1.12]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events ‐ Hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3477</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.08 [1.68, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00107"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-07.png?filename=nCD006127-CMP-001-07.ppt&amp;title=1.7&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%207%20Adverse%20events%20%E2%80%90%20Hypotension.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.7</div> </div> <hr class="top"><img data-id="CD006127-fig-00107" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-07.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 7 Adverse events ‐ Hypotension."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 7 Adverse events ‐ Hypotension. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006127-tbl-0003"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of DR at 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3053</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.80 [0.71, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00201"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-01.png?filename=nCD006127-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%201%20Incidence%20of%20DR%20at%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.1</div> </div> <hr class="top"><img data-id="CD006127-fig-00201" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-01.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 1 Incidence of DR at 4 to 5 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 1 Incidence of DR at 4 to 5 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1659</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.84 [0.73, 0.98]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1394</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.72 [0.56, 0.93]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Progression of DR, 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4589</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.88 [0.73, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00202"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-02.png?filename=nCD006127-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%202%20Progression%20of%20DR%2C%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.2</div> </div> <hr class="top"><img data-id="CD006127-fig-00202" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-02.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 2 Progression of DR, 4 to 5 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 2 Progression of DR, 4 to 5 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3810</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.94 [0.81, 1.09]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>779</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.73 [0.51, 1.06]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Combined incidence and progression of DR, 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2587</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.63, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00203"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-03.png?filename=nCD006127-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%203%20Combined%20incidence%20and%20progression%20of%20DR%2C%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.3</div> </div> <hr class="top"><img data-id="CD006127-fig-00203" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-03.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 3 Combined incidence and progression of DR, 4 to 5 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 3 Combined incidence and progression of DR, 4 to 5 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1966</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.81 [0.57, 1.16]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>621</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.72 [0.48, 1.08]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Incidence of PDR/CSME at 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6573</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.95 [0.83, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00204"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-04.png?filename=nCD006127-CMP-002-04.ppt&amp;title=2.4&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%204%20Incidence%20of%20PDR%2FCSME%20at%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.4</div> </div> <hr class="top"><img data-id="CD006127-fig-00204" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-04.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 4 Incidence of PDR/CSME at 4 to 5 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 4 Incidence of PDR/CSME at 4 to 5 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4033</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.01 [0.87, 1.16]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2540</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.76 [0.56, 1.02]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Visual acuity (loss of 3 lines or more), 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2326</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.06 [0.85, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00205"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-05.png?filename=nCD006127-CMP-002-05.ppt&amp;title=2.5&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%205%20Visual%20acuity%20%28loss%20of%203%20lines%20or%20more%29%2C%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.5</div> </div> <hr class="top"><img data-id="CD006127-fig-00205" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-05.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 5 Visual acuity (loss of 3 lines or more), 4 to 5 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 5 Visual acuity (loss of 3 lines or more), 4 to 5 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1546</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.12 [0.95, 1.32]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>780</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.83 [0.51, 1.36]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events ‐ All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6709</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.86 [0.64, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00206"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-06.png?filename=nCD006127-CMP-002-06.ppt&amp;title=2.6&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%206%20Adverse%20events%20%E2%80%90%20All%20cause%20mortality.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.6</div> </div> <hr class="top"><img data-id="CD006127-fig-00206" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-06.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 6 Adverse events ‐ All cause mortality."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 6 Adverse events ‐ All cause mortality. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5704</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.02 [0.74, 1.42]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1005</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.51 [0.29, 0.89]</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD006127-tbl-0004"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of DR, 1.5 to 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1953</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.80 [0.66, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00301"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-003-01.png?filename=nCD006127-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%201%20to%202%20years%2C%20Outcome%201%20Incidence%20of%20DR%2C%201.5%20to%202%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.1</div> </div> <hr class="top"><img data-id="CD006127-fig-00301" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-01.png" alt="Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 1 Incidence of DR, 1.5 to 2 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 1 Incidence of DR, 1.5 to 2 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1555</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.83 [0.66, 1.03]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>398</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.74 [0.50, 1.11]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Progression of DR, 1.5 to 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4132</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.08 [0.89, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00302"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-003-02.png?filename=nCD006127-CMP-003-02.ppt&amp;title=3.2&amp;caption=Comparison%203%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%201%20to%202%20years%2C%20Outcome%202%20Progression%20of%20DR%2C%201.5%20to%202%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.2</div> </div> <hr class="top"><img data-id="CD006127-fig-00302" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-02.png" alt="Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 2 Progression of DR, 1.5 to 2 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 2 Progression of DR, 1.5 to 2 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1921</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.22 [0.86, 1.73]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2211</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.02 [0.81, 1.29]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Combined incidence and progression of DR, 1.5 to 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>803</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.54 [0.29, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00303"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-003-03.png?filename=nCD006127-CMP-003-03.ppt&amp;title=3.3&amp;caption=Comparison%203%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%201%20to%202%20years%2C%20Outcome%203%20Combined%20incidence%20and%20progression%20of%20DR%2C%201.5%20to%202%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.3</div> </div> <hr class="top"><img data-id="CD006127-fig-00303" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-03.png" alt="Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 3 Combined incidence and progression of DR, 1.5 to 2 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 3 Combined incidence and progression of DR, 1.5 to 2 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>323</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.29 [0.08, 1.01]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>480</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.62 [0.41, 0.94]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Incidence of PDR, 1.5 to 2 years, Type 1 diabetes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>340</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.58 [0.04, 9.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD006127-fig-00304"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-003-04.png?filename=nCD006127-CMP-003-04.ppt&amp;title=3.4&amp;caption=Comparison%203%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%201%20to%202%20years%2C%20Outcome%204%20Incidence%20of%20PDR%2C%201.5%20to%202%20years%2C%20Type%201%20diabetes.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.4</div> </div> <hr class="top"><img data-id="CD006127-fig-00304" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-04.png" alt="Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 4 Incidence of PDR, 1.5 to 2 years, Type 1 diabetes."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 4 Incidence of PDR, 1.5 to 2 years, Type 1 diabetes. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> </section> </section> <div class="figures-list"> <div class="figure" id="CD006127-fig-0001"> <img data-id="CD006127-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-AFig-FIG01.png" alt="Results of searching for studies for inclusion in the review"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Results of searching for studies for inclusion in the review</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-fig-0001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-AFig-FIG01.png?filename=nCD006127-AFig-FIG01.ppt&amp;title=1&amp;caption=Results%20of%20searching%20for%20studies%20for%20inclusion%20in%20the%20review&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-AFig-FIG01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-0002"><img data-id="CD006127-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-AFig-FIG02.png" alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Missing cells indicate that study did not measure corresponding review outcomes."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Missing cells indicate that study did not measure corresponding review outcomes. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-fig-0002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-AFig-FIG02.png?filename=nCD006127-AFig-FIG02.ppt&amp;title=2&amp;caption=Risk%20of%20bias%20summary%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20for%20each%20included%20study.%20Missing%20cells%20indicate%20that%20study%20did%20not%20measure%20corresponding%20review%20outcomes.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-AFig-FIG02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00101"><img data-id="CD006127-fig-00101" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-01.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 1 Incidence of retinopathy at 4 to 5 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 1 Incidence of retinopathy at 4 to 5 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00101" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-01.png?filename=nCD006127-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%201%20Incidence%20of%20retinopathy%20at%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00102"><img data-id="CD006127-fig-00102" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-02.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 2 Progression of retinopathy at 4 to 5 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 2 Progression of retinopathy at 4 to 5 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00102" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-02.png?filename=nCD006127-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%202%20Progression%20of%20retinopathy%20at%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00103"><img data-id="CD006127-fig-00103" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-03.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 3 Combined incidence and progression of DR, 4 to 5 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 3 Combined incidence and progression of DR, 4 to 5 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00103" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-03.png?filename=nCD006127-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%203%20Combined%20incidence%20and%20progression%20of%20DR%2C%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00104"><img data-id="CD006127-fig-00104" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-04.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 4 Incidence of PDR/CSME at 4 to 5 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 4 Incidence of PDR/CSME at 4 to 5 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00104" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-04.png?filename=nCD006127-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%204%20Incidence%20of%20PDR%2FCSME%20at%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00105"><img data-id="CD006127-fig-00105" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-05.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 5 Visual acuity (loss of 3 lines or more), 4 to 5 years in type 2 diabetics."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 5 Visual acuity (loss of 3 lines or more), 4 to 5 years in type 2 diabetics. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00105" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-05.png?filename=nCD006127-CMP-001-05.ppt&amp;title=1.5&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%205%20Visual%20acuity%20%28loss%20of%203%20lines%20or%20more%29%2C%204%20to%205%20years%20in%20type%202%20diabetics.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00106"><img data-id="CD006127-fig-00106" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-06.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 6 Adverse events ‐ All cause mortality."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 6 Adverse events ‐ All cause mortality. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00106" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-06.png?filename=nCD006127-CMP-001-06.ppt&amp;title=1.6&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%206%20Adverse%20events%20%E2%80%90%20All%20cause%20mortality.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00107"><img data-id="CD006127-fig-00107" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-07.png" alt="Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 7 Adverse events ‐ Hypotension."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years, Outcome 7 Adverse events ‐ Hypotension. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00107" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-001-07.png?filename=nCD006127-CMP-001-07.ppt&amp;title=1.7&amp;caption=Comparison%201%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%204%20to%205%20years%2C%20Outcome%207%20Adverse%20events%20%E2%80%90%20Hypotension.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-001-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00201"><img data-id="CD006127-fig-00201" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-01.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 1 Incidence of DR at 4 to 5 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 1 Incidence of DR at 4 to 5 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00201" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-01.png?filename=nCD006127-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%201%20Incidence%20of%20DR%20at%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00202"><img data-id="CD006127-fig-00202" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-02.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 2 Progression of DR, 4 to 5 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 2 Progression of DR, 4 to 5 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00202" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-02.png?filename=nCD006127-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%202%20Progression%20of%20DR%2C%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00203"><img data-id="CD006127-fig-00203" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-03.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 3 Combined incidence and progression of DR, 4 to 5 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 3 Combined incidence and progression of DR, 4 to 5 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00203" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-03.png?filename=nCD006127-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%203%20Combined%20incidence%20and%20progression%20of%20DR%2C%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00204"><img data-id="CD006127-fig-00204" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-04.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 4 Incidence of PDR/CSME at 4 to 5 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 4 Incidence of PDR/CSME at 4 to 5 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00204" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-04.png?filename=nCD006127-CMP-002-04.ppt&amp;title=2.4&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%204%20Incidence%20of%20PDR%2FCSME%20at%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00205"><img data-id="CD006127-fig-00205" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-05.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 5 Visual acuity (loss of 3 lines or more), 4 to 5 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 5 Visual acuity (loss of 3 lines or more), 4 to 5 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00205" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-05.png?filename=nCD006127-CMP-002-05.ppt&amp;title=2.5&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%205%20Visual%20acuity%20%28loss%20of%203%20lines%20or%20more%29%2C%204%20to%205%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00206"><img data-id="CD006127-fig-00206" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-06.png" alt="Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 6 Adverse events ‐ All cause mortality."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years, Outcome 6 Adverse events ‐ All cause mortality. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00206" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-002-06.png?filename=nCD006127-CMP-002-06.ppt&amp;title=2.6&amp;caption=Comparison%202%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20hypertension%2C%204%20to%205%20years%2C%20Outcome%206%20Adverse%20events%20%E2%80%90%20All%20cause%20mortality.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-002-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00301"><img data-id="CD006127-fig-00301" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-01.png" alt="Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 1 Incidence of DR, 1.5 to 2 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 1 Incidence of DR, 1.5 to 2 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00301" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-003-01.png?filename=nCD006127-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%201%20to%202%20years%2C%20Outcome%201%20Incidence%20of%20DR%2C%201.5%20to%202%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00302"><img data-id="CD006127-fig-00302" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-02.png" alt="Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 2 Progression of DR, 1.5 to 2 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 2 Progression of DR, 1.5 to 2 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00302" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-003-02.png?filename=nCD006127-CMP-003-02.ppt&amp;title=3.2&amp;caption=Comparison%203%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%201%20to%202%20years%2C%20Outcome%202%20Progression%20of%20DR%2C%201.5%20to%202%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00303"><img data-id="CD006127-fig-00303" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-03.png" alt="Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 3 Combined incidence and progression of DR, 1.5 to 2 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 3 Combined incidence and progression of DR, 1.5 to 2 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00303" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-003-03.png?filename=nCD006127-CMP-003-03.ppt&amp;title=3.3&amp;caption=Comparison%203%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%201%20to%202%20years%2C%20Outcome%203%20Combined%20incidence%20and%20progression%20of%20DR%2C%201.5%20to%202%20years.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD006127-fig-00304"><img data-id="CD006127-fig-00304" src="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-04.png" alt="Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 4 Incidence of PDR, 1.5 to 2 years, Type 1 diabetes."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years, Outcome 4 Incidence of PDR, 1.5 to 2 years, Type 1 diabetes. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-fig-00304" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/ppt/CDSR/CD006127/image_n/nCD006127-CMP-003-04.png?filename=nCD006127-CMP-003-04.ppt&amp;title=3.4&amp;caption=Comparison%203%20Blood%20pressure%20control%20versus%20no%20%28or%20less%29%20control%20by%20type%20of%20diabetes%2C%201%20to%202%20years%2C%20Outcome%204%20Incidence%20of%20PDR%2C%201.5%20to%202%20years%2C%20Type%201%20diabetes.&amp;citation=Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, 1. Art. No.: CD006127. DOI: http://dx.doi.org/10.1002/14651858.CD006127.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD006127.pub2/media/CDSR/CD006127/image_n/nCD006127-CMP-003-04.png">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD006127-tbl-0001" class="summary-of-findings framed"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Blood pressure intervention/intensive blood pressure intervention compared with placebo/standard intensive blood pressure intervention for diabetic retinopathy</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> type 1 or type 2 diabetics </p> <p><b>Settings:</b> diabetes and ophthalmology clinics </p> <p><b>Intervention:</b> blood pressure intervention/intensive blood pressure intervention (anti‐hypertensive medication or intense anti‐hypertensive medication, or intense lifestyle intervention and medication) </p> <p><b>Comparison:</b> placebo/standard blood pressure intervention (anti‐hypertensive medication) </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>No. of participants<br> (trials)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo/standard blood pressure intervention</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Blood pressure intervention/intensive blood pressure intervention</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Incidence of retinopathy at 4 to 5 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>285 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>228 per 1000</b> <br> (202 to 262) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.80</b> (0.71 to 0.92) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3053</p> <p>(6 trials)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> <b>moderate</b><sup>1,3</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Progression of retinopathy at 4 to 5 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>185 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>163 per 1000</b> <br> (135 to 194) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.88</b> (0.73 to 1.05) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4105<br> (4 trials) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> <b>moderate</b><sup>1,3</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Combined incidence and progression of</b> </p> <p><b>diabetic retinopathy, 4 to 5 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>269 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>210 per 1000</b> <br> (169 to 261) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.78</b> (0.63 to 0.97) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2587<br> (5 trials) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2,3</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Incidence of PDR/CSME at 4 to 5 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>133 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>126 per 1000</b> <br> (110 to 144) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.95</b> (0.83 to 1.08) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6089<br> (6 trials) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> <b>moderate</b><sup>1,3</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Visual acuity at 4 to 5 years</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>207 per 1000</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>219 per 1000</b> </p> <p>(176 to 275)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.06</b> </p> <p>(0.85 to 1.33)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2326</p> <p>(2 trials)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> <b>moderate</b><sup>2,3</sup> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse events ‐ All‐cause mortality</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>30 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>26 per 1000</b> <br> (19 to 34) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.86</b> (0.64 to 1.14) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6709<br> (7 trials) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> <b>moderate</b><sup>1,3</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse events ‐ Hypotension</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>66 per 1000</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>137 per 1000</b> <br> (111 to 170) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 2.08</b> (1.68 to 2.57) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3477 (3 trials)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> <b>moderate</b><sup>1,3</sup> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br> <b>CI:</b> confidence interval; <b>CSME:</b> clinically significant macular edema; <b>RR:</b> risk ratio; <b>PDR:</b> proliferative diabetic retinopathy </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) Working Group grades of evidence<br> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded for risk of bias (‐1) because of considerable numbers of participants lost to follow‐up in some trials.<br> <sup>2</sup> Downgraded for inconsistency (‐1) I<sup>2</sup> &gt; 50%.<br> <sup>3</sup> The studies had different comparisons including intensive blood pressure control versus moderate blood pressure control for hypertensives and blood pressure control intervention versus placebo for normotensives. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-tbl-0001" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006127-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Baseline characteristics of Type 1 diabetics in included studies</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="2" bgcolor="#ffffff"> <p><b>Characteristic</b> </p> </td> <td align="center" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>DIRECT</p> </td> <td align="center" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0011">EUCLID</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0013">RASS</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0006">Chase</a> </p> </td> </tr> <tr> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Prevent‐1</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Protect‐1</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Number enrolled</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1421</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1905</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>530</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>285</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Number analyzed</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1421</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1905</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>354</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>223</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Age</b>, years (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>32</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>34</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>21</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Men</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>57</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>58</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>47</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>75</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>White</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>97</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>98</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>98</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Diabetes duration</b>, years (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.7</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.0</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14.5</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.2</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.9</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Current smoker</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Systolic blood pressure</b> (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>116</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>117</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>123</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>120</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>115</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Diastolic blood pressure</b> (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>74</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>81</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>70</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Body‐mass index</b> (kg/m<sup>2</sup>; mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24.0</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24.6</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24.7</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25.7</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>HbA1c</b> (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.1</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.5</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.5</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.4</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Retinopathy, worse eye</b>, %<sup>2</sup> </p> </td> <td align="center" valign="" colspan="5" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Number of participants with gradeable baseline photographs</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1421</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1905</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>354</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>223</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS ≤ 20: None or microaneurysms only</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>49</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>38</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>34</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>44</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS 31 to 37: Mild non‐proliferative</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>42</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>41</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>56</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS 41 to 53: Moderate or severe non‐proliferative</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS &gt; 53: Proliferative or pan‐retinal photocoagulation</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Percentages based on number of participants enrolled.<br> <sup>2</sup> Percentages based on number of participants with gradeable photographs.<br> ‐ Indicates no data were available in the study publications found. </p> <p>Data shown for <a href="./references#CD006127-bbs2-0013">RASS</a> includes the number of participants analyzed for retinopathy outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Baseline characteristics of Type 1 diabetics in included studies</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-tbl-0005" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006127-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span>&nbsp;<span class="table-title">Baseline characteristics of normotensive or treated hypertensive Type 2 diabetics in included studies</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Characteristic</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0010">DIRECT Protect 2</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0003">ACCORD EYE</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0001">ABCD (1)</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0012">Pradhan</a> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Number enrolled</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1905</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1590</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>480</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Number analyzed</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1905</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1263</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>480</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>35</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Age</b>, years (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>57</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>61</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>59</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>51</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Men</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>54</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>54</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>46</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>White</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>96</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>70</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>74</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Diabetes duration</b>, years (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.8</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Current smoker</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Systolic blood pressure</b> (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>133</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>138</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>136</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Diastolic blood pressure</b> (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>76</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>84</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Body‐mass index</b> (kg/m<sup>2</sup>; mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>29.4</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>32.4</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>31.5</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>26.9</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>HbA1c</b> (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.2</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.3</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.6</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.6</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Previous myocardial infarction</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2</p> </td> <td align="center" valign="" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>12<sup>3</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Previous stroke</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.4</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.5</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Retinopathy, worse eye</b>, %<sup>2</sup> </p> </td> <td align="center" valign="" colspan="4" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Number of participants with gradeable baseline photographs</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1905</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1261</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>463</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS ≤ 20: None or microaneurysms only</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>28</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>49</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS 31 to 37: Mild non‐proliferative</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>54</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td align="center" valign="" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>46</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS 41 to 53: Moderate or severe non‐proliferative</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>36</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS &gt; 53: Proliferative or pan‐retinal photocoagulation</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup> Percentages based on number of participants enrolled.<br> <sup>2</sup> Percentages based on number of participants with gradeable photographs.<br> <a href="./references#CD006127-bbs2-0003">ACCORD EYE</a> data based number of participants in the blood pressure trial.<br> <sup>3</sup> History of cardiovascular event.<br> ‐ Indicates that specific data were not reported in the publications from the trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span>&nbsp;<span class="table-title">Baseline characteristics of normotensive or treated hypertensive Type 2 diabetics in included studies</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-tbl-0006" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006127-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span>&nbsp;<span class="table-title">Baseline characteristics of hypertensive Type 2 diabetics in included studies</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Characteristic</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0004">ADVANCE/AdRem</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0015">UKPDS/HDS</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0005">BENEDICT</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0002">ABCD (2)</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0007">DEMAND</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0014">Steno‐2</a> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Number enrolled</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2130</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1148</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1209</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>470</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>380</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>160</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Number analyzed</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1241</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1148</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>550</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>470</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>258</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>149</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Age</b>, years (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>66</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>56</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>62</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>58</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>61</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>55</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Men</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>61</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>55</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>54</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>68</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>74</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>White</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>48</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>87</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>99</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>66</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Diabetes duration</b>, years (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.0</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.6</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.9</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.6</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.8<sup>3</sup> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Current smoker</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>22</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Systolic blood pressure</b> (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>143</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>160</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>152</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>155</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>147</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>148</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Diastolic blood pressure</b> (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>79</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>94</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>98</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>88</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Body‐mass index</b> (kg/m<sup>2</sup>; mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>27.7</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>29.6</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>28.7</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>31.8</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>29.6</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>29.9</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>HbA1c</b> (mean) </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.4</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.9</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.9</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.6</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.6</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Previous myocardial infarction</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Previous stroke</b>, %<sup>1</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Retinopathy, worse eye</b>, %<sup>2</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Number of participants with gradeable baseline photographs</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1602</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>929</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>550</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>431</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>237</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>160</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS ≤ 20: None or microaneurysms only</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>82</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>67</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>84</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>81</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>79</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS 31 to 37: Mild non‐proliferative</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="center" valign="" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>25</p> </td> <td align="center" valign="" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>15</p> </td> <td align="center" valign="" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>55</p> </td> <td align="center" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>19</p> </td> <td align="center" valign="" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>17</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS 41 to 53: Moderate or severe non‐proliferative</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ETDRS &gt; 53: Proliferative or pan‐retinal photocoagulation</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Percentages based on number of participants enrolled.<br> <sup>2</sup> Percentages based on number of participants with gradeable photographs.<br> <sup>3</sup> Median, estimated from median values of treatment arms.<br> ‐ indicates that specific data were not reported in the publications from the trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span>&nbsp;<span class="table-title">Baseline characteristics of hypertensive Type 2 diabetics in included studies</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-tbl-0007" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006127-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span>&nbsp;<span class="table-title">Comparison of outcomes within participant subgroups: type 1 normotensive diabetics, type 2 normotensive or treated hypertensive diabetics, and type 2 hypertensive diabetics</span></div> <tbody> <tr> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Outcomes</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type 1 normotensives</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type 2 normotensives or</b> </p> <p><b>treated hypertensives</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type 2</b> </p> <p><b>hypertensives</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Incidence of retinopathy</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Direction of effect</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors BP intervention over placebo</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors BP intervention over placebo</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors intensive BP intervention over standard BP intervention</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR [95% CI]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 [0.69 to 0.97]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.94 [0.69 to 1.27]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.72 [0.56 to 0.93]</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p># trials (participants)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1421)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (238)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (1394)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Progression of retinopathy</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Direction of effect</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors placebo over BP intervention</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors BP intervention over placebo</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors intensive BP intervention over standard BP intervention</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR [95% CI]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.03 [0.82 to 1.29]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.89 [0.73 to 1.08]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.73 [0.51 to 1.06]</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p># trials (participants)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1905)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1905)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (779)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Combined incidence and progression of retinopathy</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Direction of effect</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors BP intervention over placebo</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors intensive BP intervention over standard BP intervention</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR [95% CI]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 [0.66 to 1.03]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.55 [0.35 to 0.88]</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p># trials (participants)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4 (2436)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (151)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Incidence of PDR/CSME</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Direction of effect</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors placebo over BP intervention</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>neither</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors intensive BP intervention over standard BP intervention</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR [95% CI]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.03 [0.80 to 1.32]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.00 [0.83 to 1.19]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.76 [0.56 to 1.02]</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p># trials (participants)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (2128)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 (1905)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (2540)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Adverse events: all‐cause mortality</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Direction of effect</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors placebo over BP intervention</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors placebo over BP intervention</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>favors intensive BP intervention over standard BP intervention</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR [95% CI]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.08 [0.50 to 2.29]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.01 [0.70 to 1.45]</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.51 [0.29 to 0.89]</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p># trials (participants)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (3322)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (2382)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3 (1005)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>BP: blood pressure<br> CI: confidence interval<br> CSME: clinically significant macular edema<br> PDR: proliferative diabetic retinopathy<br> RR: risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span>&nbsp;<span class="table-title">Comparison of outcomes within participant subgroups: type 1 normotensive diabetics, type 2 normotensive or treated hypertensive diabetics, and type 2 hypertensive diabetics</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-tbl-0008" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006127-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span>&nbsp;<span class="table-title">Comparison of ACEi drugs with other classes of anti‐hypertensives</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Outcome</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial identifier</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comparator class</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR (95% CI)</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incidence of DR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0007">DEMAND</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ACEi + CCB</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.48 (0.13, 1.86)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Progression of DR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0015">UKPDS/HDS</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>beta‐blocker</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.01 (0.75, 1.35)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>Combined incidence and progression of DR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0001">ABCD (1)</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>CCB</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.33 (0.93, 1.92)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0002">ABCD (2)</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>CCB</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.93 (0.71, 1.21)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0013">RASS</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ARB</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.89 (0.49, 1.63)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Regression of DR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0005">BENEDICT</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>non‐ACEi</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.44 (0.22, 0.87)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All‐cause mortality</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD006127-bbs2-0015">UKPDS/HDS</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>beta‐blocker</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.88 (0.64, 1.20)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>ACEi: angiotensin‐converting enzyme inhibitor<br> ARB: angiotensin receptor blocker<br> CCB: calcium channel blocker<br> DR: diabetic retinopathy<br> RR: risk ratio<br> CI: confidence interval </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span>&nbsp;<span class="table-title">Comparison of ACEi drugs with other classes of anti‐hypertensives</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/full#CD006127-tbl-0009" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006127-tbl-0002" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of retinopathy at 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3053</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.80 [0.71, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1421</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 [0.69, 0.97]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1632</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.63, 0.96]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Progression of retinopathy at 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4589</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.88 [0.73, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1905</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.03 [0.82, 1.29]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2684</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.81 [0.65, 1.01]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Combined incidence and progression of DR, 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2587</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.63, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2436</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 [0.66, 1.03]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>151</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.55 [0.35, 0.88]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Incidence of PDR/CSME at 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6573</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.95 [0.83, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2128</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.03 [0.80, 1.32]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4445</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.89 [0.70, 1.13]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Visual acuity (loss of 3 lines or more), 4 to 5 years in type 2 diabetics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2326</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.06 [0.85, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events ‐ All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6709</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.86 [0.64, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3322</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.08 [0.50, 2.29]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3387</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 [0.60, 1.12]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events ‐ Hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3477</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.08 [1.68, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Blood pressure control versus no (or less) control by type of diabetes, 4 to 5 years</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-tbl-0002" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006127-tbl-0003" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of DR at 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3053</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.80 [0.71, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1659</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.84 [0.73, 0.98]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1394</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.72 [0.56, 0.93]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Progression of DR, 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4589</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.88 [0.73, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3810</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.94 [0.81, 1.09]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>779</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.73 [0.51, 1.06]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Combined incidence and progression of DR, 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2587</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 [0.63, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1966</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.81 [0.57, 1.16]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>621</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.72 [0.48, 1.08]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Incidence of PDR/CSME at 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6573</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.95 [0.83, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4033</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.01 [0.87, 1.16]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2540</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.76 [0.56, 1.02]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Visual acuity (loss of 3 lines or more), 4 to 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2326</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.06 [0.85, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1546</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.12 [0.95, 1.32]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>780</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.83 [0.51, 1.36]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse events ‐ All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6709</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.86 [0.64, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.1 Normotensives/treated hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5704</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.02 [0.74, 1.42]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2 Hypertensives</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1005</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.51 [0.29, 0.89]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Blood pressure control versus no (or less) control by type of hypertension, 4 to 5 years</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-tbl-0003" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD006127-tbl-0004" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of DR, 1.5 to 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1953</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.80 [0.66, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1555</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.83 [0.66, 1.03]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>398</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.74 [0.50, 1.11]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Progression of DR, 1.5 to 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4132</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.08 [0.89, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1921</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.22 [0.86, 1.73]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2211</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.02 [0.81, 1.29]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Combined incidence and progression of DR, 1.5 to 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>803</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.54 [0.29, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 Type 1 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>323</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.29 [0.08, 1.01]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Type 2 diabetes</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>480</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.62 [0.41, 0.94]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Incidence of PDR, 1.5 to 2 years, Type 1 diabetes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>340</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.58 [0.04, 9.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Blood pressure control versus no (or less) control by type of diabetes, 1 to 2 years</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD006127.pub2/references#CD006127-tbl-0004" class="tableList">Navigate to table in Review</a></div> </div> </div> <section class="translation-notes-modal" style="display: none" data-modal-title="Translation notes" data-modal-class="translation-notes" data-ok-btn-selector=".ok-btn"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD006127-note-1203">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD006127-note-1208">Español</a> </li> <li class="section-language"> <a class="" href="hr#CD006127-note-1207">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD006127-note-1206">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD006127-note-1205">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD006127-note-1204">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" id="citeProcText" data-load-error="Unable to load citation data"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a href="#" class="addthis_button_citeulike at300b btn btn-link">CiteULike</a></li> <li><a href="#" class="addthis_button_mendeley at300b btn btn-link">Mendeley</a></li> <li><a href="#" class="citation-btn-refworks at300b btn btn-link" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <h4>Copy or download citation</h4> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button type="button" class="btn btn-link">Plain text</button></li> <li class="citation-option" data-option="endnote"><button type="button" class="btn btn-link">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button type="button" class="btn btn-link">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button type="button" class="btn btn-link">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button type="button" class="btn btn-link">BibteX</button></li> </nav> <div class="citation-content"> <pre id="citationContent" tabindex="0" data-load-error="Unable to load citation data"></pre> </div> <div class="clearfix"> <form class="download-citation-form" method="GET" target="citation-download-iframe" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=citation-citeproc&p_p_cacheability=cacheLevelPage&p_p_col_id=column-1&p_p_col_count=1"> <input type="hidden" id="siteId" name="siteId" value="" /> <input type="hidden" id="downloadType" name="downloadType" value="" /> <input type="hidden" id="style" name="style" value="" /> <input type="hidden" id="articleId" name="articleId" value="" /> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay" /><input name="p_p_lifecycle" type="hidden" value="2" /><input name="p_p_state" type="hidden" value="normal" /><input name="p_p_mode" type="hidden" value="view" /><input name="p_p_resource_id" type="hidden" value="citation-download" /><input name="p_p_cacheability" type="hidden" value="cacheLevelPage" /><input name="p_p_col_id" type="hidden" value="column-1" /><input name="p_p_col_count" type="hidden" value="1" /> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withAbstract"> <input class="checkbox" type="checkbox" name="withAbstract" /> <span class="checkbox-label">Include abstract</span> </label> </div> </form> <iframe title="Citation download frame" name="citation-download-iframe" src="" style="display: none; visibility: hidden" aria-hidden="true"></iframe> </div> </div> </div> </div> <div class="print-modal" style="display: none;" data-modal-title="Print this review"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input title="Select/deselect all" type="checkbox" class="print-options-select-all" checked="checked" /> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i class="fa fa-print" aria-hidden="true"></i> Print</button> </div> </div> <div class="download-stats-data-modal" style="display: none;" data-modal-title="Download statistical data"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <p> Downloaded data can only be viewed using <a class="external" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/tools/review-production-tools/revman-5" target="_blank">Review Manager software.</a> </p> <p> Please note that: <ul> <li>data are only available for Cochrane Reviews that contain one or more forest plots; and</li> <li>data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.</li> </ul> </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input type="hidden" name="content-disposition" value="attachment" /> <input type="hidden" name="mime-type" value="application/octet-stream" /> <p class="print-options-controls"> <input type="checkbox" class="download-stats-data-toc-check-box" aria-label="I agree to these terms and conditions" /> <span class="checkbox-label" aria-hidden="true">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i class="fa fa-download" aria-hidden="true"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" style="display:none;" data-modal-title="Share this review"> <div class="add-this"> <div class="addthis_toolbox addthis_default_style addthis_32x32_style"> <nav class="stacked-nav-list"> <li> <a href="#" class="addthis_button_twitter at300b" title="Tweet">Twitter</a> </li> <li> <a href="#" class="addthis_button_mendeley at300b" target="_blank" title="Mendeley">Mendeley</a> </li> <li> <a href="#" class="addthis_button_facebook at300b" title="Facebook">Facebook</a> </li> <li> <a href="#" class="addthis_button_linkedin at300b" target="_blank" title="LinkedIn">LinkedIn</a> </li> <li> <a href="#" class="addthis_button_email at300b" target="_blank" title="Email">Email</a> </li> <li> <a href="#" class="addthis_button_whatsapp at300b" target="_blank" title="WhatsApp">WhatsApp</a> </li> <li class="clearfix"> <a href="#" class="addthis_button_more btn primary pull-right" target="_blank" title="View more"> <i class="fa fa-plus" aria-hidden="true"></i> View more</a> </li> </ul> </div> </div> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button type="button" class="btn btn-link" id="figureOptionBtn">Figures</button></li> <li class="table-options-btn-container"><button type="button" class="btn btn-link" id="tableOptionBtn">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div id="figureThumbnails" class="figure-thumbnails is-visible"></div> <div id="tableThumbnails" class="table-thumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a href="#" class="figure-viewer-menu-toggle"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-table-show-text="Show table list" data-table-hide-text="Hide table list" data-figure-show-text="Show thumbnails" data-figure-hide-text="Hide thumbnails">Hide thumbnails</span> </a> <a href="#" class="figure-viewer-zoomin"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a href="#" class="figure-viewer-zoomout"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a href="#" class="figure-viewer-nav previous"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a href="#" class="figure-viewer-nav next"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_  portlet-static portlet-static-end kaleo-designer-portlet " id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a title="Cochrane logo" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/">
<img class="footer-logo logo-part-1" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-1.png" alt="Cochrane logo" /> <img class="footer-logo logo-part-2" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-2.png" alt="" /> </a> </div> <nav class="footer-links"> <ul class="root"> <li class="footer-item"> <a class="footer-item-link" href="/about-cochrane1">About Cochrane</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/evidence" target="_blank">Cochrane.org</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank">Who we are</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NJYXT5SPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Get involved</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX665WNWTYE63PMNYXG4DTMFYGKLUQPJUB/" target="_blank">Consumer Network</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-funders-and-partners" target="_blank">Partners</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYXZ5DQPF4XT7LNF3SX8Z5IPJRX63JPN73GH/" target="_blank">Colloquium</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news" target="_blank">In the news</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/publications">Publications</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="/library">Cochrane Library</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/" target="_blank">Library Homepage</a> </li> <li class="footer-item"> <a class="footer-item-link" href="cdsr/about-cdsr" target="_blank">Cochrane Reviews (CDSR)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/central" target="_blank">Trials (CENTRAL)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cca/about" target="_blank">Cochrane Clinical Answers</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/cochrane-library-app" target="_blank">Cochrane Library App</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cdsr/journal-club" target="_blank">Journal Club</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/podcasts" target="_blank">Podcasts</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/community">Community</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Community</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/" target="_blank">Archie log-in</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/PS3GC4LPNFYGPLUDN7SXR6UBN3TT655TMH/" target="_blank">Training and support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/NWTYI4DQMS3T6Z5QMNVHEZLPMVYG86UH/" target="_blank">Methods</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/help" target="_blank">Software</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news/jobs" target="_blank">Jobs and opportunities</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/contact-us">Contact Us</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/contact" target="_blank">General enquiries</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/help/contact-us" target="_blank">Cochrane Library support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/chief-executive-officers-office/team" target="_blank">Chief Executive Officer</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/editorial-methods/team" target="_blank">Editor in Chief</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-global-community" target="_blank">Cochrane groups</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/media" target="_blank">Media</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/accessibility" target="_blank">Accessibility</a> </li> </ul> </li> </ul> </nav> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/advertisers">Advertisers & Agents</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Help & Support</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/terms-and-conditions">Terms & Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright &copy; 2000 - 2020 by <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUYNFXGK8JPMNYXN/" class="">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br /> Review our <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUYNFXGK8JPMNYXN/en-gb/privacy"><strong>Privacy Policy</strong></a> </p> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MW4T675JNSTYTLUDN7XB/"><img class="logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_wiley-footer-logo.png" alt="Wiley logo" /></a> </div> </div> <span class="wiley-semi-circle"></span> </div> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" style="display: none" data-modal-title="Feature in English only" data-modal-class="english-only-modal"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script src="/cochrane-theme/vendor/ie9.js?t=1581422282000" type="text/javascript"></script> <!--<![endif]--> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/theme.js?t=1581422282000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/checkout.js"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MN3G865UNWRYE43NMNTG6LUDPJYYG65TMWUC655TMH/widget/v2.0/widget.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MRZXE8DIHB4XC63SNWYHPN3PMNXG87LEM33G85UVF3YGK7A/assets/embed.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006127\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006127\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006127\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006127\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006127\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581422282000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a href="#" class="rh-nav-close-btn"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a href="#" class="rh-nav-open-btn"> <span>Review tools & navigation</span> </a> </div> <iframe title="Print frame" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" aria-hidden="true"></iframe> <div class="mobile-navigation"> <div class="close-container"> <a href="#" class="main-nav-back-btn" aria-label="Navigate back"><i class="fa fa-chevron-left"></i></a> <a href="#" class="main-nav-close-btn" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="ymag__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006127.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006127.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<a href="/en/browse-by-topic" class="btn secondary">Browse </a>
<a href="/en/advanced-search" class="btn secondary advanced-search-button">Advanced search</a>
</div>
<div class="menu-items parent">
<ul>
<li class="nav-root-item parent">
<a href="#" title="Select language" class="language-selection-title-link">
<span class="mobile-nav-language-title">Select your preferred language</span><span class="icon fa fa-caret-down"></span>
<ul class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="fdkn__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div id="active-content-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div id="active-portal-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="/en/cdsr/doi/10.1002/14651858.CD006127.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD006127.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</ul>
</a>
</li>
<li class="parent">
<a class="mobile-link signin" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006127.pub2%2Freferences" data-redirect="false" rel="nofollow">
Sign In
</a>
</li>
</ul>
<div class="menu-items-footer">
<div class="utility-links">
<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/" class="cochrane-link" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
<div class="basic-login-form-content" style="display: none;" data-modal-title="Sign in">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="dbam__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1583246258181" /> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value="" /> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true" /> <input checked class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onClick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true" /> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user-registration" target="_blank" class="btn secondary">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" style="display: none;" data-modal-title="Institutional login">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="obft__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text">
</div>
<button class="btn primary" type="submit" name="button">Go</button>
</div>
<div id="institutionLookupErrorDiv" class="message error" style="display:none">
'<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
</div>
</div>
<input type="hidden" id="entityId" name="entityId" value="">
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="joiu__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1583246258185" /> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD006127&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value="" /> </div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true" /> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" style="display: none;" data-modal-title="Unlock the potential of Cochrane evidence">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="wpdq__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text"> </div> <button class="btn primary" type="submit" name="button">Go</button> </div> <div id="institutionLookupErrorDiv" class="message error" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input type="hidden" id="entityId" name="entityId" value=""> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'> <input type="hidden" name="openlabel" id="openlabel" value='Open access'> </div> </section> </div> </div>  <script>window.urlTitle="/cdsr/doi/10.1002/14651858.CD006127.pub2";addthis_config={pubid:"ra-593597d01cdf9a55",ui_508_compliant:true};addthis_share={url:window.location.href,title:document.title};</script> <script src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-593597d01cdf9a55"></script> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> </body> </html> 